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Immunohistochemistry images from an EMVI-positive tumour (a. & b.) and 
an EMVI-negative tumour (c. & d.) stained for metalloproteinase 2 (MMP2). 
a. b. 
   c. d. 
MMP2 was demonstrated to be associated with EMVI-status in resected rectal cancers 
(p<0.0001), was an accurate predictor of EMVI-status (Test Accuracy 0.90, AUC >0.95), and 
was superior to methylation status as an EMVI-status discriminator. Furthermore, MMP2 was 
associated with worse disease-free and overall survival in rectal cancers (p=0.030 and 0.049, 
respectively). Full results in Chapter 7.
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Summary 
Colorectal cancer (CRC) is the third most frequent cancer and the second leading cause of 
cancer death worldwide. Each year, one million people will develop CRC, and 40-50% will 
die within five years. Furthermore, rectal and distal sigmoid cancers are known to present at a 
later stage and have a poorer prognosis than other colonic cancers. Rectal cancers that 
demonstrate pathological extramural vascular invasion (EMVI-positive) are known to have a 
poorer prognosis than those that do not (EMIV-negative), and EMVI has is acknowledged as 
an important risk factor for systemic recurrence, local recurrence and death. Additionally, 
EMVI status influences the need for pre- and post-operative chemoradiation (CRT); which may 
influence survival outcomes.   
Aberrant DNA methylation is emerging as a carcinogenic mechanism and potential biomarker 
in colorectal cancer. This study investigates the association between hypermethylation and 
EMVI in vivo and in vitro. Firstly, the in vivo associations between hypermethylation, EMVI, 
and clinical and histopathological outcomes are examined. Secondly, an investigation of the 
effects of demethylation on invasive colorectal cell lines in vitro aims to illuminate the genetic 
and cellular mechanisms that underlie methylation-dependent pathological cellular behaviour. 
Finally, highlighted biologic mechanisms are investigated in vivo to discover if there is an 
association with EMVI and survival outcomes. By these means the axis of association between 
hypermethylation, EMVI, and clinical outcomes is investigated. The investigation is conducted 
within the framework of consensus molecular subtyping in colorectal cancer, and in 
concordance with current methodologies of assessing DNA methylation status. 
The primary findings demonstrate that EMVI is associated with hypermethylation in vivo, but 
that there is no direct correlation between hypermethylation and disease-free (DFS) or overall 
survival (OS). In vitro, demethylation of hypermethylated colorectal cancer cells, by means of 
established demethylating agent 5-azacytidine and putative demethylator RRx-001, reduces 
their propensity to migrate and invade. Demethylation in vitro is also associated with changes 
in the expression of the metalloproteinases involved in the metabolism of the basement 
membrane and the epithelial-to-mesenchymal transition and tumour metastasis, notably MMP2 
and TIMP2. Changes in expression were confirmed at transcriptomal and proteomic levels in 
response to demethylation. In vivo, MMP2 expression was shown to be statistically 
significantly associated with EMVI, DFS, and OS, and was also independently predictive of 
EMVI, raising the possibility that it could act as a diagnostic and predictive biomarker in rectal 
cancers. 
These findings indicate a mechanistic association between hypermethylation and EMVI, 
mediated by methylation-dependent expression of metalloproteinases. Metalloproteinase 
expression, specifically MMP2, may act as a potential biomarker for EMVI and correlates to 
survival outcomes in rectal cancer. 
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1.1 Colorectal Cancer 
1.1.1 Structure & Function of the Colon & Rectum 
The colon and rectum constitute the large bowel/intestine, and along with the anal canal, form 
the final portion of the alimentary tract.  Together, the colon and rectum are approximately 
160cm in length, extending from the ileocaecal junction with the small bowel (marked by the 
ileocaecal valve) to the anal verge and skin of the perineum.  The primary function of the colon 
and rectum is to absorb water and salts form the bowel content before it is expelled, the rectum 
also acting as a reservoir for stool prior to evacuation.  The constituent portions of the colon 
are the caecum, right or ascending colon, transverse colon, left or descending colon, and 
sigmoid colon.  The colon and rectum are comprised of concentric layers with different 
structure and function, the innermost of which is the mucosa (predominantly columnar 
epithelium with mucous producing goblet cells), followed by the neurovascular submucosa, 
then the muscularis propria (two layers of smooth muscle, the innermost circumferential and 
the outer in discontinuous longitudinal bands called taeniae coli), and finally the serosa or 
adventitia (depending on relationship to the peritoneum).  At the distal end of the sigmoid colon 
the taeniae coli converge as they pass over the sacral promontory to form the rectum as a 
distinct anatomical portion of the large bowel.   
 
The rectum itself is approximately 15cm in length and is divided into thirds dependent upon 
its peritoneal relations; the upper rectum having a peritoneal covering on three sides (anterior 
and bilateral), the mid rectum having only an anterior covering of peritoneum, and the low 
rectum being entirely below the peritoneal reflection completely enveloped in its mesentery.  
The classical boundary of the rectum and its supporting mesentery below the peritoneal 
reflections is described by the plane of complete mesorectal excision (CME), originally 
described in Heald’s seminal work1.  The rectum is also different from the colon in its relation 
to the abdominal and pelvic peritoneal cavity; being entirely located within the confines of the 
bony pelvis.  This is of particular importance when considering both the relative limitations of 
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surgical access to the rectum compared to the colon, and its relationship to significant visceral, 
neurovascular, bony, and other structures located in the pelvis.   
 
As the rectum reaches the pelvic floor the smooth muscular fibres constituting its outer wall 
condense, and with the contribution of the skeletal muscles of the adjacent pelvic floor, the 
anal sphincter complex is formed, investing within it the anal canal.  The canal itself is 2-4cm 
in length, and as well as its role as a sphincter, is also marked by the change from the columnar 
epithelium of the colon and rectum to the squamous epithelium of the skin at the pectineal line.  
Due the different nature of its epithelium, the anus possesses pathology that is specific to itself 
and quite different to that of the colon and rectum, especially when considering carcinogenesis, 
and thus is outside the remit of this thesis. 
 




The blood supply to the colon and rectum is primarily comprised of terminal branches of the 
superior mesenteric artery (which also supplies the majority of the small bowel) and the inferior 
mesenteric artery, both of which originate from the abdominal aorta.  Classically, the watershed 
between these two arterial systems is defined as the transition from mid-gut to hind-gut, two 
thirds of the way across the transverse colon where the marginal artery forms an arcade 
connecting the two.  A third arterial supply is also provided by the middle and inferior rectal 
arteries, which are terminal branches of intermediate arteries originating from the internal iliac 
artery.  The venous drainage of the colon and rectum reflects the arterial in its peripheral 
distribution, but instead of returning blood to the systemic circulation directly, blood is diverted 
through the liver first via the portal venous system.  The exception to this is in the low rectum 
where the haemorrhoidal veins return venous blood to the systemic circulation directly via the 
internal iliac veins.  The lymphatic drainage mirrors the arterial system and comprises the 
superior and inferior mesenteric lymph node chains, which themselves drain to the pre-aortic 
nodes at levels corresponding to the origin of the arteries. 
 
As well as absorbing water and forming and storing stool, the colon and rectum allow the 
bacterial fermentation of residual organic matter and act as a reservoir of bowel flora; the 
colorectal microbiome.  Although the colon does not play an active role in absorption of 
nutrients, it does however absorb some of the products of bacterial fermentation, importantly 
fat-soluble vitamin K, a key factor in blood coagulation and calcium metabolism.  Beyond 
fermentation, the colorectal microbiome is attracting significant interest as a potential factor in 
cancer and other (particularly inflammatory) processes in the large intestine, both from a 




1.1.2 Epidemiology of Colorectal Cancer 
Colorectal cancer (CRC) is a highly prevalent cancer in Western societies, with approximately 
140,000 new cases and 52,000 deaths (estimated) in the United States in 20184.  In the UK the 
figures are 42,000 and 16,000, respectively5.  Globally CRC is the third most common cancer 
in men (10.0% of total cancer) and the second most common cancer in women (9.2% of total 
cancer).  Approximately 45% of those diagnosed die of the disease despite treatment6.  The 
overall lifetime risk of developing colorectal cancer is 1 in 22 (5.5%) for men and 1 in 24 
(5.15%) for women in the United States, although incidence is highly variable internationally.  
The incidence of CRC per 100,000 ranges from 4.1 (India) to 49.1 (Czech Republic) in men, 
and from 3.9 (India) to 39.5 (New Zealand) in women, with broadly higher incidence in North 
America, Europe (including ex-Soviet nations), and Oceania, and lower incidence in South 
America, Africa, and Southern Asia7.  Although incidence had generally remained consistent 
in most developed nations, mortality is slowly declining, although this is primarily observed in 
long-industrialised nations with developed healthcare systems (Figure 1.1 a-d). 
 
Although the incidence of CRC is highest in older populations (median age at diagnosis is 70 
years), it may affect any age, although is uncommon under the age of 50 years.  The increased 
risk of CRC in later life is the primary factor in the design of the national bowel screening 
programme in the UK, which offers screening in the form of faecal occult blood testing to both 
men and women over the age of 60 years, or a one-off colonoscopy to those of 55 years 
(regional variation dictating).  The age at which screening begins is however under current 
review and is likely to decrease to 50 years in the near future.  Screening ceases at 74 years of 
age.    By 2012, the UK screening programme had identified almost 15,000 cancers, of which 
a significantly higher proportion were found at an earlier stage than in the un-screened 
population8.  Uptake of screening is generally good (approximately 55%), and an up to 18% 







Figure. 1.2  Incidence (a & b) and mortality (c & d) of CRC (male and female) – selected 
countries.  WHO International Agency for Research on Cancer: Global Cancer Observatory 
(http://gco.iarc.fr ) (accessed 28th August 2018). 
a.       b. 
 
 





c.       d. 
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1.1.3 Aetiology of Colorectal Cancer 
The primary unmodifiable risk factor in CRC is age; the median age at diagnosis being 70 years 
in Western societies10.  The association with increased age is due to cumulative generalised 
DNA and cell damage that occurs during ageing, although specific aberrations at the genomic, 
epigenomic, transcriptomic, and other mechanistic levels are constantly being hypothesised, 
tested, and proposed.  Colorectal cancers affecting younger patients are more frequently 
encountered in the hereditary cancer syndromes, which account for 2-5% of all CRC11.  These 
syndromes are frequently characterised by the presence of polyps and are associated with 
highly penetrant inherited mutations and clinical syndromes, such as Lynch syndrome, familial 
adenomatous polyposis, MUTYH-associated polyposis, and hamartomatous polyposis.  The 
detection of such syndromes through familial screening, given the high risk of CRC, frequently 
prompts prophylactic colectomy, although a significant proportion present sporadically12.  As 
well as the small percentage of hereditary CRC associated with specific syndromes, it is 
estimated that a further 20-30% of CRC is linked to heritable mutation(s), although the loci are 
not characterised13. 
 
A further significant non-modifiable risk factor for the development of CRC is inflammatory 
bowel disease (IBD: Crohn’s and ulcerative colitis), although the incidence has been reducing 
in recent years.  The pathogenesis of CRC in IBD is due to chronic inflammation of the colon 
and rectum, and thus anti-inflammatory therapies for IBD are effective at reducing the lifetime 
risk of developing cancer.  Correspondingly, the severity of inflammation, length of exposure, 
and extent of colitis are all positively correlated with risk of CRC14.  For ulcerative colitis the 
incidence is approximately 3 cases of CRC per 1000 patient-years (0.3% annually), 
corresponding to approximate risk of 2%, 8%, and 18% at 10, 20, and 30 years disease-
exposure, respectively15.  The corresponding risk in Crohn’s disease is 3%, 5.5%, and 8%, 
respectively16. 
 
Beyond non-modifiable risk factors, it is estimated that 54.3% of CRC is preventable due to 
population-level exposure to numerous modifiable risk-factors17.  Foremost amongst these 
factors are smoking, obesity, lack of dietary fibre, and consumption of red/processed meat; 
contributing 6.8%, 11.5%, 28.0%, and 12.5% to the excess cancer burden, respectively, based 
upon a population attributable fractions analysis.  Alcohol (dose dependent18), ionising 
radiation, and insufficient exercise contributed smaller but measurable effects.   
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The risk of developing CRC from smoking is directly proportionate to the number of cigarettes 
smoked per day, the number of years an individual has smoked, and the pack-year metric; and 
is measurable as a relative risk (RR) based on meta-analysis as 1.20 (95% confidence interval 
(CI): 1.10-1.30), compared to never-smokers.  The effect is greater in men than women (RR 
1.38 vs 1.06) and is persistent following cessation of smoking19.  Smokers (RR 1.26) and 
former-smokers (RR 1.11) also suffer a significantly higher all-cause mortality following a 
diagnosis of CRC compared to never-smokers, based on a random effects hazard ratio model20. 
 
Obesity (BMI ³30), and to a lesser extend overweight (BMI ³25.0-29.9), are independent risk 
factors for CRC, especially in men.  Of particular concern is visceral/abdominal obesity, where 
each increase in BMI of 1 kg/m2 infers an increased risk (RR 1.03)21. Various mechanisms are 
suggested, including metabolic syndrome and the effects of insulin resistance, and 
dysregulating of adipocytokines.  Hand-in-hand with obesity, type-2 diabetes has also been 
demonstrated to show an increased risk of CRC (Hazard Ratio (HR) 1.26, CI 1.18-1.33), with 
risk increasing with duration of risk-exposure22.  
 
The role of dietary fibre in reducing the risk of colorectal cancer has long been the subject of 
speculation, and a number of mechanisms have been postulated, including bulking and dilution 
of luminal toxins, decreased transit time, and short-chain fatty acid metabolism of fibre by the 
microbiome, amongst others23.  A meta-analysis of dietary fibre intake and risk of developing 
CRC demonstrated that there was an inverse correlation between increased fibre intake and 
risk, and that this correlation was dose dependent (10% RR reduction per 10g/day total dietary 
fibre)24.  The effects were observable for total dietary fibre, wholegrain fibre, and cereal fibre, 
but no association was discernible with fibre sourced from fruit, vegetables, or legumes.  The 
authors of this interesting analysis suggest that the bulking and decreased transit time 
associated with cereal fibre may be causal in this relationship, although they do admit that there 
is likely to be an element of confounding due to the insulin-sensitising and excess-weight 
preventing effects of a high-fibre diet. 
 
Consumption of red (fresh) and processed meat is associated with an increased risk of 
developing CRC, although the data is somewhat heterogeneous25.  In a recent meta-analysis, 
consumption of one portion of processed red meat per day was associated with a pooled 
increase in CRC risk (HR 1.15, CI 1.01-1.32), but this increased for tumours located in the 
distal colon and rectum (HR 1.36, CI 1.09-1.69)26.  Interestingly, the data for fresh red meat 
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suggested a reduced risk of distal cancers (HR 0.75, CI 0.69-0.82), but a possible increased 
risk for proximal cancers (statistically non-significant).  Although the mechanism for these 
effects remains contentious, the addition of nitrates and nitrites in processed meat, and the 
increase in mutagenic heterocyclic amines caused by cooking (and especially burning) meat 
are proposed as the most likely mechanisms27, 28. 
 
1.1.4 Staging and Histopathological Standards in Colorectal Cancer 
Current standards for the staging of colorectal cancer are set by the American Joint Committee 
on Cancer (AJCC), 8th Edition29, 30, and were formally adopted for practice in the UK from 
January 2018 (the previous 2 editions having been bypassed due to lack of supporting 
evidence)31.  Broadly, tumours are staged dependent on their depth of invasion through the 
bowel wall (T stage), by lymph node spread (N stage), and metastatic spread (M stage).  A 
composite of these three scores (TNM) is then used to provide an overall Stage (I-IV), which 
is intended to stratify survival related to the disease.  The gold-standard for staging is 
histopathological examination of the resected tumour, although at different stages of the 
patient’s treatment staging may be performed using other modalities (such as MRI), or 
following therapies (such as neoadjuvant chemo-radiotherapy).  To aid in differentiating how 
staging has been performed a prefix may be added to the TNM system to indicate modality 
(e.g. p: pathological staging; c: clinical staging), or to indicate whether therapies have been 
applied (e.g. yp: pathological staging post chemo-/radiotherapy). 
 
Historically, the Dukes’ and Bussey Classification (Stages A-C) has been used to characterise 
the local and nodal extent of colorectal cancer, with the later addition of Stage D by Turnbull 
to denote metastatic spread32, 33.  This system is still advocated for use in parallel with the AJCC 
classification by the Association of Coloproctology of Great Britain and Ireland (ACPGBI) in 
their current (2017) guidelines for the management of cancer of the colon, rectum, and anus34. 
To aid in the classification of colorectal cancers it is important that strict standards are set in 
the reporting of histopathological specimens.  This is crucial not just in determining the extent 
of an individual’s disease, and therefore their management, but also for audit, research, and 
strategy for the local, national, and international management of colorectal cancer.  To this end 
a minimum-reported dataset is published by the Royal College of Pathologists (latest edition 
2017), setting standards for histopathological examination of resected specimens35.  As well as 
a macroscopic description of the tumour and the basic tumour characteristics that comprise the 
TNM classification system, the core dataset also includes information that may aid in 
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prognostic stratification, such as the degree of tumour differentiation, the presence of mucin, 
and extra-mural and peri-neural invasion.  Estimation of tumour regression following 
neoadjuvant therapy is also included in the minimum dataset (where appropriate) and is based 
upon the four-tier system (0-3) proposed by Ryan36.  Increasingly, genetic and molecular 
biomarkers are also employed in the characterisation of colorectal cancers, and routine testing 
for mismatch repair (MMR) status (see 1.3.4) (and subsequently BRAF V600 E and/or MLH1 
analysis) to distinguish sporadic cancers from Lynch Syndrome is now considered part of the 
core dataset for reporting colorectal cancers37.  Additionally, testing targeted at genes 
associated with response to EGFR therapies (KRAS and NRAS codons) may be performed in 
patients with metastatic colorectal cancers to identify those who may benefit from treatment38. 
 
1.1.5 Survivorship and Outcomes in Colorectal Cancer 
Survival following diagnosis and treatment for colorectal cancer is primarily dependent on the 
stage at which the cancer was diagnosed, with earlier stage cancers translating into improved 
survivorship; and is the premise of colorectal cancer screening programmes.  Approximately 
80% of individuals diagnosed with colorectal cancer undergo surgery39.  Data form the 
American Cancer Society suggest that the 5-year survival from Stage I colon and rectal cancer 
is approximately 92% and 88%, respectively, falling to 12% and 13% respectively for Stage 
IV cancer40.  This data is summarised in Table 1.1.  Patients who are elderly, present as an 
emergency, or have a high number of comorbidities are at an increased risk of dying compared 
to the background risk10, 41.  For patients with Stage III or high-risk Stage II disease, the addition 
of adjuvant chemotherapy to surgery increases 5-year survival across the population by 5%, 
although we currently lack the ability to predict which individuals will benefit.  Unfortunately, 
recurrence following treatment with curative intent in colorectal cancer is approximately 45%, 
of which only 5-10% of patients may be eligible for further “curative” surgery42.   
 
Beyond staging, the factors affecting the risk of recurrence are not well understood. Follow-up 
after treatment with curative intent is aimed at identifying recurrence early (especially lung and 
liver metastasis), and thus increasing the chances of surgical management or eliciting a better 
response to chemo- or immunotherapy.  The detection of metachronous tumours and polyps is 
also facilitated by follow-up, as well as providing psychological and social support to 
potentially vulnerable patients43.  There is some variation in the protocols for following-up 
patients, but a combination of CEA and CT-scanning at 6-monthly intervals initially, and then 
declining over time, is the mainstay of assessment, augmented with colonoscopy or other 
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imaging modalities where necessary44.  Recent meta-analysis has demonstrated that more 
intensive follow-up regimes have shortened the time to detection of recurrence by up to 10 
months, although this has so far failed to translate into statistically significant population 
survival benefit45.  Effective follow-up is also important for MDT and audit purposes, is key 
to delivery of many of these services in the Colorectal Clinical Nurse Specialist, and is 
reassuring for patients46.   
 
Table 1.1. 5-year survival following diagnosis of colon or rectal cancer, by AJCC Stage40. 
 
AJCC Stage I IIA IIB IIIA IIIB IIIC IV 
Colon 92% 87% 65% 90% 72% 53% 12% 





1.2 Treatment for Colorectal Cancer 
1.2.1 Surgery for Colorectal Cancer 
The primary therapy for colorectal cancer is surgery, with approximately 80% of patients 
diagnosed with CRC undergoing surgery with curative intent.  The surgical strategy employed 
is based upon the anatomical location of the tumour(s) and the associated lymphovascular 
package.  Segmental resection of the affected colon or rectum in association with its draining 
lymph nodes and vasculature reduces the local recurrence by excising the primary tumour plus 
any local macro- or micro-metastasis.  Broadly, tumours of the right colon require right 
hemicolectomy, tumours of the left colon a left hemicolectomy or sigmoid colectomy, and 
tumours of the rectum an anterior or abdominoperineal resection. For metachronous tumours 
affecting the left and right hemicolons, or where a heritable or sporadic pro-carcinogenic field-
change in the colonic mucosa is suspected or proved, excision of larger portions of or the whole 
colon (with or without the rectum) may be performed as a subtotal or total colectomy (or 
panproctocolectomy).  If a tumour has invaded structures/organs beyond the normal plane of 
excision (T4), these may be amenable to resection en bloc.  In the majority of cases, following 
resection of the affected colon or rectum, an anastomosis may be formed between the remaining 
proximal and distal bowel in order to restore gastrointestinal continuity, although a temporary 
or permanent ostomy may be constructed depending on a number of technical or patient factors. 
 
Although the enduring principles of surgery for colonic cancer were laid down by Cuthbert 
Duke and Lockhart-Mummery at St Marks Hospital in the 1950’s, and standards for rectal 
cancer surgery by Heald in 1982 in Basingstoke, recent advances in technique and 
perioperative management have improved outcomes for patients.  Enhanced recovery after 
surgery (ERAS) programmes have been demonstrated to be safe and effective in reducing 
perioperative morbidity and reducing the length of hospital stay following surgery47.  The 
administration of carbohydrate-rich drinks immediately prior to surgery has also been shown 
to reduce insulin resistance and facilitates gastrointestinal recovery48.  The role of mechanical 
bowel preparation is still controversial, but a growing body of evidence suggests that it is 
unnecessary in the majority of situations, with rectal resection and the formation of a (low) 
colo-rectal anastomosis being the possible exception49, 50.  However, as the role of the 
colorectal microbiome becomes better understood, and intraoperative fluorescence 
technologies become more widely adopted, the role and nature of mechanical (or microbiomal) 
bowel preparation will likely change51, 52. 
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Laparoscopic techniques now have an accepted role in surgery for CRC.  Laparoscopic 
resection of colonic cancers has been demonstrated to be equivalent to open resection in terms 
of R0 resection rate and nymph node harvest, but superior in terms of length of hospital stay, 
post-operative pain, wound healing, wound infection, blood loss, and risk of incisional hernia. 
The Association of Coloproctology of Great Britain and Ireland (ACPGBI) guidelines for the 
surgical management of colorectal cancer support the implementation of laparoscopic 
techniques in all suitable cases (recommendation grade A)53.  The case for laparoscopic surgery 
in rectal resection is less well evidenced.  Although many of the same short-term advantages 
of laparoscopy may be apparent as for colonic resection, the ALaCaRT and ACOSOG Z5061 
trials failed to demonstrate non-inferiority of laparoscopic surgery compared to open for core 
pathological criteria54, 55.  Despite these rather disappointing findings, the data is deemed 
insufficiently significant to prevent the application of laparoscopic techniques to rectal 
resection, and the ACPGBI support its implementation (recommendation grade B)53. As yet, 
there is no substantial evidence to support the use of robotic surgery in either routine colorectal 
cancer surgery or selected challenging rectal cancer cases, although long-term outcome data 
still awaited56. 
 
1.2.2 Emergent Surgical Strategies for Rectal Cancer 
Surgery for rectal cancer is increasingly being considered as a highly sub-specialised practice 
within general colorectal surgical practice.  The challenges of operating on the rectum due to 
the confines of the bony pelvis and close proximity of significant neurovascular structures (e.g. 
iliac vessels and major branches, sciatic and obturator nerves) and other organ systems (e.g. 
male or female urogenital systems) requires specialist expertise and increasingly specialised 
techniques.   
 
For large polyps and early cancers (T1 and early T2) transanal techniques such as transanal 
endoscopic microscopic surgery (TEMS) and transanal minimally invasive surgery (TAMIS) 
have increased the options available for surgical excision and organ preservation57, 58.  
Currently there is no consensus regarding whether one technique is superior to the other due to 
a lack of controlled trials and limited adoption, but early outcomes suggest that either technique 
is oncologically acceptable compared to traditional rectal excision59, 60.  For patients with more 
advanced disease that require formal rectal resection, but who may be predicted to be 
operatively challenging due to a low tumour position, narrow (usually male) pelvis, or obesity, 
a transanal total mesorectal excision (TaTME) may be performed with laparoscopic abdominal 
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assistance.  The aim of this technique is to perform the most challenging component of the 
procedure transanally, thus improving oncological resection and facilitating laparoscopic 
resection with the benefits of a faster return to GI function, shortening length of hospital stay, 
and lower postoperative morbidity61, 62.  Currently the evidence base for an advantage in 
performing TaTME is poor, although data submission to the centralised international registry 
is designed to alleviate this issue63, 64.   
 
Locally advanced rectal cancers (LARC) and locally recurrent rectal cancers (LRRC) pose 
additional challenges to surgeons as they extend beyond the planes of classical TME.  As 
successful surgery is dependent upon an R0 resection it is frequently necessary to resect 
adjacent structures that are not typically included in a standard rectal resection, either as partial 
composite resections (e.g. portions of the posterior wall of the vagina, sections of sacral nerve, 
or anterior table of sacral vertebrae), or as whole organs (e.g. total pelvic exenteration)65, 66.  
Evolving techniques in surgery (resectional and reconstructive), as well as improved 
perioperative care (physiotherapy, clinical psychology, etc) are driving advances to 
increasingly extensive resections67, 68.  Again, due to limited numbers of patients undergoing 
beyond-TME excisions for LARC and LRRC the evidence base is not strong, and thus 
international collaborative work is aimed resolving this deficiency69. 
 
The converse side of the management paradigm from exenteration is the possibility for organ 
preservation and watch-and-wait strategies, largely brought about due to advances in 
neoadjuvant therapies70, 71.  Up to 30% of patients treated with nCRT may experience a 
complete pathological response (pCR) and benefit from a watch-and-wait strategy of no-
surgery and close observation, and for those who do not undergo pCR but do undergo 
downsizing/down-staging an organ preserving surgery such as TEMS or TAMIS may be 
appropriate72-74.  Currently, however, there is no reliable method of predicting which patients 
will respond to nCRT before it is administered and there is no level I evidence supporting a 
watch-and-wait strategy.   Many patients will not respond or progress during nCRT treatment, 
some becoming technically inoperable or medically unfit for surgery, and for those who do 
have a good response there is much debate as to the best interval between therapy and surgery75.  
The current basis for predication and assessment of response is MRI, although PET-CT and 
endorectal ultrasound (ERUS) also have a role36.  Additional tumour and patient factors 
including new molecular means of stratification of risk and response are being sought76, 77.   
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1.2.3 Chemotherapy for Colorectal Cancer 
Chemotherapy has three roles in the management of colorectal cancer; prior to surgery to 
increase the operability of tumours and outcomes following surgery (neoadjuvant 
chemotherapy), following surgery with curative intent to reduce the chance of recurrence 
(adjuvant chemotherapy), and in the metastatic or palliative setting.   
 
The role of neoadjuvant chemo-radio therapy (nCRT) in rectal tumours where the resection 
margin is threatened or breached is established78-80.  Data from the FFCD 9203 trial 
demonstrated that local recurrence rates were halved from 16.5% to 8.1% (p<0.05) and pCR 
improved from 3.4% to 11.6% (p<0.05) with the addition of neoadjuvant chemotherapy to 
radiotherapy, although overall 5-year survival was not improved79.  However, the NSABP R-
03 trial demonstrated that an improvement in DFS was achievable, with trend towards 
increased OS81.  There is currently a degree of variation between guidelines for administration 
of nCRT, although long-course 5-fluorouracil (5-FU) or capecitabine neoadjuvant 
chemotherapy combined with radiotherapy (45-50.4 Gy) is the basis of most protocols.  
Patients deemed at lower risk or unsuitable for long-course therapy may be offered short-course 
protocols based on local guidance, although PCR rates are lower in this group82.  The role of 
adjuvant CRT following nCRT is contentious, especially given the EORTC 22921 trial of over 
one thousand patients, where no DFS or OS advantage was observed with the addition of CRT 
following neoadjuvant therapy83.  Currently there is no role for neoadjuvant chemotherapy for 
the management of colon cancer, although this is the subject of ongoing clinical trials led by 
the FOxTROT Collaborative84.  Early outcomes from this study suggest that for locally 
advanced but operable colon cancers (T3/4), neoadjuvant chemotherapy and sensitivity-
specific immunotherapy improves 2-year recurrence rates (personal communication – 
unpublished). 
 
Adjuvant chemotherapy for colorectal cancer should be offered to all patients with high-risk 
Stage II and all Stage III disease who have undergone surgery with curative intent to reduce 
the chance of local and systemic recurrence85.  The current guidance offers a choice of a six-
month course of capecitabine as monotherapy, or folinic acid with 5-FU and oxaliplatin 
(FOLFOX), to begin within six weeks of the date of surgery86.  A pooled analysis of 
randomised trial data for both regimes (including DFS as well as relapse-free survival (RFS)) 
indicates an increase in DFS at 5-years from 42% to 58%, and an increase in OS from 51% to 
64%, compared for surgery alone for stage III colon cancer.  The same regimes are employed 
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for high-risk stage II and stage III cancers of both the colon and rectum, despite the majority 
of evidence pertaining to stage III colon cancers.  The choice between regimes is determined 
between the patient, clinician, and local protocols, as there is not significant evidence for 
superiority between regimes on either a clinical effectiveness or cost effectiveness analysis, 
although the primary cited evidence is limited to only three trials (X-ACT, MOSAIC, and 
NSABP C-07)87-89. Capecitabine is a precursor of 5-FU and can be administered orally in tablet 
form or by intravenous infusion.  Its primary mechanism of action is as an inhibitor of 
thymidylate synthase and thus preventing the synthesis of thymidine; a nucleotide required for 
DNA replication.  As this action is not cancer-specific other rapidly regenerating tissues such 
as the normal gastrointestinal mucosa may be affected, resulting in common side effects such 
as diarrhoea, abdominal pain, nausea and vomiting, and mucositis.  More rarely hand-foot 
syndrome and myelosuppression may occur.  Each of these side-effects may be dose-limiting, 
and administration is contraindicated in myelosuppression and severe hepatic or renal 
impairment.  Oxaliplatin is a platinum-based agent administered by intravenous infusion that 
prevents DNA replication by causing DNA cross-linking.  As well as myelosuppression and 
gastrointestinal side-effects, the most common side-effect of oxaliplatin is peripheral 
neuropathy, which may have a cumulative effect over the course of multiple administrations.   
The chemotherapy treatment options for patients with locally advanced and/or metastatic 
colorectal cancer, whether potentially operable or not, are multiple and therefore local 
protocols and patient preference determine practice85.  First- and second-line regimes combine 
FOLFOX protocols with irinotecan as a single agent or in combination with 5-FU (FOLFIRI).  
Capecitabine and oxaliplatin in combination may also be used as a first-line therapy, followed 
by FOLFIRI.  Irinotecan is a plant-derived cytotoxic alkaloid that inhibits both DNA 
replication and transcription by interference with the topoisomerase-1 enzyme, which is 
responsible for regulating DNA double-helix winding during these processes. For patients 
intolerant of 5-FU based regimes raltitrexed may also be considered, its action similarly 
focused on thymidylate synthase although by a different action and having a different side 
effect profile90.  Tegafur (a 5-FU pro-drug) is also licensed for use as a first-line therapy in 




1.2.4 Biological Therapies for Colorectal Cancer 
Patients with metastatic colorectal cancer may benefit from monoclonal antibody (mAb) 
therapy if they over-express epidermal growth factor receptor (EGFR) and are (K)RAS 
(Kirsten RAt Sarcoma oncogene) wild-type91.  Both cetuximab (chimeric m-IgG1) and 
panitumumab (human recombinant m-IgG2) act by specifically binding EGFRs and blocking 
the activating ligand, thus inhibiting activation of tyrosine kinase and a cascade of intracellular 
signalling pathways that promote DNA synthesis and cell proliferation.  Both agents in 
combination therapy with FOLFOX have been shown in clinical trials (OPUS and PRIME) to 
be superior to FOLFOX alone in terms in improved PFS and OS, although the numbers of 
patients benefiting from therapy were more modest than anticipated based on RAS status92, 93.  
One possible reason for mAb therapy response to correspond poorly to RAS status is the 
discovery of an increasing number of RAS mutations that are outside the standard analysis 
(RAS G13D and NRAS, for example), thus leading to unexpected EGFR therapy resistance.  
These findings have affected several recent trials and may steer management towards a smaller 
proportion of patients being eligible for mAb therapy, but with a higher response rate94. Two 
further mAb, bevacizumab and aflibercept, which are targeted towards the vascular endothelial 
growth factor receptor (VEGF), have also reported outcomes that do not indicate superiority to 
more conventional regimes and are thus not recommended by NICE for patients with metastatic 
CRC, although they remain licensed95-98. 
 
1.2.5 Radiotherapy for Colorectal Cancer 
Radiotherapy in the context of colorectal cancer is predominantly focused on the neoadjuvant 
treatment of locally advanced or locally recurrent rectal cancer65.  Long-course neoadjuvant 
chemoradiotherapy (CRT) has been the established preference for T3/4 N1/2 rectal cancers for 
over 20 years, and in association with TME offers the best chance of complete excision and 
increases OS & DFS81, 99.  Strategies aimed at increasing the dose and accuracy of pre-/intra-
operative radiotherapy have been trialled, notably in the form of rectal brachytherapy and intra-
operative radiotherapy, although results have not been conclusive and currently these practices 
are largely confined to trials100-102.  There is however a shifting attitude towards radiotherapy 
for LARC with the advent of increasingly effective chemotherapy and immunotherapy 
regimes103.  One possibility is that chemotherapy alone may be as effective as CRT, and thus 
negate the requirement for radiotherapy altogether, theoretically reducing the risk of poor 
wound healing, anastomotic breakdown, and more challenging operating planes, and is the 
subject of the ongoing PROSPECT trial104.  Another perspective is that radiotherapy should be 
 31 
applied in the neoadjuvant setting only after neoadjuvant chemotherapy has been administered 
and had an opportunity to cause tumour involution; a methodology referred to as induction 
chemotherapy.  This approach is currently undergoing investigation in a number of different 
trials, including the E-LARC Study and UK BACCHUS trial105, 106.  Radiotherapy may also be 
employed in the palliative setting, especially where symptoms such as per-rectum bleeding are 
distressing to patients, or for LRRC where the pelvis has not previously been irradiated. 
 
1.2.6 Associated Therapies in Colorectal Cancer 
In addition to surgery and clinical- and medical-oncological therapies, a range of other 
strategies may be employed to treat CRC.  Colonic stents are becoming an increasingly 
versatile tool in combating colorectal cancer, especially in the frail and elderly, palliative, or 
emergency setting (up to 20% of presentations) as a bridge to definitive therapy.  Early 
outcomes form the CReST trial found that mortality and length of hospital stay were no 
different between emergency surgery and stent groups, but that the rate of permanent stoma 
formation was significantly lower in the stent group (45% vs 69%, p<0.001)107.  Oncological 
outcomes are awaited.  The Enhanced Recovery After Surgery (ERAS) programme has also 
helped deliver improvement in perioperative care, especially with respect to facilitating a 
reduced time to normal gastrointestinal function, early return to mobility, and reduced length 
of inpatient admission.  These improvements have been won by standardising care as much as 
possible, improving patient education, early enteric feeding, reducing unnecessary drain and 
nasogastric tube use, early mobilisation, optimising perioperative pain management, and 
auditing of practices47.  Carbohydrate loading, optimisation of the use of blood products, 
advanced stoma care, and venous thromboembolism prophylaxis (VTE) are also important 




1.3 The Genetic & Genomic Basis of Colorectal Cancer 
1.3.1 The Vogelstein Model 
The development of sporadic colorectal cancer has long been considered as a step-wise 
progression along the adenoma-to-carcinoma pathway, and the genetic processes underlying 
this sequence were formulated by Vogelstein108, 109.  The basis of this model is that sequential 
mutation in the adenomatous polyposis coli (APC) gene, and subsequent KRAS and TP53 
mutations leads to increasing adenomatous changes in the colonic mucosa, resulting in polyps 
and eventually to dysplasia and invasion.   
 
The first sequence in this pathway is brought about by APC mutation and subsequent 
dysregulation of the Wnt/b-catenin canonical signalling pathway.  APC mutation leads to 
inappropriate intracellular accumulation of b-catenin due to inactivation of the destruction 
complex, resulting in activation of transcription factors governing the cell cycle.  Mutations in 
this pathway are detected in up to 90% of sporadic colorectal cancers, and specific autosomal-
dominant inherited mutations in APC are responsible for familial adenomatous polyposis 
(FAP)110.  Secondly, KRAS is a proto-oncogene that regulates the cell cycle by activating 
growth factors, cell signalling, and glucose transportation via the MAPK-pathway.  When 
mutated, deactivation and subsequent negative-signalling is disrupted leading to increased 
signalling and uncontrolled cellular proliferation111.  The important role of KRAS in CRC 
therapy is underscored by its impact on the efficacy of EGFR immunotherapies as discussed in 
Section 1.2.4, although the relatively high proportion of patients with advanced cancers who 
are KRAS wild-type demonstrates that it is not a necessary mutation in the classical pathway.  
Thirdly, the role of the heterozygosity in TP53 gene (and its related protein p53) is established 
in tumour suppression, where its acts to stimulate DNA repair, arrest the cell cycle, initiate 
apoptosis, and moderate telomere response. Loss heterozygosity is associated with a number 
of different cancers, including CRC (also breast, endometrial, and renal tumours), although the 
association with mutation and risk of cancer is not linear112, 113.  However, in the colorectal 
adenoma to carcinoma pathway, loss of TP53 function is detected in approximately 25% of 
adenomas with no adverse features and 50% of adenomas with foci of invasion, underlining its 
likely causative contribution to carcinogenesis114. Additional mutations in PIK3CA (a 
phosphorylation-related kinase oncogene) and allelic deletion of segments of chromosome 18q 
encoding the DCC (deleted in colorectal carcinoma) gene (tumour suppressor) cumulatively 
drive carcinogenesis as a core set of oncogenic mutations115. 
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Figure 1.3 The multi-step genetic model of colorectal carcinogenesis (adapted from Pino, et. al.)115. 
 
 
These cumulative genetic insults are thought to underlie many colorectal cancers, although due 
to the relatively short lifespan of individual colorectal mucosal cells and the low background 
rate of mutation, the likelihood of any single cell developing the multiple mutations required 
to undergo carcinogenic change is limited.  What underlies the accelerated process of mutation, 
therefore opening the opportunity for multiple tumourigenic transformations, is loss of 
genomic stability116, 117.  There are several processes thought to underlie the development of 
genomic instability, each of which may contribute to malignant transformation, but in the 
context of CRC the primary factors are microsatellite instability (MSI) and chromosomal 
instability (CIN)118. 
 
1.3.2 Key Signal Transduction Pathways in CRC  
Several key signal transduction pathways play an important role in CRC carcinogenesis, and 
are implicated in the Vogelstein and other models of cellular dysregulation. Although 
frequently presented as isolated pathways, these signal transduction pathways are in fact 
complex webs that govern cellular homeostasis; controlling vital processes such as cellular 
proliferation, apoptosis, cell-cell adhesion, and metabolism.  The primary genes/proteins 
governing signal transduction pathways in CRC are APC/b-catenin, EGFR, KRAS, and BRAF.  
A schematic representation of these pathways and their interdependent relationships is 
demonstrated in Figure 1.3. 
Activation of Wnt signalling through APC mutation, typified by the germline mutations that 
define FAP, is an important initiator of CRC carcinogenesis108.  APC dysfunction is identified 
in 70% of CRC, and has widespread intracellular effects, including regulation of cellular 
proliferation, differentiation, apoptosis, and chromosomal segregation, although its primary 
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pathological effect when dysfunctional is to increase cytoplasmic and nuclear b-catenin and 
thus drive cell proliferation and invasion through activation of T-cell factor/lymphoid enhancer 
factor (LEF) transcription factors119, 120.  Downstream tumourigenic effects of increased LEF 
activity are modulation of tissue remodelling via the urokinase receptor, plasminogen 
activation system, and tight-junction proteins120. 
The epidermal growth factor receptor (EGFR) is a transmembrane protein which acts as a 
receptor for extracellular ligands, binding of which modulates intracellular signalling cascades 
that are intimately associated with cell proliferation, adhesion, and  migration121.  As discussed 
previously, EGFR has a role in the biologic therapy of colorectal cancers, the efficacy of which 
may be determined by KRAS and BRAF mutation.  Modulation of EGFR activity, its 
downstream signalling pathway, and other associate genes is an active research area for novel 
chemotherapeutics122-124. 
The KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) gene encodes a small GTPase that 
is primarily involved in regulating cell division, acting as an on-off switch for intracellular 
signal transduction via both vertical (nuclear-directed) and horizontal (cytoplasmic) pathways.  
The role of KRAS in CRC has long been established and forms a central tenet of the Vogelstein 
model of carcinogenesis109.  When mutated, the negative (inhibitory) effects of the RAS are 
lost, allowing cell proliferation and inhibition of apoptosis.  KRAS mutations are very common 
in colorectal cancers (35-40%), especially those located in the proximal colon, and form a 
distinct morphological subset associated with polyps, mucin formation, and MSI125, 126. As 
discussed in Section 1.2.4, KRAS mutations are important in determining the sensitivity of 
CRC to biologic therapies 
BRAF is a gene located on chromosome 7q34 that encodes a 94 kDa protein called 
serine/threonine-protein kinase B-Raf, which acts as the common lead point for the RAS-RAF-
MEK-ERK-MAP kinase signalling pathway [modulated by PKC as well as RAS]127.  As well 
as being associated with a poor prognosis in CRC, BRAF mutations are also associated with 
15% of all human cancers, as well as some birth defects128.  Activation of proto-oncogenes, 
particularly those associated with apoptosis and programmed cell death, underlies BRAF’s role 
in carcinogenesis, and may be associated with CIMP, particularly in the frequently encountered 
BRAFV600E mutant129, 130.  BRAF-dependent signalling is also a potential therapeutic target 
in cancers, with successful biologic therapies having been developed for treatment of 
melanomas131.  Currently, there are no specific therapies directed against this pathway for 
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BRAF-mutant CRC, although the role of biologic agents for metastatic CRC is being 
explored132, 133. 
 
Figure 1.4  Schematic representation of APC, EGRF, KRAS, and BRAF signal transduction 







1.3.3 Tumour Suppressors - TP53 & 18q 
TP53 is a gene located on the short arm of chromosome 17 that codes for a corresponding 
protein (p53) which has a critical role in tumour suppression.  The majority of mutations are 
missense mutations that occur in a number of common loci; leading to inactive and long-lived 
proteins.  In response to a wide range of signals, including oxidative stress, DNA damage, and 
abnormal intracellular signalling (including RAS), p53 coordinates a multitude of cellular 
actions by initiating the transcription of genes associated with cellular metabolism, apoptosis 
(especially caspase regulation), cell cycle regulation, immunological signalling and response, 
and cell differentiation135.  p53 mutations are widely reported in human cancers, and are present 
in at least 70% of invasive CRC, as well as 25% of adenomas and 50% of polyp cancers, 
indicating the early and likely necessary contribution to CRC formation114.   
 
Approximately 70% of CRC demonstrate allelic loss at chromosome 18q, although the 
suspected tumour suppressor genes located here have not been demonstrated to be common in 
CRC136.  Examples of such genes are the unfortunately named Deleted in Colorectal Cancer 
gene (DCC), which is only found in 6% or tumours, and the SMAD2 (20% of tumours) and 
SMAD4 (10% of tumours) genes involved in TGF-b signalling137, 138.  Loss of heterozygosity 
of the Cables gene, which is located on chromosome 18q, has however been associated with 
colorectal cancer (70% LOH), although its role in carcinogenesis is not well defined139. 
 
1.3.4 Microsatellite Instability & Mismatch Repair  
Microsatellite Instability (MSI) describes a situation linked to defective mismatch repair 
(MMR) where repeating motifs of non-coding DNA are introduced during the S-phase of DNA 
replication, leading to cells demonstrating a high degree of mutability140.  Mutations may take 
the form of single base substitutions or short insertions or deletions, which are accumulated 
over time to form multiple-repeated motifs known as microsatellites (typically 1-6bp, repeated 
up to 50 times).  The most common microsatellite in human DNA is the dinucleotide repeat of 
cytosine and adenine (i.e. CACACACACACACA…), leading to a frame-shift mutation in the 
daughter strand of DNA and subsequent protein inactivity141.  International standards for the 
diagnosis and classification of MSI were developed by international consensus and depend on 
a panel of five validated microsatellites for clinical and research use142.  Tumours may be 
classified as MSI-high (MSI-H), ³ 2/5 microsatellites; MSI-low (MSI-L), 1/5 microsatellites; 
or MSI-stable (MSI-S), £ 1/5 microsatellites but dependent of further characterisation.   
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Approximately 15% of CRC express MSI (12% sporadic, 3% Lynch syndrome); 
predominantly due to defects in the mutL homologues (MLH1 & MLH3) and mutS 
homologues (MSH2, MSH3, MSH6) involved in MMR143.  CRCs expressing a high degree of 
MSI (MSI-H) have a slightly better prognosis compared to those with an MSI stable or low 
(MSI-S / MSI-L) phenotype144.  Autosomal-dominant inherence of mutations in MMR genes 
(primarily MSH2, MLH1, and MSH6) characterises Lynch syndrome (Hereditary Non-
Polyposis Colorectal Cancer – HNPCC), a heritable CRC syndrome which carries an 80% 
lifetime risk of CRC145.  MSI is also associated with hypermethylation, particularly CpG island 
methylations phenotype high (CIMP), often affecting MMR genes such as MLH1, leading to 
silencing146. This form of genomic instability is most commonly associated with the serrated 
pathway and BRAF mutations that are more commonly observed in the right colon, although 
many of the gene mutations are shared with the classical adenomatous pathway found 
throughout the colon and rectum.  Where this sub-type of tumour is found within the rectum it 
may represent a less favourable molecular subtype125, 147-150. 
 
1.3.5 Chromosomal Instability (CIN) 
CIN is a process where portions of chromosomes are either deleted or amplified 
asymmetrically, leading to an asymmetric distribution of DNA on mitosis and subsequent 
aneuploidy of daughter cells.  It should be noted that errors in chromosomal distribution during 
mitosis are common in normal tissues (approximately 1%), so for criteria to be met for CIN an 
aneuploidic mitosis must occur in at least 20% of divisions151, 152.  This must be assessed based 
on an evaluation of a population of cells in reference to a standard population, rather than 
observations of individual cells without reference.   CIN results from mutations affecting 
several processes:  Chromosome segregation defects, typified by anaphase promoting 
complex/C dysfunction as a result of MAD (Mitotic Arrest Deficient) and BUB (Budding 
Uninhibited by Benzimidazoles) mutation; telomere dysfunction resulting in a failure of cells 
to naturally undergo senescence; and loss of DNA damage response characterised by loss of   
TP53 function115.   
 
CIN is present in up to 70% of sporadic CRC, although the methods of determining CIN and 
the subsequent differences in classifying CIN has led to some discrepancy across the body of 
literature, although CIN is generally determined as a binary feature of tumours (CIN-positive 
or CIN-negative)153, 154.  However, the cellular processes that underlie CIN are not mutually 
exclusive of those that drive MSI and CIMP, and thus a proportion (up to 25%) of CRC will 
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demonstrate an overlapping picture of CIN and MSI155.  CIN-positivity is associated with a 
worse outcome in CRC; meta-analysis demonstrating higher hazard-ratios for later stage and 
decreased progression-free survival for CIN-positive tumours156.  The specific cellular 
pathways that lead to colorectal carcinogenesis are shared between the genomic aberrations; 
dysfunction in EGFR, BRAF, and KRAS are again implicated as the victims of CIN within the 
“mutator phenotype” population of cells that have developed intrinsic genomic instability157.  
The specific role of APC mutations in CIN is also significant; as APC is associated with 
microtubule and centrosome function in cytoskeletal regulation, and thus mitotic dysfunction, 
which itself leads to CIN158, 159.   
 
1.3.6 DNA Methylation & CpG Island Methylator Phenotype  
DNA hypermethylation and the CpG island methylator phenotype (CIMP) are another 
significant contributor to the genomic pathogenesis of colorectal cancer and is a key epigenetic 
mechanism for altering gene expression.  As previously discussed, CIN is present in 
approximately 70% of CRC and MSI-H in 15%, with an overlap of the two accounting for 
25%.  There are however a significant proportion of sporadic tumours that do not demonstrate 
either CIN or MSI, and of the tumours where CIN or MSI is demonstrated many do not have 
the classical Vogelstein mutations in APC, KRAS, and TP53160, 161.  The third genomic 
mechanism underlying CRC carcinogenesis is thought to be abnormal DNA methylation, and 
in particular CIMP.   
 
DNA methylation refers to the addition of a methyl group to the 5-position of cytosine in DNA 
by DNA methyltransferase (DNMT), to produce 5-methylcytosine (Figure 1.4)162, 163.  
Methylation is an active process and is performed by three DNMTs; DNMT1, DMNT3A, and 
DNMT3B, which are located on chromosomes 19, 2, and 20, respectively.  The DNMT family 
are structurally similar, although 3A and 3B have a slightly lower molecular weight of 100-
101kDa, whilst DNMT1 is 183 kDa.   Each shows a maximum efficiency for methylation of 
CpG dinucleotides, and especially islands that are hemi-methylated, although DNMT1 is the 
most efficient and acts as the primary de novo DNA methylator following DNA replication in 
cell division164.  Each uses S-adenosyl methionine (SAM) as a methyl donor.  An RNA 




The most frequent location for methylation of cytosine within DNA is at the CpG dinucleotide 
pairs that occur sporadically throughout the genome, of which 80-90% are normally methylated 
in humans.  Beyond sporadic CpG pairs, dinucleotide CpG islands (repetition motifs of greater 
than 200bp) also exist throughout the DNA (1-2% of total) but are not methylated in healthy 
cells.  These CpG islands are often found in the promotor regions of ubiquitously expressed 
proteins and are thought to facilitate efficient transcription.  When these regions become 
(pathologically) methylated, especially in the context of MSI, they are referred to as 
hypermethylated CpG islands and affected cells are said to express CIMP, although this process 
also occurs with ageing and does not always indicate carcinogenesis165.  Hypermethylation 
usually results in silencing of the downstream gene. 
 




Both hypo- and hypermethylation have a role in CRC carcinogenesis, although 
hypermethylation is understood to be the predominant process.  Global demethylation has been 
observed in CRC in the context of specific locus hypermethylation and in association with 
chromosomal instability, and thus a concept of methylation-redistribution has been proposed, 
although the hypothesis is contentious166-169.  The mechanisms that underlie hypermethylation 
gene silencing are not well understood, although interactions between aberrantly 
hypermethylated DNA and factors that inhibit transcription such as histone deacetylases and 
polycomb proteins are thought to dominate, as well as inhibiting pro-transcriptomic agents 
such as RNA polymerase II170.  These effects may be mediated by a relatively newly 
characterised group of proteins that express a common domain called the methyl-CpG-binding 
domain (MBD), which acts to facilitate inhibitory chromatin restructuring by recruitment of 
histone deacetylases171.  Irrespective of the mechanism, it is accepted that the hypermethylation 
of CpG islands in the promotor regions of a number of genes significantly associated with 
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CRC, including APC, p16INK4a, and TIMP3, is a genuine epigenetic event that contributes to 
carcinogenesis by gene silencing172-175. 
 
Unfortunately, there is no standard definition of CIMP, even within studies focusing on CRC.  
Early attempts focused on assessing panels of gene promotor regions that were chosen by 
candidate gene analysis, leading to the ‘classic’ panel of five loci as described by Park, and 
including a number of methylated in tumours (MINT) sites176, 177.  An alternative panel was 
later proposed by Weisenberger based on cluster analysis, and a further panel by Ogino which 
discriminated between high- and low-level methylation178-180.  As techniques have evolved 
further panels were proposed, although whole genome analysis has facilitated a wider 
understanding of the methylation status of CRC, and techniques in the field are still evolving181.  
Table 1.2 summarises previously proposed panels for assessing CIMP, with a brief note on 
their attributes and contribution. 
 
Table 1.2. Summary of CIMP panels and their differing attributes (adapted from Curtin)165. 
 
Study CIMP Panel Markers Note 
Toyota, et.al. 177 CDKN2A (p16), MINT1, MINT2, MINT12, 
MINT17, MINT25, MINT27, MINT31, 
MLH1, THBS1. 
Pioneering work to identify 
markers that distinguish CIMP 
from age-related methylation. 
Park, et.al. 176 CDKN2A, MINT1, MINT2, MINT31, 
MLH1. 
“Classic” or traditional panel. 
Weisenberger, et.al. 178 CACNA1G, IGF2, NEUROG1, RUNX3, 
SOCS1. 
“New” panel based on stepwise 
screen of 195 markers. 
Ogino, et.al. 162 CACNA1G, CDKN2A, CRABP1, MLH1, 
NEUROG1. 
Selected markers to distinguish 
high-level from low-level 
methylation. 
Shen, et.al. 182 CIMP1: MINT1, MLH1, RIZ1, TIMP3, 
BRAF mutation; CIMP2: MINT2, MINT27, 
MINT31, Megalin, KRAS mutation. 
Examined 27 CpG sites, proposed 
optimal epigenetic and genetic 
markers to identify CIMP1, 
CIMP2, or CIMP-. 
Tanaka, et.al. 183 CACNA1G, CDKN2A, CHFR, CRABP1, 
HIC1, IGF2, IGFBP3, MGMT, MINT1, 
MINT31, NEUROG1, p14, RUNX3, SOCS1, 
WRN. 
Correlation structures of markers 
and CIMP differ by KRAS and 
BRAF status. 
Ang, et.al. 184 202 CpG sites differentially methylated 
between tumour and normal. 
Comprehensive DNA methylation 
profiling in 807 cancer genes. 
Kaneda & Yagi 185 Group 1: IGF2, LOX, MINT1, MINT2, 
MINT31, MLH1, RUNX3, SOCS1; Group 2: 
ADAMTS1, DUSP26, EDIL3, ELMO1, 
FBN2, HAND1, IGFBP3, NEUROG1, 
RASSF2, STOX2, THBD, UCHL1. 
Comprehensive DNA 
epigenotyping of genome wide 
regions identified two groups 




Of the studies examining methylation panels Kaneda and Yagi is the most exhaustive, as a 
whole-genome approach to assessing CIMP status was undertaken by employing a two-way 
unsupervised hierarchical clustering method and quantitative methylation techniques185.   This 
study clearly demonstrated that CIMP status was clustered into three distinct groups (DNA 
methylation epigenotypes); CIMP-High(-H), CIMP-Intermediate(-I), and CIMP-Low(-L), 
with grouped methylation markers determining the classification of each epigenotype186.  The 
CIMP-H group was found to correlate strongly with BRAF mutation and MSI-high, and CIMP-
I with KRAS mutation, but that classification into each of the epigenotypes was independent 
of mutational analysis.  Of the three sub-classifications, CIMP-I with KRAS mutation 
demonstrated the poorest prognosis.  The loci used for the Kaneda and Yagi classification are 
outlined in Table 1.3, divided into those strongly associated with CIMP-H (Group1) and those 
with CIMP-I and -L (Group 2).  The epigenotyping system is described below. 
• CIMP-High if ³ 2/3 of Group 1 markers are methylated, irrespective of Group 2 
markers 
• CIMP-Intermediate if 1/3 Group 1 markers and ³3/5 Group 2 markers is methylated 
• CIMP-Low if £1 Group 1 markers is methylated and £2 Group 2 markers is methylated 
 
1.3.7 Other Epigenetic Factors 
Cytosine methylation is only one epigenetic factor influencing gene expression and 
physiological and pathological phenotype.  Another key epigenetic process governing gene 
expression is histone modification by protein methylation, phosphorylation, or other covalent 
processes; thus effecting chromatin structure187, 188.  There is increasing evidence that histone 
modification may be important in the pathogenesis of colorectal cancer, and several histone-
methylation enzymes (acetyltransferases and demethylases) have been associated with 
oncogenic or tumour-suppressor roles189.  As the process of histone modification is dynamic 
and modifiable it presents an opportunity for therapeutic intervention, although this avenue of 
therapeutics is in its infancy190, 191. 
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Table 1.3 Group 1 and 2 methylation markers for Kaneda and Yagi epigenotype classification. 
 








16p13 STAT induced STAT-inhibitor (suppressor of cytokine 
signalling – SOCS): negative feedback loop signalling in 
inflammatory cytokine pathways. 
MINT1 APBA-1, 
X11, IN10 
9q21 Member of the X11 protein family: believed to be 
involved in signal transduction pathways. 
hMLH COCA1, 
HNPCC2 
3p22 DNA MMR gene.  Part of the MutL-alpha complex.  








5q31 Interacts with CREB-binding protein as a transcription 
activating co-factor. Protein complex demonstrates 
histone acetyltransferase activity. 
THBD THRM, 
CD141 





5q33 Basic loop-helix-loop transcription protein found in 
myocardium and associated with vasculogenesis. 
ADAMTS1 METH1 21q21 Multimodular proteins demonstrating a variety of active 
domains including metalloproteinase activity, 
disintegrin-like domain, and thrombospontin type 1 
motif.  Inhibitor of tissue remodelling and anti-
angiogenesis. 
IGFBP3 IBP-3,  
BP-3 
7p12 One of six insulin-like growth-factor binding proteins; 
acts to transport IGFs and modulate interaction at cell 
surface and at nucleus.  High circulating levels associated 





1.3.8 Consensus Molecular Subtyping in Colorectal Cancer 
The process of carcinogenesis is now accepted to be an imbalance between the cell-cycle 
control mechanism and the development of mutations. Evolving from the Vogelstein model, 
three overlapping genomic and epigenomic pathways are implicated in genomic instability and 
the carcinogenesis process; chromosomal instability (CIN), microsatellite instability (MSI), 
and an epigenetic mechanism resulting from DNA hypermethylation called CpG island 
methylator phenotype (CIMP)161. The relationship between these mechanisms and the 
influence of the tumour inflammatory and immunological microenvironment is complex; and 
as a greater understanding of the transcriptomic pathways that influence the cancer cell 
phenotype is developed, the true complexity of CRC tumorigenesis is emerging118.   
 
One of the earlier molecular classifications for CRC that incorporated methylation status, as 
well as MSI, CIN, and histopathological characteristics was the Jass Classification161.  This 
system separated CRC into five categories that demonstrate a degree of overlap; broadly 
dividing the serrated from the adenomatous pathways, and splitting the total population 60%-
40% between CIMP-negative and CIMP-positive, and CIMP-positive further into 20% CIMP-
H and 20% CIMP-L.  Unfortunately, subsequent studies aiming to stratify cohorts of patients 
with CRC based on Jass’ classification and then to examine if there is a prognostic significance 
to the Jass phenotypes have failed both to adequately stratify patients based on the classification 
and have not demonstrated any significant prognostic implications.  The proportions of cancers 
defined by CIMP status in subsequent studies has also been variable, with Zlobec identifying 
an approximately 7%, 43%, and 50% split between CIMP-H, -I, and -L, and 41% of tumours 
not being able to be classified according to the Jass Classification192.  What was important 
about this early work, however, was that it introduced the concepts of different molecular 
pathways and classifications to CRC and provided a framework for their investigation161, 193. 
 
Subsequent studies, many of which were based on whole-genome sequencing and global 
methylation characterisation, proposed various molecular classifications for CRC and 
attempted to validate them against large clinical and pathological datasets (Table 1.4)194-201.  
Most of these systems have subsequently been abandoned due to failures in external validation, 
although components of each have been incorporated into and/or informed the subsequent 




Table 1.4  Molecular & Phenotypical Subtyping in Colorectal Cancer 
 
Study Classifications Primary Differentiators Note 
Jass, et.al.161 
2007 
Types I - V CIMP-H, -L, -Nil; 
MSS/MSI-L, MSI-H 
Types I & II associated with 
serrated pathway, IV & V with 
Vogelstein, III with either 
Perez-Villamil, et.al.197 
2012 
Clusters 1 - 4 MSS, MSI;  
Histology (mucinous);  
% stromal content; 
BRAF V600E 
Emphasis on the role of the 
tumour microenvironment to 




Types 1 & 2: 
subdivided into 
1.1, 1.2, 1.3, 2.1, 
& 2.2 
EMT (mesenchymal vs 
epithelial);  MSI, MSS; 
Pathway upregulation 
Demonstrated stratification 
across 74 immortalised cell lines 
and differentiation in response to 
in vitro therapies 
Budinska, et.al.194 
2013 
Types I – V MSS, MSI; BRAF 
V600E; p53; KRAS 
Division into typically crypt-like 
(upper & lower), CIMP, 
mesenchymal, or mixed 
expressional clusters  
De Sousa, et.al.195 
2013 
Types 1 – 3 CIN+ve, -ve; MSS, MSI; 
CIMP-H, -L 
Type 3 (MSS CIMP-H) 




Subtypes C1 – C6 Wnt; MSS, MSI; 
CIN+ve, -ve; KRAS 
Subtypes C4 (stem cell-like) & 
C6 associated with worse relapse-
free survival  
Sadanandam, et.al.199 
2013 
Subtypes 1 - 6 Wnt; Crypt location; 
MUC2 & TFF3; 
“Inflammatory” 
Subtypes reflect distinct normal 
crypt cell types and exhibit 
“stemness”. Response to 




Types A, B, & C BRAF V600E; EMT 
expression; MSS, MSI 
Subtypes may predict prognosis 
and response to chemotherapy 
Guinney, et.al.201 
2015 





of previous molecular & 
phenotypic studies 
Four streams of subtyping with 






Current consensus suggests four identifiable molecular subtypes (CMS1-4) based on 
transcriptomic analysis, the first of which is based upon a high degree of underlying MSI and 
hypermethylation (including CIMP), as opposed to CIN (Figure 1.5)118, 201, 202.  The further 
three pathways are based on chromosomal instability with APC dysfunction and the Vogelstein 
model of compound genetic insult, but subsequent canonical divergence between phenotypes 
displaying divergent metabolic or inflammatory phenotypes.  This collaborative study, based 
on the large-scale pooling of cohorts and bioinformatic methodologies, has helped 
characterised CRCs and framed the ongoing discourse in precision medicine as it will apply to 
the disease.  Although not clinically validated (except for KRAS wild-type anti-EGFR 
therapies), predictive biomarkers are emerging that may in future help guide therapies to 
facilitate treatment based on individual tumour biology; resulting in less wasteful and more 
effective care. 
 






1.4 General Aims of this Thesis 
Previous work has demonstrated that extramural vascular invasion (EMVI) has an inverse 
relationship to KRAS mutation, indicating a CIN dominated pathway in this tumour phenotype 
more typical of the classical adenoma-to-carcinoma pathway often found the distal colon and 
rectum203. MSI-high tumours on the other hand have been associated with serrated polyps and 
a high prevalence of BRAF mutations in the proximal colon, although a significant percentage 
affects the rectum and may represent a pathologically worse molecular subtype125, 147-149. There 
is however no current biomarker available to accurately predict the presence of EMVI, 
although it is suspected that MSI hypermutation and hypermethylation may be the 
predominating tumourigenic processes in this phenotype. 
 
This thesis will investigate the relationship between methylation and EMVI in rectal cancers, 
its implications for prognosis, and seek to illuminate the biological processes that underlie any 
relationship.  Each chapter will set out its own objectives, methodologies, results, and 
conclusions; although the body of work as a whole should constitute a unified enquiry based 
on this overarching aim.  Three principle methodologies will be employed throughout this 
investigation; assessment of the methylation status of resected rectal cancers and the correlation 
to prospectively collected clinical and histopathological datasets; in vitro studies of 
methylation in colorectal cancer tissue models, the manipulation of methylation in such 
models, and biological consequence; and a mechanistic analysis of both tissue models and 







2.1 Overarching Considerations & Ethics 
2.1.1 Patient Selection 
The primary aim of this research was to investigate the relationships between DNA 
methylation, the pathophysiology of rectal adenocarcinoma (especially extramural vascular 
invasion), and the mechanisms that underlie any relationship.  The key to linking cellular 
processes with clinical outcomes lies in the dual analysis of DNA extracted from patient tissue 
samples and the corresponding clinicopathological data.  All patients included in this study 
were drawn from a prospectively maintained database of all patients undergoing treatment for 
rectal cancer at a single centre (Abertawe Bro Morgannwg University Health Board (ABMU) 
Singleton & Morriston Hospitals – Swansea Colorectal MDT).  Although primarily a local 
MDT, the Swansea Colorectal MDT has a supra-regional practice in the management of 
advanced pelvic malignancy requiring sub-specialised surgical and oncological expertise, and 
therefore captures a greater-than-normal frequency of advanced rectal cancers undergoing 
treatment with curative intent.  Each of the patients included in this study have had surgical 
treatment for rectal cancer with curative intent, but patients receiving neoadjuvant therapy 
(nCRT) have been excluded.  
 
Patients who have received neoadjuvant therapy have been excluded due to the likelihood that 
DNA extracted from tumours previously exposed to nCRT will have undergone epi-/genetic 
alterations that will serve as confounding factors in analysis.  Currently, there is no substantive 
evidence to associate methylation status with response to nCRT, although there is some 
equivocation between single/multi locus and whole-epigenome studies, and neoadjuvant 
demethylation is being explored as a therapeutic augmentation to traditional nCRT in other 
organ systems148, 204, 205.  Further exclusion criteria were patients with inflammatory bowel 
disease, known or suspected high-risk of familial cancer syndromes, recurrent cancers, non-
adenocarcinoma tumour types (melanoma, squamous, GIST, etc), and tumours identified as 
rectosigmoid and beyond 15cm from the anal verge.  All patients received pre-operative 
diagnosis consistent with the prevailing guidelines (most recent; ACPGBI 2017206), and 
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retrieved specimens were retrieved from Singleton Hospital Pathology Department and 
screened by consultant histopathologist for quality and appropriate tumour representation in 
accordance with the validated Royal College of Pathologists colorectal cancer minimum 
reporting datasheet207. 
 
2.1.2 Database Maintenance & Anonymisation 
A prospective database of all patients undergoing treatment at the Swansea Colorectal MDT 
was maintained throughout and prior to the investigation.  Data was primarily extracted directly 
from the MDT meetings themselves by use of a standard data proforma and real-time data input 
to the database but was also cross-referenced against a number of clinical and public health 
resources.  Basic demographic information was captured from patient records presented at 
MDT, and radiological, histopathological, and further clinical data was harvested from 
respective hospital digitised services.  Patient deaths were cross-checked against the NHS 
Wales Informatics Service (Myrddin), and cancer specific outcomes against the Cancer 
Information Network System Cymru (CaNSIC) database.  Following identification of patients 
that met inclusion criteria and extraction of raw data from the database, investigators were 
blinded during the experimental phases of the data collection by use of a dual-labelling 
methodology (random number allocation) so that no patient-identifiable data was present 
during laboratory analysis.  The two datasets were recombined for dual analysis.  All data was 




Ethical approval was granted by South West Wales REC (Project Ref No.:11/WA/0256), and 
sponsored by the R&D Department, Abertawe Bro Morgannwg University LHB, Morriston 
Hospital, Swansea. Consent was not required in accordance with the Human Tissue Act (2004).  
All data was handled in accordance with the Data Protection Act (1988 & 2018) and GCP 
guidelines, and all investigators held current GCP certification208. 
  
 49 
2.2 Materials & General Methods 
2.2.1 Laboratory Equipment, Consumables, & Reagents 
Throughout this research a great variety of laboratory equipment and consumables was 
employed during specific processes, each of which will be described in detail in the methods 
section of each chapter.  Described here are the materials and general methods that are common 
to multiple sections of the research and which will not be described in detail again later.  Where 
these consumables constitute a bought-in kit they will be listed in section 2.2.6, but thereafter 
be referred to by their kit name, except where kit modification or process optimisation has 
taken place.  The exceptions to the above are listed below (Table 2.1).  Items of occasional use 
are not listed.  A laboratory safety folder was maintained throughout. 
 
Table 2.1. Laboratory Equipment & Consumables 
Item Supplier 
100bp DNA Ladder Promega, USA 
2-well Tissue Culture / Wound Healing Inserts (500µm) Ibidi GmbH, Germany 
30% Acrylamide-1 Bis Soln (37.5:1) Sigma-Aldrich (Merck), USA 
Albumin (bovine) Serum Sigma-Aldrich (Merck), USA 
Ammonium Persulfate Sigma-Aldrich (Merck), USA 
BICELL Cellular Cryopreservation Vessel NIHON FREEZER, Japan 
Borate Fisher Scientific, USA 
Centrifuges (various) Various 
CorningÒ MatrigelÒ Invasion Chamber  
(6-well plate, 8.0 micron pore) 
Corning (Merck), USA 
Cryovial 1.8ml SPL Life Sciences, USA 
EpiTectÒ PCR Control DNA QIAGEN, Germany 
Ethanol Fisher Scientific, USA 
Ethylenediaminetetraacetic acid (EDTA) Fisher Scientific, USA 
Interlukin-6 (IL-6) Human (recombinant) Sigma-Aldrich (Merck), USA 
L-Glutamine Fisher Scientific, USA 
Glassware, including microscope slides and cover slips 
(reusable & single use) 
Various 
GoTaqÒ Hot Start Green Master Mix Promega, USA 
Grant Dry Block Heater (variable temperature) Fisher Scientific, USA 
Falcon Tubes 15ml & 50ml (Collar / Conical) Fisher Scientific, USA 
Freezers: -20°C & -80°C Various & New Brunswick Scientific 
Fume Hood Clean Air, Ltd 
Horse Serum Gibco (Fisher Scientific), USA 
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Ice Machine (crushed) Hoshizaki, Japan 
Isopropanol Fisher Scientific, USA 
L-Glutamine Gibco (Fisher Scientific), USA 
Light Microscopes x5, x10, x20, x40 (+/- oil) Various 
Methanol Fisher Scientific, USA 
Microcentrifuge Tubes Eppendorf, Germany 
Milli-Q Water Purification System for Type 1 Ultrapure 
Water 
Millipore (Merck), USA 
Multi-well Cell Culture Plates (6, 12, 24) Corning (Merck), USA 
Nuclease-Free Water (Ambion) Sigma-Aldrich (Merck), USA 
Paraformaldehyde Sigma-Aldrich (Merck), USA 
PCR Plates (96 well) Bio-Rad, USA 
PCR Biofilm Bio-Rad, USA  
pH Meter Mettler Toledo, USA 
pH Buffers for Calibration  Sigma-Aldrich (Merck), USA 
Phosphate Buffered Saline (PBS) Gibco (Fisher Scientific), USA 
Pipette Tips (Tip One System) – various volumes StarLAB, UK 
Pipette Tips (Aspiration) – various volumes Corning (Merck), USA 
Scalpels (disposable) Swann-Morton, UK 
ScanLaf Tissue Culture Hood (Class 2) BioGene, Denmark 
Silver Nitrate Sigma-Aldrich (Merck), USA 
Sodium Hydroxide Sigma-Aldrich (Merck), USA 
Tetramethylethlenediamene (TEMED)  Sigma-Aldrich (Merck), USA 
Thermometers (immersion; digital & liquid) Various 
Thinpipette Focus Fixed Volume 5µl, 50µl, 300µl, 1000µl 
(+ various single & multi-channel) 
Fisher Scientific, USA 
 
Tris (hydroxylmethyl) aminomethane Sigma-Aldrich (Merck), USA 
Trypan Blue Solution (0.4%) Sigma-Aldrich (Merck), USA 
Tissue Culture Flasks 25cm2 and 75cm2 (vented) Corning (Merck), USA 
Vectashield Mounting Medium with DAPI Vector Labs (Maravai LS), USA 
Vortex Various 
Water Baths (37°C) Various 
Xylene Fisher Scientific, USA 




2.2.2 Programmable Equipment 
A variety of programmable laboratory equipment was employed at various stages of this 
research; including but not limited to automated and real-time PCR equipment, microscopes, 
and tissue-bloc processors.  Each item of equipment, its set-up, programming, and analysis will 
be discussed in the methods section of the relevant chapter; but are listed in Table 2.2. 
 
Table 2.2. Programmable Laboratory Equipment. 
Item & Description Supplier 
ChemiDoc XRS+ System 
- Gel imaging & product analysis 
Bio-Rad, USA 
etaluma 560 Inverted Live-Cell Microscope 
- Time-lapse wide-field microscopy 
etaluma, USA 
IN Cell Analyser 2000 
- Automated wide-field cell analysis 
GE Life Sciences, USA 
IQ-5ä  Real-Time PCR System 
- RT PCR & product analysis system  
Bio-Rad, USA 
Metafer Automated Slide-Scanning Platform   
- Automated fluorescence slide-scanning & image capture 
MetaSystems Group, Germany & USA 
NanoDropÒ 1000 UV Vis Spectrophotometer  
- DNA, RNA, and Protein yield & purity analysis 
Labtech (Fisher Scientific), USA 
Olympus BX51 Fluorescence Microscope 
- Multi-filter programmable fluorescence microscopy 
Olympus, Japan 
T100ä Thermal Cycler 
- PCR & Microcentrifuge heater block 
Bio-Rad, USA 
Ventana Benchmark ULTRA 
- Automated slide processing and IHC 






5-azacytidine (AZA) is a pyrimidine ring analogue of the DNA and RNA nucleotide cytidine.  
After transportation into cells, 5-AZA undergoes de-oxy metabolism to form 5-aza-2′-
deoxycytidine, which can then be incorporated into DNA in place of cytidine. Once in C-G 
dinucleotide formation, DNA methyltransferases (DNMT) bind AZA to catalyse methylation 
but are inhibited from being released (normally by beta-elimination of the covalent bond at the 
5-carbon position) by the presence of a nitrogen209, 210.  By this mechanism, DNMT activity is 
inhibited by sequestration of the DNMT enzyme and subsequent failure of de-novo methylation 
during DNA replication and repair.  AZA does not actively demethylate DNA by competitive 
inhibition of the DNMT’s active site, by direct removal of methyl groups from methylated 
cytosine, or by upregulation of the base excision repair enzyme OGG1 in response to oxidative 
stress211. Due to the necessity of DNA replication to effect demethylation, the cellular and 
clinical effects of AZA are only evident following multiple cell cycles212.  DNA demethylation 
by AZA has been shown to activate previously silent genes, initiate decondensation of 
chromatin, and induce cellular differentiation; ultimately leading to significant changes in 
cellular phenotype213-215. 
 
AZA was supplied by Sigma-Aldrich (now Merck), Germany [A2385].  AZA has a molecular 
formula of C8H12N4O2, a molecular weight of 244.20, and its structure is shown in Figure 
2.1216.  AZA was stored at -20°C in its dehydrated form (as shipped), and was dissolved in 
DMSO/H2O prior to use, where after it was stored at -80°C for a maximum of one week.  
 




The effect of demethylation with AZA on DNA are global, and pan-demethylation 
(hypomethylation) has been demonstrated to contribute to chromosomal instability (CIN) and 
even to induce malignant transformation in vivo; patterns of global demethylation have been 
observed in a variety of malignant conditions, including T-cell lymphomas (murine model), 
and human prostate and hepatocellular carcinoma168, 217, 218.  The consequence of these findings 
is that AZA may itself be mutagenic due to whole-genome demethylation, and thus some 
authors have suggested that this may limit its use as a therapeutic agent168.  The global 
demethylating effects of AZA at therapeutic doses have however been challenged, with parallel 
studies examining the demethylating effects of AZA on preserved Alu elements in patients 
receiving treatment for myelodysplastic disorders indicating that, at therapeutic doses, AZA 
has only a moderate demethylating effect169.  The authors of this study speculate that the doses 
of AZA employed in previous in vitro and murine models were not representative of normal 
physiological conditions (the authors report “extreme modelling”), but they do concede that 
LINE-1 hypomethylation was observed in their own study of colorectal cancers, although to a 
less significant degree.  The association between CIN and hypomethylation was also 
investigated in colorectal cell-lines with differing expression of CIN as part of the same 
investigation, although only a minor, non-statistically significant decrease in methylation 
between CIN+ and CIN- cell lines were discovered (p=0.48)169.  Other cell-line work has 
however demonstrated AZA (and its de-oxy derivatives) to be an effective demethylator of 
oncogenic hypermethylated promotor regions, such as the C/EBPd tumour suppressor in acute 
myeloid leukaemia (AML)219.  In this study, microarray analysis of U937 cells treated with 
AZA derivatives demonstrated that 274 transcripts were significantly upregulated, including 
the entire C/EBP family, although C/EBPd showed a 10-fold expressional increase following 
demethylation.  These findings correlated to the clinical finding that AML patients 
demonstrated hypermethylation at the C/EBPd promotor region. 
 
AZA was initially licenced in 2004 by the Federal Drug Administration in the USA for use in 
all types of myelodysplastic syndrome, including AML, based on one randomised control study 
and two single-arm studies212, 220, 221. Unfortunately, the complete response rate in the treatment 
arms of these studies was low (16%), although a return to normal blood counts and bone 
marrow morphology was observed.  A partial response was observed in a greater number of 
patients (19%), but individuals receiving the treatment remained therapy-dependent, with 
relapse of bone marrow failure following treatment withdrawal.  Side-effects were observed in 
a significant proportion of patients, including 16% who developed severe liver dysfunction, 
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although minor gastrointestinal and haematological side effects were more common. Despite 
these poor beginnings, more recent studies employing decitabine (a de-oxy derivative of AZA) 
showed a greater response rate without increased toxicity or safety concerns, although overall 
survival was not statistically better between treatment arms, although trend was demonstrated 
in older (>70yrs) patient groups, especially for de novo AML rather than secondary disease222.   
 
There is currently no role for AZA in the treatment of solid-organ tumours, including colorectal 
cancer (CRC).  Early trials of demethylating agents for a variety of solid-organ tumours, based 
on the success of therapy for myelodysplastic disorders, were both speculative and 
disappointing; with very little if any clinical response observed in a mixed cohort of end-stage 
tumours223, 224.  When identified as a separate cohort, the results specifically for CRC were 
especially poor; decitabine monotherapy producing no tumour regression whatsoever in any 
patient, and a less than 10% response (defined in this study as regression or stable disease) 
when used in combination therapy. Further studies on patients with end-stage solid-tumour 
disease also showed no clinical effectiveness when decitabine was combined with a histone 
deacetylase inhibitor (sodium phenylbutyrate), although toxicity was limited and there were no 
adverse drug-related events225.   
 
More recently, the potential role of AZA as a chemo-sensitizer in CIMP-high solid tumours 
has been suggested, based on the observation that CIMP-high has been associated with chemo-
resistance in colorectal and other tumours226, 227.  In vitro and xenograft studies have also 
indicated that demethylation may restore sensitivity to 5-FU therapy in colorectal and other 
cancer models228, 229.  Early clinical outcomes have suggested that AZA derivatives may restore 
partial chemotherapy sensitivity to treatment-refractory non-small cell lung cancers and 
ovarian cancers, although the numbers in these studies are small and the benefits (in terms of 
PFS) were marginal230, 231.  Unfortunately, these results have not been observed in early clinical 
trials in CRC.  In one trial, twenty-six treatment-refractory patients (fourteen CIMP-high) were 
treated with AZA in addition to standard chemotherapy (CAPOX) to determine if chemo-
sensitivity could be restored; no patient responded and there was no correlation between CIMP-
status and PFS232.  A similar study of forty-seven patients with advanced treatment-refractory 
liver metastasis of colorectal origin also showed no clinical response (by RECIST standards) 
to combined AZA and entinostat therapy, although tumours demonstrating demethylation had 
a slight improvement in PFS233, 234.  
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2.2.4 RRx-001 
RRx-001 (formerly ABDNAZ) is a novel compound produced by modification of the by-
products of solid rocket propellant manufacture and has shown some activity suggesting it may 
have chemotherapeutic or chemo-sensitising properties235-237.  RRx-001 acts as an alkylating 
agent, covalently binding nucleophilic targets following liberation of a bromine (the leaving 
group) in a non-selective and non-reversible manner.  This action is similar to that observed 
with traditional non-selective alkylating agents such as nitrogen mustard (mustard gas) and 
nitrosoureas, each of which can cause potentially devastating DNA, RNA, and protein damage 
leading to significant toxicity or death238.  At a cellular level RRx-001 has been shown to 
increase reactive nitrogen and oxygen species; resulting in direct DNA damage, increased 
gH2AX expression reflecting breakage in dsDNA, and apoptosis237.  The chemotherapeutic 
mechanisms of RRx-001 are however not well understood, although on in vivo modelling, 
action on the b-cysteinyl residue of haemoglobin and other circulating thiols (glutathione and 
cysteine) by nucleophilic substitution is believed to underlie the production of circulating 
nitrogen oxides; thus modulating redux reactions in the circulation and modifying tumour 
microvasculature through nitrogen dependent pathways. In early trials, RRx-001 did not 
demonstrate significant “off-target” toxicity, possibly due to the rapid alkylation of haem- 
components on administration, thus limiting damage to tissues not reached until after the 
compound has given up its leaving group235, 239. 
 
RRx-001 was supplied by EpicentRx under experimental licence.  RRx-001 is a cyclic nitro 
compound with molecular formula C5H6BrN3O5, a molecular mass of 268.02, and a molecular 
structure as shown in Figure 2.2.  RRx-001 was stored at room temperature in its dehydrated 
form (as shipped), and was dissolved in DMSO/H2O prior to use, where after it was stored at -
80°C for a maximum of one week. 
 





RRx-001 was initially investigated as a potential tumour chemo/radio re-sensitiser in the 
context of end-stage metastatic disease and was trialled against a number of solid organ 
tumours, including colorectal cancer, and has demonstrated favourable outcomes236, 237, 240.  
The role and mechanisms of small molecule agents in re-establishing tumour sensitivity is not 
well understood, but some emerging theories suggest epigenetic mechanisms underlie this 
phenomenon.  Supporting this theory are the observations that demethylating agents (including 
AZA) and histone deacetylating inhibitors have all been shown to have some ability to induce 
tumour re-sensitisation in previously refractory disease, raising the possibility of “rewriting the 
epigenetic code” as a means of modulating a tumour’s response to therapy241, 242.  RRx-001 has 
been demonstrated to cause global DNA demethylation in squamous-cell cancer cell lines in 
vitro (SCC VII), and reduce DNMT1 and DNMT3a expression in a time-and dose-dependent 
manner243.  In this study, global DNA demethylation was comparable to that observed with 
equivalent doses of AZA, although at an individual gene level there was a high degree of 
variance in the effects; some loci demonstrating hyper-and some hypo-methylation. 
 
In clinical trials RRx-001 has been shown to be biologically active at safe doses in target 
populations (those with advanced metastatic solid organ tumours), and to be a potent generator 
of reactive nitrogen and oxygen species in vivo244, 245.  A number of case reports and Phase I 
trials against metastatic or end-stage Non-Small and Small Cell Lung Cancers, squamous 
tumours, prostate cancers, and melanomas have indicated that RRx-001 may have beneficial 
effects when combined with previously exhausted chemo- or radio-therapeutic strategies246-251.  
A current Phase III trial is examining the role of RRx-001 in platinum-treatment-refractory 
Small Cell Cancer (lung & non-lung), with progression-free survival of 12 months the primary 
outcome, estimated to be complete by 2020252. RRx-001 has also been shown to have 
immunomodulating effects in the tumour microenvironment in neuroendocrine tumours, and 
has demonstrated the ability to enhance tumour-related macrophage polarisation and T-
lymphocyte infiltration253-256.  Further studies have suggested a link between RRx-001 induced 
demethylation and activation of interferon responsive genes in colorectal cell lines (HCT 116); 
inhibiting tumour cell growth and activating cellular anti-viral defence by “viral mimicry”257.   
 
Despite a growing body of research into the cellular and tumour-related effects of RRx-001, 
the exact mechanisms of its action are not well understood, and it is likely that it acts via 
number of different mechanisms that contribute to its effect.  There is however reliable 




Methylation specific PCR primers were selected, designed, and optimised by myself and other 
members of the research group based on previous enquiry204, 258.  Metalloproteinase pathway 
cDNA primers were selected from open-source references by the author and optimised in-
house.  Each primer was ordered through Sigma-Aldrich; and is summarised in Table 2.3.  
PCR conditions will be described in relevant chapters. 
 
Table 2.3 Primers. U, Un-Methylated; M, Methylated; FWD, Forward; REV, Reverse; MW, 
Molecular Weight; DM, Dimerization; 2nd, Secondary (VW – very weak; W – Weak; M – 
Moderate; S – Strong). 
 
Name MW DM 2nd Sequence 5’-3’ 
hMLH U FWD 7477 No None AGAGTGGATAGTGATTTTTAATGT 
hMLH U REV 7534 No None ACTCTATAAATTACTAAATCTCTTC 
MINT1 U FWD 8603 No None AATTTTTTTATATATATTTTTGAAGTGT 
MINT1 U REV 6603 No None AACAAAAAACCTCAACCCCACA 
SOCS1 U FWD 9332 No None TTTTTTGGTGTTGTTTGGAGGTTGGATTTT 
SOCS1 U REV 10681 No None AAAACAAAACAATAAACTAAAACACTACAAAACCA 
HAND1 U FWD 6233 No None AATAGTTTAGGGTGTTGGTT 
HAND1 U REV 5700 No None AAATTTTACACTCAACCCA 
ADAMTS1 U FWD 7831 No None GTGAGTAATATTGTAGTTAAGGTGG 
ADAMTS1 U REV 7582 No  None AAAACAAAAAAACACTCTAAAACTCC 
NEUROG U FWD 7482 No None TTGTTGGTTAATTGGTGGTGTTGT 
NEUROG U REV 7459 No VW CATTACCTCAACCACTAATCACCCA 
IGFBP3 U FWD 7704 No None TTATTTTGGTTTTTATATAGTGGTT 
IGFBP3 U REV 7573 No None AACAAAAAACAACTAATCCTCAACA 
THBD U FWD 7407 No None ATGTGTTTGTTTTTATTTGGTGTT 
THBD U REV 6618 No None CATAACTAACCAAAAACCCACA 
hMLH M FWD 5514 No M GATAGCGATTTTTAACGC 
hMLH M REV 7261 No None TCTATAAATTACTAAATCTCTTCG 
MINT1 M FWD 7939 No None AATTTTTTTATATATATTTTCGAAGC 
MINT1 M REV 5407 Yes None AAAAACCTCAACCCCGCG 
SOCS1 M FWD 5881 No None TTGTTCGGAGGTCGGTTT 
SOCS1 M REV 6088 No None ACTAAAACGCTACGAAACCG 
HAND1 M FWD 6203 No None AATAGTTTAGGGCGTTGGTC 
HAND1 M REV 5419 No None AATTTTACGCTCAACCCG 
ADAMTS1 M FWD 7891 No None GTGAGTAATATCGTAGTTAAGGCGG 
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ADAMTS1 M REV 7629 No None CTAAAACAAAAAACGCTCTAAAACG 
NEUROG1 M FWD 6492 No None AATTTATGTTCGCGGGAGGTC 
NEUROG1 M REV 6024 No None ACCAACTTAACCCGAACCGA 
IGFBP3 M FWD 6737 No None TTTCGGTTTTTATATAGCGGTC 
IGFBP3 M REV 6689 No None AAAAAACGACTAATCCTCAACG 
THBD M FWD 6385 No None CGTTCGTTTTTATTCGGCGTC 
THBD M REV 5678 No None GCCAAACCCCATCTCATCG 
MMP2 cDNA FWD 6926 No None TTTCCATTCCGCTTCCAGGGCAC 
MMP2 cDNA REV 7473 No None TCGCACACCACATCTTTCCGTCACT 
MMP9 cDNA FWD 5979 No None CCTGCCAGTTTCCATTCATC 
MMP9 cDNA REV 6019 No None GCCATTCACGTCGTCCTTAT 
MMP11 cDNA FWD 6133 No W GGGGATGTCCACTTCGACTA 
MMP11 cDNA REV 6262 No None CAGTGGGTAGCGAAAGGTGT 
MMP13 cDNA FWD 6057 No None AACATCCAAAAACGCCAGAC 
MMP13 cDNA REV 6109 No None GGAAGTTCTGGCCAAAATGA 
TIMP2 cDNA FWD 7135 No W GGCGTTTTGCAATGCAGATGTAG 
TIMP2 cDNA REV 6975 No W CACAGGAGCCGTCACTTCTCTTG 
TIMP4 cDNA FWD 6087 No W AGACCTCACAGGCTCAGTCG 
TIMP4 cDNA REV 6029 No W CATTCCTGCCAGTCAGCCTG 
bACT FWD 5492 No None GATGGCCACGGCTGCTTC 






To facilitate the reproducibility and maintenance of standards across replications of 
experimental cycles, and to provide literature-referenced and evidenced methodologies, a 
number of bought-in experimental kits were employed.  Kits reduced the necessity for in-house 
method design and development and were also a convenience.  Deviations or optimisation of 
kit protocols will be discussed in each relevant chapter methodology.  Kits are listed in Table 
2.3. 
 
Table 2.3  Kits 
Name Use Supplier 
DNeasyÒ Blood & Tissue Kit DNA extraction & purification. QIAGEN, Germany 
EpiQuikä DNMT Activity/ 
Inhibition Assay Ultra Kit 
(colourimetric) 
Measurement of DNMT activity or 
inhibition based on nuclear 
extracts. 
Epigenetek, USA 
EpiQuikä Nuclear Extraction Kit Nuclear protein extraction. Epigenetek, USA 
ImprintÒ DNA Modification Kit One-step DNA bisulfite 
conversion & post-modification 
clean up. 
Sigma-Aldrich (Merck), USA 
MethylFlashä Global DNA 
Methylation (5-mC) ELISA Easy 
Kit (colorimetric) 
Detection of global DNA 
methylation. 
Epigenetek, USA 
QuantiFastÒ SYBRÒ Green RT-
PCR Kit 
Quantitative one-step PCR. QIAGEN, Germany 
QuantiTectÒ Reverse 
Transcription Kit 
Reverse transcription of RNA to 
cDNA with gDNA wipe-out 
QIAGEN, Germany 
RNeasyÒ Mini Kit RNA extraction & purification. QIAGEN, Germany 
RT2 First Strand Kit cDNA synthesis for RT PCR QIAGEN, Germany 
RT2 Profilerä PCR Array – 
Human Tumour Metastasis 
Pathway & process specific 





2.2.7 Antibodies & Immunofluorescence 
Antibodies were employed at two stages during this research; firstly during expressional 
analysis and assessment of knock-down by indirect immunofluorescence (IIF) in cell culture 
experiments, and secondly during immunohistochemistry (IHC) of tissue microarrays.  Each 
process will be discussed in detail in the relevant chapter, but antibodies employed are listed 
in Table 2.4. Appropriate horse-radish peroxidase conjugated secondary antibodies were used 
for Western Blotting. 
 
Table 2.4 Antibodies 
 Name Supplier 
IIF
 
MMP-2 Monoclonal Antibody [sc-13594] (mouse, IgG) Santa Cruz Biotech, USA 
TIMP-2 Monoclonal Antibody [sc-365671] (mouse, IgG) Santa Cruz Biotech, USA 
TIMP-4 Polyclonal Antibody [PA5-30228] (rabbit, IgG) Fisher Scientific, USA 
IH
C 
MMP-2 Monoclonal Antibody [EPR1184] (rabbit, IgG) Abcam, USA 
MMP-9 Polyclonal Antibody [ab38898] (rabbit, IgG) Abcam, USA 
MMP-11 Polyclonal Antibody [ab119284] (rabbit, IgG) Abcam, USA 
TIMP-2 Monoclonal Antibody 3A4 [ab1828] (mouse, IgG) Abcam, USA 




 Goat Anti-Rabbit IgG H&L Alexa Fluor
Ò 488 [ab150077] Abcam, USA 
Goat Anti-Mouse IgG H&L Alexa FluorÒ 488 [ab_2534060] Fisher Scientific, USA 




Table 2.5 summarises the primary computer software employed during this research (not 
including benchtop equipment with integrated software – see section 2.2.2), including plug-
ins, but excluding web browsing software and operating systems. 
 
Table 2.5  Software  
Name & Edition Primary Role 
Image J (v.1.51) Image analysis 
Image Lab 6.0.1 Gel analysis 
Lumaview v.17.11.04 Time-lapse microscopy 
Metafer 4 v. 3.8.5 (MSearch)  Slide handling and microscopy 
Microsoft Office (Word v.16.12, Excel v.16.12) Word processing, data handling & analysis 
XLStat, Addinsoft (v.2017) Plug-in statistics package for MS Excel 
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2.3 Cell Lines & Culture 
2.3.1 Cell Lines 
2.3.1.1 DLD-1 
The primary cell line used as a model for rectal cancer throughout this research is DLD-1, 
originally sourced from the European Collection of Animal Cell Cultures (ECACC 90102540), 
and maintained in-house (average passage 7)259.  DLD-1 is a human colon epithelial cell line 
derived from an adenocarcinoma in a male patient (also the source of colorectal cell lines HCT-
15, HCT-8, and HRT-18)260.  DLD-1 have a 2n = 46 pseudodiploid karyotype. DLD-1 has an 
adherent growth mode and is best cultured in RMPI 1640 + 2mM glutamine + 10% foetal 
bovine serum (FBS).  DLD-1 was selected as it is a widely used cell line for the investigation 
of colorectal cancer in vitro and has been used extensively in the proceeding and preparatory 
studies for this research204.  DLD-1 demonstrates a high level of microsatellite instability and 
is CIMP-positive across two epigenomes commonly examined in tumour DNA methylation 
research, in addition to our own methylation panel, and thus serves as a good model for 
investigating consensus molecular subtype I tumours.  DLD-1 is also CIN-negative and BRAF 
wt, but demonstrates KRAS G13D amino acid substitution relating to underlying mutation261, 




Human foetal lung fibroblasts, HFL-1, were used as positive controls for 
immunocytochemistry of metalloproteinase expression in knockdown experiments, originally 
sourced from the European Collection of Animal Cell Cultures (ECACC 89071902), and 
maintained in-house (average passage 5)263.  HFL-1 have a 2n = 46 diploid karyotype.  HFL-1 
has an adherent growth mode and is best cultured in Ham’s F12 + 2mM glutamine + 1% NEAA 
+ 10% FBS. 
 
2.3.2 Cryopreservation 
Cells were grown to a maximum of 70% confluency and then washed twice with sterile 
phosphate buffered saline (PBS), lifted with trypsin, and then washed a further two times with 
PBS by serial centrifugation and re-suspension.  Cells were then diluted to a concentration of 
1x106 cells ml-1, spun to pellet, and resuspended in FBS and DMSO at a ratio of 9:1 maintaining 
the starting concentration.  Aliquots of 1ml were then transferred to cryovials and frozen for 
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24 hrs at -80°C in a BICELL Cellular Cryopreservation Vessel.  Frozen cryovials were then 
transferred to liquid nitrogen at -196°C for long-term storage. 
 
2.3.3 Cell Seeding & Maintenance 
Standard laboratory personal protective equipment (lab coat and gloves) were employed to 
maintain personal protection and prevent cross-contamination.  Surfaces were washed with 
70% ethanol and allowed to air dry.  All culture took place in ScanLaf Class II Tissue Culture 
Hoods.  Frozen cells were incubated at 37°C with 5% CO2 prior to seeding, and all culture 
media & solutions (PBS, trypsin, etc) were pre-warmed to 37°C.  Active, adherent cell lines 
were detached from their growing environment by incubating in warmed trypsin for 5-10 
minutes after washing.  
 
Cell lines were maintained in their growth medium of preference (see section 2.3.1) at a 
maximum of 70% confluency.  Cells were initially seeded at a concentration of 3x104 cell ml-
1 based on published cell growth rate / doubling times in 75cm2 flasks (working volume 
typically 25mls) and allowed to proliferate.  Cells were maintained in flasks for a maximum of 
four days between splitting, and concentrations were determined using a Beckman Coulter 
Counter.  Cells were removed from maintenance culture and split to experimental flasks 
(typically 25cm2, working volume 5mls) or other culture environments according to protocol; 














DNA Hypermethylation as a Predictor of 




3.1.1 Epidemiology of Rectal Cancer 
Colorectal cancer (CRC) is the third most frequent cancer and the second leading cause of 
cancer death worldwide264. Each year, one million people will develop CRC, and 40-50% will 
die within five years265. Furthermore, rectal and distal sigmoid cancers are known to present at 
a later stage, and have a poorer prognosis than other colonic cancers266.  Data from the 
Surveillance, Epidemiology, and End Results programme (SEER) indicates that between 1995 
and 2008 there were 110,607 cases of rectal cancer recorded in the US (estimated population 
capture 25%), representing approximately 30% of all colorectal cancers267.  Patients presenting 
were on average five years younger than those with colonic cancer (median age 67 vs 72 years; 
p=<0.001) and were more likely to be male (56.8%; p=<0.001).  This data is in keeping with 
the most recent National Bowel Cancer Audit from the UK (NBOCA 2018), where of the 
30,541 patients diagnosed with colorectal cancer between April 2016 and March 2017, 8,514 
(27.9%) had a rectal cancer, and of whom 53% progressed to major resection and 7% to local 
excision268.  A recent European population-based study of 139,457 patients with colorectal 
cancer from England, Denmark, Norway, and Sweden demonstrated that the pooled (all stages) 
3-year survival from rectal cancer in England was actually better than that for colon cancer 
(69.7% vs 63.9%), but that survival for both cancer locations was worse in England compared 
to the other Northern European countries269.  Survival in England was notably worse in stage 
II and III rectal cancers (and stage IV colon cancer), as demonstrated in Figure 3.1, with the 
number of patients undergoing surgery for rectal cancer lowest in England (59.9%) when 
compared to other nations (highest: Sweden, 70.8%).  A systematic review of surgery for 
locally advanced or locally recurrent rectal cancer (1016 patients) demonstrated a mean overall 
survival of 31 months and median 5-year survival of 32%270. 
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Figure 3.1 Northern European age-standardised survival for rectal adenocarcinoma 





3.1.2 Extramural Vascular Invasion in Rectal Cancer 
Extramural vascular invasion (EMVI) is characterised by the presence of organised tumour in 
the vessels adjacent to the primary tumour beyond the muscularis propria and has been reported 
in approximately 25% of resected rectal tumours, although the reported incidence has varied 
between 17% to 70%271-273.  Despite its recognition within pathological specimens for some 
time, defining and recording its presence as a separate entity from other T3 tumours has not 
been consistent, although the current reporting criteria issued by the Royal College of 
Pathologists stipulates that it is a mandatory reporting criterum207, 274, 275.  EMVI has been 
demonstrated to be an important risk factor for systemic recurrence, local recurrence and death, 
independent of T stage272, 273, 276-279. Additionally, EMVI status influences the need for 
neoadjuvant chemoradiotherapy and adjuvant chemotherapy, as it has been demonstrated that 
chemoradiation (CRT) can cause vessel fibrosis in EMVI-positive tumours; which may 
influence survival outcomes85, 280. 
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Although magnetic resonance imaging (MRI) has an undisputed role in defining involvement 
in the circumferential resection margin (CRM) in rectal cancers, as demonstrated in the 
MERCURY trials, it’s role in assessing EMVI not threatening the CRM is not as well 
defined281-284.  The outcome of the MERCURY II trial (2016) demonstrated the diagnostic 
accuracy of MRI in predicting CRM involvement in low rectal cancers, and in stratifying them 
into “safe” and “unsafe” groups that would or would not benefit from neoadjuvant radiotherapy 
and/or sphincter saving surgery285.  This prospective validation also demonstrated the utility of 
MRI in assessing “safety” following neoadjuvant therapy, allowing the potential for sphincter-
saving operations to be considered for those who had shown disease response.   
 
However, the seminal study of MRI assessed EMVI led by G. Brown in Cardiff in 2003 
suggested that there was a weighted agreement of k=0.64 between pre-operative MRI and 
histopathology, although the total study population was only 98 patients, of whom 26 had 
histologically confirmed pEMVI and of these only 18 were visible to the naked eye with 
standard staining techniques284.  The study suggested that the relatively poor concordance, even 
when compared to a naked-eye assessment of histology specimens, was the result of MRI not 
being sensitive enough to detect mrEMVI in vessels of less than 3mm.  Concordance between 
mrEMVI against pEMVI identified at microscopy would therefore be even less favourable due 
to a higher denominator.  In a subsequent study led by the same author, mrEMVI (as defined 
by a 0-5 point scoring system, later dichotomised into mrEMVI-positive or -negative), has a 
sensitivity and specificity of only 68 and 88 percent, respectively, compared to histology280.  
However, despite poor sensitivity and specificity, univariable analysis of 3-year relapse-free 
survival for each group was highly significant (35% vs 75%, p=<0.001) and corresponded well 
with outcomes based on histology.   
 
The predictive prognostic significance of MRI detected EMVI has been further evaluated in 
larger cohort studies, such as that by Bugg in 2014; this study demonstrated that within a 
population of 788 patients with rectal adenocarcinoma diagnosed between 2007 and 2012, 
26.2% had an mrEMVI-positive tumour and of this proportion approximately 25% went on to 
develop liver metastasis within 1 year, compared to 6.7% of mrEMVI-negative tumours 
(p=<0.001, RR=3.7)286.  These findings have been corroborated further by meta-analysis of 
1262 patients with rectal cancer (403 mrEMVI-positive), where EMVI was found to be 
associated with a higher chance of presenting with or developing metastasis (OR=5.68 & 
OR=3.91, respectively, both p=<0.001)287.   
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However, the lack of preoperative MRI diagnostic certainty for staging beyond CRM clearance 
was clearly demonstrated by a large meta-analysis of 21 studies by Al-Sukhni published in 
2012288.   MRI specificity for CRM involvement was 94% (95% CI 88-97) despite a high 
degree of inter-study heterogeneity, but specificity fell to 75% (95% CI 68-80) and 71% (95% 
CI 59-81) for T and N stage, respectively. 
 
The presence of mrEMVI is therefore considered an important component of pre-operative 
staging but is largely limited to its impact on the CRM.  The presence or absence of EMVI is 
included in several international reporting proformas for preoperative radiological disease 
staging, including the European Society for Medical Oncology guidelines for the diagnosis and 
management of rectal cancer and the Royal College of Radiologists guidelines for cross-
sectional imaging in cancer management289-292.  mrEMVI does not however constitute a 
specific item within of the preoperative TNM system advocated by the Union for International 
Cancer Control (UICC), which does not discriminate between a T3 primary tumour mass and 
serpiginous and/or distant vascular tumour extension as described by Brown in 2003280.  
Interestingly, the ACPGBI 2017 Guidelines for the Management of Colorectal Cancer 
(Investigation & Staging section) does not mention mrEMVI in the context of preoperative 
staging; only that threat to CRM should be assessed by MRI [Recommendation grade B] (see 
section 2.2.1 of the 2017 guidelines, p12)206.  Again, this suggests that mrEMVI is regarded as 
only significant when threatening the CRM and is not regarded as a separate pathological entity 
within the broader context of T3 disease, although conflictingly, mrEMVI is discussed in the 
same 2017 guidelines (Multidisciplinary Management section, see section 4.1.2, p28) where it 
is highlighted as a risk factor for local and distant recurrence independent of T stage (Figure 
3.2)293. However, despite discrepancies in detection and classification, pre-operative mrEMVI 
has been shown to be a poor prognostic feature irrespective of subsequent management 
strategy; mrEMVI being associated with a four-fold increase in risk of distant metastasis (52% 





Figure 3.2  Risk of local recurrence following resection of rectal cancer with curative intent 
based on preoperative MRI findings (adapted from Gollins, et.al.)293.  Note that EMVI is listed as 
an independent risk factor for a moderate increased risk of local recurrence. 
 
 
Figure 3.3  EMVI is associated with worse 3-year relapse-free survival (RFS) irrespective of 
whether it is detected preoperatively (mrEMVI) or at histopathology, irrespective of 




It is clear therefore that the presence of EMVI is a marker of poor prognosis, but it is not clear 
how this should affect management strategy.  Even in the absence of a threatened CRM 
neoadjuvant short-course radiotherapy (SCPRT) and long-course chemoradiotherapy (LC-
CRT) have been shown to reduce local recurrence by approximately 50%, although the 
absolute benefit is small (5-6%) and the numbers needed to treat are high (17-20), resulting in 
a high proportion of futile overtreatment.  Both SCPRT and LC-CRT have no effect on the risk 
of systemic recurrence or overall survival.  Despite lacklustre benefits, the most recent 
ACPGBI guidelines suggest that all patients with high-risk CRM clear disease (including 
mrEMVI positive) should be considered for either SCPRT or LC-CRT to reduce the chance of 
local recurrence [Recommendation grade A], although as shown by the NBOCA data, clinical 
practice is highly variable across MDTs268, 293.   
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The role for neoadjuvant therapy in locally advanced and CRM-threatened rectal cancer is well 
evidenced; based on multicentre international randomised-controlled trials (the Dutch trials 
and UK MRC CR07 trial)295-297.  Evidence for treatment is irrespective of whether it is EMVI 
or primary tumour extension that is threatening the CRM, and the primary benefit is in local 
disease control (LR).  The current standard of care in this situation is LC-CRT with a single-
agent fluoropyrimidine and radiotherapy, followed by surgery 6-12 weeks after treatment to 
allow tumour regression; based on large trials demonstrating the superiority of combined 
chemo- and radiotherapy (EORTC 22921 and FFCD 9203)79, 80, 99.  Neoadjuvant CRT was 
further demonstrated to be superior to adjuvant CRT, in terms of LR and reduced toxicity, in 
the German GAO/ARO/AIO-94 trial, although again, no DFS or OS benefit was evident78, 298.  
Interestingly, long-term outcomes from the German study indicate that perioperative 
complications, including anastomotic leak and wound complications were associated with poor 
overall and disease-specific survival (recurrence and metastasis), and that surgical 
complication was predictive of reduced OS based on Cox regression analysis (p=0.008).  Short-
course protocols were found to be inferior regarding pCR rates (Polish trials), although LR, 
DFS, and OS were not significantly affected (TROG trial)299-301.   
 
However, as discussed in Section 1.2.2, a significant proportion of patients will undergo a PCR 
following neoadjuvant CRT, although a further significant proportion will progress during 
therapy; including the development of EMVI, progression of EMVI, local tumour extension, 
and development of metastatic disease72-75.  The response to therapy ultimately dictates surgical 
strategy, presenting the opportunity for both organ and sphincter preserving techniques, but 
also for progression and palliation.  Currently there is no reliable pre-treatment test to aid in 
defining which patients will benefit from neoadjuvant therapy for either high-risk CRM-clear 
or CRM-threatened/involved disease, although biomarkers, including CIMP, are being 






3.1.3 Epigenetic Biomarkers in Colon & Rectal Cancer 
3.1.3.1 Introduction 
Hypermethylation and hypomethylation in colorectal cancer were first observed by Feinberg 
and Vogelstein in 1983, occurring at CpG islands and resulting in transcriptomic silencing of 
tumour suppressor genes and genes involved in DNA mismatch repair302, 303.  As associations 
are made between the development of colorectal cancer and epigenetic aberrations there is a 
potential for epigenetic analysis to help guide our diagnosis and management of colorectal 
cancer304.  Gaining an insight into tumour behaviour, including diagnosis, prognosis, and 
response to therapy by analysing epigenetic changes may potentially improve outcomes if they 
can effectively guide therapy305, 306.  Important pathways in cell regulation have already been 
implicated in the epigenetic pathogenesis of CRC; including those of the Wnt pathway 
(APC, AXIN2, DKK1, SFRP1, SFRP2, WNT5A), the CDKN2A cell-cycle genes, RAS 
signalling, and the DNA repair genes MGMT and hMLH1 & hMLH2307-309.    However, despite 
epigenetic silencing of classical tumour suppressor genes and dysregulation of other cancer-
related pathways having been demonstrated in CRC, epigenetic profiling has only been 
implemented in guiding personalised therapies in a limited number of clinical scenarios.  
Specific examples are in the management of some gliomas and prostate cancers, where in the 
case of gliomas, the hypermethylation-related silencing of O6-methylguanine-DNA 
methyltransferase (MGMT) is predictive of response to treatment by alkylating agents, 
although the beneficial response in the hypermethylated group is eventually lost and all patients 
relapse310-312. The reason for limited implementation may lie in the complexity of the epigenetic 
factors potentially involved in tumourigenesis; thus epigenome-wide studies such as the 
BLUEPRINT and NIH Roadmap projects are being performed to map the human DNA 
methylome to provide reference for investigators seeking disease-specific factors313-315.  It is 
hoped that these projects will provide the groundwork for further insight and prove as important 
for epigenetics as the Human Genome Project was for genetics.  Epigenetic techniques do not 
however have to be considered in parallel to classical genetic methods, and the combination of 
the two can usefully be applied in screening and other tests, as has already been demonstrated 
in small studies of stool DNA analysis for adenoma and carcinoma316.  It is worth noting at this 
point that much of the research into epigenetic aberrations in lower gastrointestinal cancers 
fails to distinguish colonic from rectal cancers, and thus much of the literature refers to 
colorectal cancer in general, although a small sub-population do focus on individual tumour 
sites.  This issue is highlighted by Jia in a meta-analysis of CIMP and its relationship to 
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outcomes in colorectal cancer, where only 1/30 included papers were specific to rectal 
cancer317, 318. 
 
3.1.3.2 Diagnosis  
Identifying and validating the consistency of aberrant methylation in CRC opens the possibility 
that DNA detected in serum or stool may provide a non-invasive means of diagnosing patients 
with CRC, and even detecting adenomas319.  Currently there are three commercially available 
serum tests for colorectal cancer, each of which is based up detecting hypermethylated 
(m)SEPT9 tumour DNA (Epi proColonâ 2.0; ColoVantageâ; Real Time mS9â)320-323.  Each 
test employs a qualitative PCR methodology to detect the presence of mSEPT9 (normally an 
unmethylated gene coding a protein involved in pseudopod protrusion and cell migration), but 
individually reported sensitivities range from approximately 40%-95% and specificities of 
80%-90% based on training and test cohorts of 250-1544 patients (typically 1:2 ratio of cancers 
to controls)320, 324. However, a recent meta-analysis by Song identified 25 investigations 
including 8643 participants (2613 CRC cases) examining the diagnostic accuracy of mSEPT9 
serum tests and reports that in the asymptomatic population mSEPT9 is inferior to FIT testing, 
although it may be superior in the symptomatic group325. The diagnostic accuracy described in 
this analysis was widely variable, with pooled analysis indicating the overall sensitivity for 
mSEPT9 ranged between 36.4% and 93.4%, dependent on the test algorithm employed and 
disease stage. The utility of mSEPT9 is further limited by heterogeneity in the assays and test-
models employed in binarizing or stratifying at-risk groups, its projected poor cost-
effectiveness in population-based screening, and limited utility in detecting adenomas326.  
These findings are corroborated by the American College of Gastroenterology led Multi-
Society Taskforce on Colorectal Cancer, who highlight the 48% crude sensitivity for cancer 
detection of mSEPT9 reported by Church (sensitivity ranged 35%-78%, increasing with 
disease stage), and thus do not recommend it as a diagnostic or screening test327, 328.   
 
Beyond mSEPT9, a number of other serum methylation-based diagnostic tests have been 
trialled, although in a limited manner.  A study examining the methylation status of frizzled-
related protein 2 gene demonstrated a sensitivity of 67% across serum, blood, and tumour 
samples, and a serum-based screening methodology identified methylated THBD as a potential 
biomarker for CRC, although it was only sensitive and specific (75% and 80%, respectively) 
for stage II and III disease329, 330.  Compound tests employing multiple methylation markers 
have also been trialled with a degree of success.  In a study of 243 patients, a test model (M-
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score) analysing hypermethylation at a set of four genes (APC, MGMT, RASSF2A, and Wif-
1) was sensitive (86.5%) and specific (92.1%) for the presence of sporadic colorectal cancer 
and large adenomas, translating to a positive- and negative-predictive value of 90.6% and 
88.8%, respectively (test cut-off 1.6)331. A further study based on a candidate-epigene 
methodology (restriction analysis) and subsequent microarray and RT-PCR analysis identified 
three hypermethylated markers (TMEFF2, NGFR, and SEPT9) with acceptable test 
binarization based on circulating DNA analysis between patients with colorectal cancer and 
controls, although not at a high enough level to provide a utilisable clinical test332.  Further 
studies of circulating tumour DNA methylation have proposed other epigenetic targets, 
although none has yet been translated into an implementable screening tool333, 334.  
 
Methylation-based stool tests have also been trialled, and currently a methylation analysis of 
the vimentin gene is under development in the USA, boasting a sensitivity of 83% and 
specificity of 82% irrespective of tumour location, stage, or patient age335.  However, two 
recent metanalyses of stool DNA tests, one specifically examining methylation in stool DNA, 
have demonstrated that in pooled cohorts of 2,356 and 5,876 individuals, no marker was 
superior to current screening tools in unselected populations, although methylation markers 
performed better than mutation markers (sensitivity 75% versus 67%, specificity 91% versus 
94%, respectively), all be it across different effects models (methylation fixed model; mutation 
random model)336, 337. 
 
Currently, there are no methylation-based serum or stool DNA tests that are used in the 
screening or diagnosis of CRC, including mSEPT9, and most guidelines do not directly address 
DNA based testing of any sort338.  Future evaluation of methylation-based markers such as 
hypermethylated GFRA1 and GSTM2, which were recently identified as potential diagnostic 
biomarkers in a genome-wide expressional analysis by Wei, may eventually prove fruitful if 
they can be translated into clinically utilisable tools339. 
 
3.1.3.3 Staging & Prognosis 
As previously discussed, there are multiple genes and other loci where aberrations in 
methylation have been associated with the development of colorectal cancer, and a growing 
body of evidence suggesting specific hypermethylation events occurring on the classical 
adenoma-to-carcinoma pathway, as well as the development of tumour metastasis307.  
Examples of genes that are frequently found to be methylated in the early stages of dysplasia, 
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including in aberrant crypt foci, are ITGA4, MGMT, SCL5A8, FFRP2, and MINT1340-343.  
Interesting, the study by Kim and later confirmed by Oster, suggests that hypermethylation at 
specific genes is predominantly an early feature in the adenoma-to-carcinoma pathway, as 
many of the hypermethylation events that are present in cancers are already present in early 
and late adenomas (Figure 3.4)343, 344. LINE-1 hypomethylation has also been shown to be 
associated with early adenomatous changes in the colorectal mucosa, and increased with a 
linear relationship to disease progression (adenoma-carcinoma-metastasis)345. As well as 
individually hypermethylated genes or loci, the CIMP phenotype is also detectable in late 
adenomas, particularly of the serrated subtype, but is generally not present in earlier lesions, 
leading to the speculation that this is a gateway hypermethylation event in the development of 
more advanced disease346. Despite the identification of hypermethylated genes and application 
of the CIMP phenotype, no reliable method of discriminating between hyperplastic polyps and 
sessile serrated adenomas has been reliably developed, partially because of the heterogeneity 
in CIMP studies already discussed in section 1.3.6.  As dysplastic polyps transform to invasive 
cancers further hypermethylation occurs at conserved sites, specifically CXLC12, TIMP3, ID4, 
and IRF8, although these markers have not yet proved adequate for risk-stratifying and guiding 
the subsequent management of resected polpys347. 
 
Figure 3.4  Aberrant Hypermethylation Events in the Adenoma-to-Carcinoma Pathway 





From a prognostic perspective, some aberrant methylation events have been associated with 
inferring an improved survival, such as MGMT and MLH1 hypermethylation, although 
hypermethylation of APC and p14 may infer a survival disadvantage348, 349.  Additionally, 
meta-analysis of 3440 CRC patients found that hypermethylation of p16 gene CDKN2A to be 
associated with a worse OS (HR 1.49, CI 1.28-1.74), as well as with lymphovascular invasion 
(HR 1.68, CI 1.15-2.47) and lymph node metastasis (HR 1.68, CI 1.09-2.59)350.  
Hypermethylation of HOPX-b, IGFBP3, EVL, CD109, and FLNC has also been associated 
with a worse prognosis, although the association to disease stage is less well defined in these 
cases306, 351. 
 
Since Toyota identified and first described CIMP, much of the focus relating to outcomes in 
CRC has been focused on methylator phenotypes rather than specific loci177, 317.  CIMP is 
known to be associated with differing clinical and molecular characteristics in colorectal cancer 
and has previously been linked to outcomes when associated with MSI status and BRAF 
mutation178, 352.  These studies have not, however, demonstrated an independent relationship 
between CIMP and outcomes for a number of reasons; firstly, due to lack of statistical power 
and the necessity of compound modelling, but more importantly due to the heterogeneous 
methodologies employed in determining CIMP.  In Dahlin’s study of 604 patients from two 
Swedish databases, CIMP-L was found to be associated with poor survival compared to CIMP-
negative irrespective of microsatellite status, but inconsistently across cohorts in MSS groups.  
CIMP-H was also found to have a worse prognosis in the MSS groups, but the effect was lost 
in pooled analysis352.  No relationship was evident between CIMP and cancer specific survival 
in the MSI pools.  In this study the proportion of CIMP-negative patients was approximately 
50%, with CIMP-L and CIMP-H contributing 35% and 15%, respectively.  MSI was associated 
with CIMP-H, although statistical significance for RR was not achieved due to the small 
numbers involved (HR not interpretable on multivariate analysis).  Although the datasets and 
the methodology of assessing methylation at each gene promotor region (bisulfite conversion 
and MethlyLight Q-RT-PCR) in this study are robust, the categorisation into CIMP status is 
essentially arbitrary; based on a simple and non-validated system of categorised cumulative 
numbers of methylated genes (CIMP-negative = 0 genes methylated; CIMP-L = 1-5 genes 




To further investigate the relationship between CIMP and survival outcomes Juo performed a 
meta-analysis of 33 studies including 10,635 patients which demonstrated that CIMP is 
significantly associated with shorter DFS (pooled HR 1.45, CI 1.07-1.97) and OS (pooled HR 
1.43, CI 1.18-1.73) irrespective of microsatellite instability353.  The same study also examined 
survival following 5FU therapy based on CIMP status and found directly contradicting 
evidence for both survival advantage and disadvantage in different studies that lead to non-
significance in meta-analysis.  Although a strong indicator for CIMP being associated with 
poor outcomes in CRC, Juo’s meta-analysis demonstrated further that there is a high degree of 
heterogeneity in the patient cohorts included in analysis, and in the methods by which CIMP 
is classified.  Of the 33 studies included, 21 employed a dichotomised CIMP classification 
while the remainder employed a trichotomized methodology, and there was an even greater 
range of genes within each panel (ranging from 3 to 13 individual genes/loci), as well as 
methods for determining methylation status at each locus (described by Juo as, “often chosen 
arbitrarily”).  A pooled analysis of the different methodologies used to determine CIMP was 
performed by Jia and Guo in an attempt to discern if one panel was more associated with 
outcomes than another, but unfortunately no significant relationship between any one panel 
and clinical outcomes was discovered, although a consensus was reached that CIMP-positive 
as determined by any panel was likely to confer a worse survival outcome317.  The authors 
speculate that the lack of superiority in one panel over another is due to the large number of 
and high degree of overlap in the genes used in each panel, although CACN1G, IGF2, 
NEUROG1, RUNX3, hMLH1, p16, MINT1, MINT2, and MINT31 were most commonly 
used. 
 
Few studies specifically address the survival of rectal cancer patients in relation to CIMP status 
as most present mixed cohorts of colon and rectal cancers. Samowitz examines a population of 
864 cancers where 103 were found to be CIMP-positive based on a dichotomized panel of five 
genes (MHL1, MINT1, MINT2, MINT31, and CDKN2A) where ³2 loci being 
hypermethylated indicating CIMP-positive318.  The authors chose this panel and system based 
on their previous use of the method in previous publications but do not offer further justification 
beyond stating that there is currently no consensus in determining CIMP175, 354.  This study 
reports that the 5-year survival for CIMP-negative and CIMP-positive is 72.0% and 63.2%, 
respectively (p=0.04) with an unadjusted hazard rate ratio (HRR) of 1.43 (CI 1.01 – 2.01), 
although the HRR fell to 1.32 and 95% CI crossed 1.0 (0.88 – 1.97) on multivariate analysis. 
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In another study by Jo, 150 patients with locally advanced rectal cancer enrolled in two phase 
III clinical trials (CAO/ARO/AIO-94 and -04) were analysed for dichotomized CIMP status 
based on a panel of five genes (RUNX3, SOCS1, NEUROG1, IGF2, and CAGNA2G)149.  
CIMP status was associated with a worse 3- and 5-year disease-free survival for patients 
identified as CIMP-positive versus -negative (56% vs 0%, and 85% vs 75%, respectively; HR 
5.5 (CI 2.1 – 13.9). In this study, CIMP-positive was based on ³3/5 loci being hypermethylated 
and accounted for only 10% of the study population.  
 
 
3.1.3.4 Response to Therapies 
There are conflicting reports of the impact of epigenetic events in the response of CRC to 
chemo- and radiotherapy, and the field is plagued by the same inconsistencies in methodology 
that limit the analysis of methylation in diagnosis and outcomes.  Williamson reviews the 
development of CIMP as a marker for outcomes in rectal cancer, specifically in response to 
neoadjuvant therapy, summarising the findings that both hypermethylation and 
hypomethylation may have important prognostic roles in defining the response of lower 
gastrointestinal cancers to CRT. However, as study cohorts are frequently a mix of colon and 
rectal cancers there is inconsistency in CIMP-determining methodologies and in definitions of 
response to therapy (such as tumour regression grades - TRG) there is no consensus148.   
 
Specific examples of aberrant methylation affecting response to therapies have however been 
reported, including hypermethylated MGMT which is found in approximately 40% of CRC. In 
a phase II study of 68 patients with metastatic disease who have exhausted other therapies, 
methylated MGMT has been associated with a response to dacarbazine, where no response was 
detected in patients with the non-methylated gene355, 356. Furthermore, Sun reports that a greater 
reduction of methylated MGMT in circulating tumour DNA was observed in patients 
demonstrating a good response to CRT (assessed by TRG) compared with those that did not 
respond well, although the number of participants in this study was extremely limited357.  
Molinari identified that methylation of the TIMP3 tumour suppressor gene was found to be 
different between tumours categorised on the basis of their TRG (ANOVA, p<0.05), although 
it was not differentially methylated between tumour and healthy tissues prior to treatment.  The  
case series was also restricted to 74 patients, limiting its predictive value, and the only markers 
found to be differentially methylated between cancerous and healthy tissue were ESR1, 
CDH13, RARB, IGSF4, and APC, although none of these genes was predictive of response to 
 76 
therapy or changed in methylation status following therapy358.  In a study of 155 stage II and 
III tumour samples, Kawakami showed that LINE-1 hypomethylation was associated with a 
better response to adjuvant oral fluoropyrimidine therapy and overall survival compared to 
patients with high LINE-1 methylation359.   
 
As well as potential predictors of favourable response, methylation has also been identified as 
a predictor of poor response.  In a study by Ebert, hypermethylation of the TFAP2E gene was 
associated with poor response to CRT irrespective of regime, demonstrating a less that 10% 
tumour-regression rate compared with 82% of tumours with hypomethylated gene(p<0.001)360.  
Williamson also showed that CIMP assessed on the two-panel approach advocated by Kaneda 
and Yagi was significantly associated with EMVI, which itself was found to be an independent 
predictor of poor disease-related outcomes, in line with the wider literature185, 186, 204.  However, 
in the previously discussed study by Jo, no association was found between CIMP status and 




Methylation is emerging as an important biomarker in colorectal cancer.  Its limitations are 
partly in the complexity of epigenetic events that are detectable in the carcinogenic pathway 
and discriminating between what is significant and what may be incidental.  Additionally, 
divergence in methodologies for assessing individual gene promotor hypermethylation and in 
classifying CIMP has led to a lack of robustness in the evidence supporting its role CRC.  This 
problem is not limited to CRC but is also a factor in defining the role of epigenetics in other 
tumour types, including gastric, breast, and many others361-363.  The problems are however 
more acute in rectal cancer as it is most commonly included in broader cohorts of colorectal 
cancer; limiting the insight into what is increasingly becoming regarded as a separate disease 






3.2 Aims & Objectives 
 
Rectal cancer is a disease that has a unique natural history and poses specific challenges to 
patients, clinicians, and scientists.  Disease-specific outcomes for rectal cancer are worse than 
those for colonic cancers, as demonstrated by worse disease-free and overall survival.  Rectal 
cancer also presents operative challenges that are generally not applicable to colonic tumours, 
especially when considering operating within the bony pelvis and constructing a “low” 
anastomosis. From a patients’ perspective, pelvic surgery is frequently morbid and associated 
with the risk of significant side-effects and even death.  Locally-advanced and locally-recurrent 
rectal tumours also frequently require neoadjuvant chemoradiotherapy (nCRT) to improve 
resection rates and reduce local recurrence, the administration of which is largely based on 
radiological staging.  The presence of extramural vascular invasion (EMVI) is an important but 
inconsistently assessed component of this evaluation, meaning a proportion of patients with 
EMVI who may benefit from nCRT do not receive it.  However, not all patients that are eligible 
for neoadjuvant therapy will benefit from it, and some may be better treated by primary surgery. 
Currently there is no method of predicting which tumours will respond to neoadjuvant therapy. 
 
The role of epigenetic aberrations in colorectal cancer is not well defined.  Methylation 
analysis, including CpG Island Methylator Phenotype (CIMP) classification, has been 
suggested as important in defining the pathogenesis, diagnosis, prognosis, and response to 
therapy of colorectal cancer; although currently there is no defining evidence of a clinically 
utilisable methylation-based investigation that is significant in managing individual patients 
with rectal cancer. 
 
The general aims of this chapter are to investigate the methylation status of rectal cancers based 




3.3 Material & Methods 
3.3.1 Patient Selection, Data Collection, & Storage 
One hundred consecutive rectal cancer patients were extracted from the prospectively 
maintained database as described in section 2.1.1 & 2.1.2, and in accordance with the ethics 
laid out in section 2.1.3. As previously stated, patients were neoadjuvant therapy naïve, and 
exclusion criteria also included patients with hereditary or other identifiable predispositions to 
carcinogenesis, such as inflammatory bowel disease.  Patients who had received locoregional 
radiotherapy or prior chemotherapy within 10 years for other malignant diseases (such as 
radiotherapy for prostate cancer or previous chemotherapy for breast cancer) were also 
excluded.  All patients underwent index surgery between January 2010 and May 2013 at a 
single centre (ABMU, Morriston Hospital, Swansea, SA6 6NL, UK) by a team of surgeons 
participating in the Swansea Pelvic Oncology MDT.   
 
Tumour height was defined as low rectal (within 5cm of the anus), mid rectal (5-10cm form 
the anus), or high (³10cm from the anus) dependent on the lowest extent of the tumour on 
initial MRI.  Tumours at the rectosigmoid junction where the bulk of the tumour was located 
in the sigmoid, negating a TME excision, were excluded.  Gender was dichotomised.  Tumour 
characteristics were defined as per the ACPGBI or Royal College of Pathology guidelines with 
respective relation to pre-operative (mTNM) or postoperative (pTNM) staging and other 
tumour characteristics (CRM, differentiation, EMVI)35, 206.  All patients underwent full pre-
operative staging as described by the ACPGBI guidelines; including computed tomography of 
thorax, abdomen, and pelvis; high-resolution magnetic resonance imaging of the pelvis; and in 
selected cases, endorectal ultrasound206.  All cases were confirmed by biopsy taken pre-
operatively at endoscopy and cases other than adenocarcinoma (squamous, melanoma, 
sarcoma, gastrointestinal stromal tumour) were excluded.  Surgical treatment included anterior 
resection, abdomino-peroneal resection, and beyond-TME procedures in keeping with 
guidelines, patient choice, and expertise (see section 1.2).  Adjuvant chemotherapy was 
administered based on current guidelines and best-practice. 
 
Investigators were blinded to individual and identifying patient data during sample processing 
and analysis by a process of anonymisation.  After the core data clinical was collected and 
samples extracted from archive, information linking samples to patient information was 
randomised and only re-associated following completion of data collection to prevent bias.  
Patient identifiable data was stored on an encrypted and password protected spreadsheet, and 
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information linking specimens for laboratory analysis to individuals was kept in a locked filing 
cabinet away from the laboratory, in keeping with the principles of NIHR Good Clinical 
Practice (GCP) and the UK Policy Framework for Health and Social Care Research364. 
 
3.3.2 Tissue Collection 
Tissue was extracted from the archives of ABMU Singleton Hospital Department of Pathology 
(Sketty Lane, Swansea, SA2 8QA, UK).  Tissues were supplied in triplicate as fixed-in-
formalin paraffin-embedded (FFPE) slides at 5µm thickness.  Slides were stained with 
haematoxylin and eosin (H&E) and checked by consultant histopathologist to ensure that each 
contained a minimum of 60% tumour.  Where tumour was less than 60% of slide tissue it was 
marked so it could be selectively dissected from the slide to provide a more representative 
sample of tumour for analysis.  Three slides were used for each patient to ensure adequate 
tumour DNA extraction. 
 
3.3.3 DNA Extraction 
Slides underwent de-waxing by submersion in 100% xylene for 5 minutes at room temperature, 
repeated twice in the laboratory fume hood.  Slides were then submerged in 100% ethanol for 
a further 5 minutes and allowed to air dry at room temperature. Tumour cells were then 
removed using a clean scalpel blade by scraping into a 1.5ml eppendorf microcentrifuge tube.  
DNA from tissues was obtained using the MasterPure Complete DNA and RNA purification 
kit (Epicentre, Illumina, Wisconsin, USA).  A mixture of 2 μl proteinase K and 300 μl of Tissue 
and Cell Lysis Solution was applied to each sample and vortexed thoroughly.  This mixture 
was then incubated at 65°C overnight (minimum 12hrs) in a heater block and then re-vortexed 
the following day. This protocol is a slight deviation from the manufacturers protocol (longer 
incubation), as a prolonged period at 65°C was shown to increase DNA yield.  Samples were 
then cooled to 37°C and 1 μl of RNase A was added to the sample and vortexed. This was 
incubated at 37°C for 60 minutes. The samples were placed on ice for 3-5 minutes before 
proceeding with DNA extraction.  
DNA extraction was performed by adding 175 μl of MPC Protein Precipitation Reagent to 300 
μl of lysed sample and vortexed vigorously for 10 seconds. The debris was pelleted by 
centrifugation at 4°C for 10 minutes at ≥10,000 x g in a microcentrifuge. The supernatant was 
transferred to a clean microcentrifuge tube, the pellet was discarded, and 500 μl of isopropanol 
 80 
was added to the recovered supernatant. The eppendorf containing the supernatant was then 
inverted 40 times to mix contents and precipitate DNA.  
The mixture was then centrifuged again 4°C for 10 minutes at ≥10,000 x g to pellet the DNA. 
The isopropanol was carefully poured off without dislodging the DNA pellet. The pellet was 
then rinsed gently twice with 70% ethanol. Residual ethanol was removed with a pipette and 
the samples were left to air dry for 10 minutes. The DNA was re-suspended in 35 μl of TE 
Buffer.  
The quantity and quality of DNA was measured at absorbance between 230nm and 320nm 
using spectrophotometry (Nanodrop ND-1000, Software v 3.1.2, Thermoscientific, Delaware, 
USA). DNA quantity was calculated by multiplying the measured concentration following 
spectrophotometry at 260nm with the dilution factor. DNA was diluted to a working 
concentration of 20ng μl-1. Purity was further assured by calculating the absorbance at 260nm 
to absorbance at 280nm ratio.  Extracted DNA was stored at -20°C during active 
experimentation and archived at -80°C when not in use. 
 
3.3.4 Bisulfite Conversion 
Methylation specific PCR (msPCR) was carried out as a two-stage process of bisulfite-
conversion and then amplification by bisulfite-specific primers, as described by Herman 
(Figure 3.5)365.  The process of bisulfite-conversion first exchanges unmethylated cytosine in 
CpG islands for uracil, and then subjects the converted DNA to parallel PCR reactions with 
primers targeted at the CpG islands of the genes of interest; one primer amplifying CpG islands 
containing uracil, and the other amplifying native methylated cytosine.  Genes with 
unmethylated CpG islands will amplify against the converted uracil primer, and those with 
methylated CpG islands will amplify against the cytosine primer.   
 
Bisulfite conversion was performed using the Imprint DNA Modification Kit (Sigma Aldrich, 
St. Louis, USA). A two-step bisulfite-conversion protocol was employed as per the 
manufacturers recommendation as a means of producing high-quality DNA from a low-
quantity input (100 pg to 10 ng); the first step performs bisulfite conversion and the second 




Figure 3.5 Bisulfite conversion & the nucleotides cytosine and uracil. 
 
The DNA modification solution was first prepared by adding 1.1 ml of DNA Modification 
Solution to 1 vial of DNA Modification Powder.   This mixture was vortexed for 2 minutes at 
room temperature and then 40 μL of Balance Solution was added, before a further brief vortex. 
The vial was examined for any undissolved particles was incubated at 65°C for 2 minutes if 
any were present, followed by further vortex.  DNA was placed in a 1.5 ml micro-centrifuge 
tube and 110 μL of the prepared DNA modification solution was then added into the DNA and 
mixed by gentle pipetting.  The mixture was the incubated at 99°C for 6 minutes and then at 
65 °C for 90 minutes.  
Clean-up was then performed by placing a spin column into a cap-less collection tube to which 
300 μL of Capture Solution had been added and allowed to sit on the column for 1 minute. The 
modified DNA solution was then placed into the spin column and centrifuged at 12,000 x g for 
20 seconds at 4°C. The flow-through was then discarded. 200 μL of an ethanol-diluted cleaning 
solution was the added to the spin column and centrifuged for 20 seconds. 50 μL of a 
balance/ethanol wash solution was added to the bottom of the spin column and incubated for 8 
minutes at room temperature. After incubation, further centrifugation for 20 seconds was 
performed and the flow-through discarded. 200 μL of 90% ethanol solution was then added to 
the spin column and centrifuged for 20 seconds and the flow-through again discarded. The cap-
less collection tube was then discarded, and the spin column placed into a 1.5 ml collection 
tube. 20 μL of elution solution was then added to the bottom of the spin column to extract the 
DNA from the column and return to solution.  The spin column and elution solution were 
incubated for 1 minute at room temperature and then centrifuged for 20 seconds. The spin 
column was then discarded, and the eluted solution collected contained the purified bisulfite 
modified DNA. Modified DNA the proceeded directly to msPCR or was stored at –20°C for 
up to 2 months.  
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3.3.5 Methylation Specific PCR (msPCR) 
All msPCR took place in the T100ä Thermal Cycler (Bio-Rad, Berkeley, CA, USA).  Oligos 
and PCR conditions had previously been sourced and optimised by colleagues in-house during 
preceding research and from previously published studies and had also been further 
interrogated against methBlast bioinformatic software for target specificity204, 365.  The genes 
targeted whose CpG islands are targeted are hMLH1, SOCS1, MINT1, THBD, IGFBP3, 
HAND1, ADAMTS1 and NEUROG1. Target genes were selected based on the Kaneda & Yagi 
system for CIMP assessment (see section 1.3.6 and 3.3.7)185.  For oligonucleotides refer to 
section 2.2.5.  Desalted oligonucleotide PCR primers (Sigma Aldrich, UK) were diluted to a 
working concentration of 10uM and stored at -20°C with all other PCR reagents.  Conditions 
for each primer are set out in Appendix I.  Preparation for each msPCR took place in laminar 
flow hoods cleaned with 70% ethanol solution and allowed to air dry under UV light to reduce 
the risk of DNA cross contamination or fouling of reactions.  PCR-grade filtered pipette tips 
were used for handling DNA and reagents, and reactions were performed in micro-eppendorfs.  
msPCR reactions were carried out in a volume of 25 μL per sample as per Table 3.1. 
 
Table 3.1 msPCR reagents. 
Constituent Volume 
GoTaqÒ Hot Start Green Master Mix 
(Promega, Madison, WI, USA) 
12.5 μL 
Nuclease Free Water (Ambion) 10.5 μL 
Forward Primer (200 nM) 0.5 μL 
Reverse Primer (200nM) 0.5 μL 
Bisulfite Converted DNA (40ng/μL) 2 μL 
 
msPCR utilised a hot-start protocol consisting of an 8-minute hot start at 95°C followed by 
denaturing at 95°C for 30 seconds, then annealing at temperatures and durations specifically 
optimised to the primers (typically 30 to 37 seconds and 50-61 oC). An extension phase at 
72°C followed and the cycle repeated. Positive controls for both the methylated and 





3.3.6 Visualisation of PCR Products 
msPCR products were visualised by gel electrophoresis on 6% polyacrylamide gels against a 
100bp DNA ladder containing 11 dsDNA fragments of 100-1000bp (in 100bp steps) & 1500bp 
(Promega, Madison, WI, USA).  Hand formed 15-lane 1.5mm polyacrylamide gels were made 
in duplicate according to the following recipe: 16 ml dH2O, 2.25 ml 10x TBE, 4 ml acrylamide, 
110 µl 10% APS, 22 µl TEMED.  This mixture was mixed by pipetting and transferred to two 
gel casts and allowed to polymerise for 60 minutes.  Gels were then submerged vertically in 
electrophoresis tanks containing 1x TBE buffer and 10µL PCR product was mixed with 2 µL 
coloured loading buffer (RETROscript, Invitrogen) and then loaded into each well. 
Electrophoresis was performed at 170V, 400mA for 25 minutes or until the loading dye had 
reached the bottom of the plate.  
 
Following electrophoresis, the gels were separated from their glass casting plates and stained 
by sequentially submerging into silver nitrate solution (1g/L) for 7 minutes and then 
submerging in formaldehyde & sodium hydroxide solution for 2 minutes until visualisation of 
bands was achieved.  Gels are then rinsed with dH2O and photographed in white light using 
Gel Doc XR (Bio-Rad) system and Quantity One software to adjust the brightness and size of 
the image (Bio-Rad). Gels were then discarded into a hazardous waste container. 
 
3.3.7 CIMP Classification 
CIMP status was classified according to the methodology described by Kaneda & Yagi185.  This 
method was chosen due to the approach taken to classifying CIMP status, as discussed in 
section 1.3.6. The epigenotyping system is again described below. 
• CIMP-High if ³ 2/3 of Group 1 markers are methylated, irrespective of Group 2 
markers 
• CIMP-Intermediate if 1/3 Group 1 markers and ³3/5 Group 2 markers is methylated 









3.3.8 Statistical Analysis 
Data analysis was performed using the Microsoft Office Excel (v.16.12) and the XLStat 
Addinsoft (v.2017) plug-in (macro).  Results were expressed as mean +/- standard error of the 
mean (SEM) where appropriate. Normalcy of data distribution was determined using a 
Kolmogorov-Smirnov test. If data were normally distributed, statistical significance was 
determined using Student’s t-test for single comparisons or one-way ANOVA where more than 
one comparison was made. If data were not normally distributed, Mann-Whitney’s test was 
used to compare unpaired means and Wilcoxon test used for paired data.  Log-Rank (Mantel-
Cox) tests were used where data was right-side skewed and censored.  Comparison of expected 
frequencies was performed with two-tailed Chi Squared or Fishers exact test if observed events 
were less than 10. Survival curves were calculated using Kaplan-Meier estimate. The null 






3.4.1 Patient and Tumour Characteristics 
There were 100 patients included in this study (44 patients with an EMVI-positive tumour and 
56 with no evidence of EMVI). Seventy patients were male, with a statistically significant 
proportion of male patients demonstrating EMVI positivity (82% positive vs 61%, p=0.022).  
The median age was 70 years (range 45 – 89 years), and patients were of a similar age in both 
groups.  Nineteen patients had died at the time analysis was undertaken (01/09/2017).  Median 
follow up was 54.2 months (IQR 25 – 68 months).  Mean overall DFS and OS were 29 and 34 
months, respectively.  When differences between both groups were analysed (Table 3.2), 
patients with EMVI-positive tumours had more advanced pathological staging by pT, pN, and 
AJCC classifications (p=0.002, p=<0.0001, and p-<0.0001, respectively).  There was a 
corresponding association between EMVI-positive tumours and the need for adjuvant 
chemotherapy (p=<0.0001).  There was, however, no statistically significant difference in 
CRM positivity (p=0.86), tumour perforation (p=0.07) or tumour differentiation (p=0.52).  
 
Figure 3.6 Resolved polyacrylamide gel demonstrating tandem-PRC products for methylated 
(M) & unmethylated (U) primers against samples (1-4) with controls & DNA ladder. Samples 
1 & 2 were methylated (strong M bands as well as U bands), samples 3 & 4 unmethylated (U 
bands only). Two negative control reactions (no template DNA) and a positive control lane 







3.4.2 CIMP Classification & EMVI 
There were a total of 51 patients with CIMP-L, 48 patients with CIMP-I, and one patient with 
CIMP-H phenotype (Table 3.3). The assessment of 40 patients’ CIMP status was conducted 
by a co-investigator, although all subsequent analysis was performed by the author.  Chi-square 
(Pearson) demonstrated a positive correlation between EMVI-positive tumours and CIMP-
intermediate epigenotype (p=<0.001).  This effect was preserved if the single CIMP-high 
sample was amalgamated with the CIMP-intermediate group (p=0.00014) and did not 
significantly affect any of the regression analysis performed henceforth. 
 
CIMP-intermediate labelling was associated with worse tumour pAJCC stage (p=0.03) and 
showed a trend towards association with the need for adjuvant chemotherapy (p=0.055), but 
was not associated with T or N stage, tumour height, sex, or CRM involvement (Table 3.4).  
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Table 3.2.  Patient and Tumour Characteristics  





Median Age (range) 72 (45-85) 69 (46-89) 0.862 
Sex (male) 36 (82%) 34(61%)  0.022* 
Tumour Height   0.34 
Upper (10-15cm) 8 (30%) 17 (27%)  
Mid (5-10cm) 23 (43%) 23 (47%)  
Lower (0-5cm) 13 (27%) 16 (27%)  
pT   0.002* 
T1 0 (0%) 1 (2%)  
T2 2 (5%) 12 (21%)  
T3 31 (75%) 41 (70%)  
T4 11 (20%) 2 (7%)  
pN   <0.0001* 
N0 8 (20%) 42 (73%)  
N1 21 (46%) 7 (14%)  
N2 15 (34%) 7 (13%)  
pAJCC   <0.0001* 
1 0 (0%) 8 (27%)  
2 8 (16%) 37 (41%)  
3 32 (75%) 9 (27%)  
4 4 (9%) 2 (5%)  
CRM +ve 1 (3%) 1 (3%) 0.86 
Tumour Perforation 6 (7%) 2 (9%) 0.07 
Tumour Differentiation   0.52 
Poor 6 (14%) 5 (9%)  
Moderate 38 (87%) 50 (89%)  
Well 0 (0%) 1 (2%)  
Non-Restorative Operation 18 (27%) 20 (46%) 0.60 
Adjuvant Chemotherapy 31 (68%) 10 (16%) <0.0001* 
Systemic Recurrence 15 (30%) 11 (13%) 0.10 
Local Recurrence 3 (7%) 3 (5%) 0.76 
 
1Pearson’s Chi Square. EMVI, Extramural Vascular Invasion; pAJCC, American Joint Cancer Committee 




Table 3.3 CIMP Classification and EMVI status 
 





CIMP-low 13 (30%) 38 (68%)  
CIMP-intermediate 31 (70%) 17 (30%)  
CIMP-high 0 (0%) 1 (2%)  
 






Table 3.4. CIMP status and association with patient and tumour factors.  
 
 CIMP-I (n=48) 
CIMP-L 
(n=51) P-value 
Median Age (range) 67 (45-89) 70 (47-89) 0.862 
Sex (male) 33 (68.8%) 36 (70.6%) 0.42 
Tumour Height   0.33 
Upper (10-15cm) 13 (27.1%) 12 (23.5%)  
Mid (5-10cm) 25 (52.1%) 21 (41.2%)  
Lower (0-5cm) 10 (20.8%) 18 (35.3%)  
pT   0.17 
T1 0 (0.0%) 1 (2.0%)  
T2 4 (8.3%) 9 (17.6%)  
T3 36 (75.0%) 36 (70.6%)  
T4 8 (16.7%) 5 (9.8%)  
pN   0.28 
N0 24 (50%) 26 (51.0%)  
N1 17 (35.4%) 11 (21.6%)  
N2 7 (14.6%) 14 (27.5%)  
pAJCC   0.03* 
1 0 (0.0%) 8 (15.7%)  
2 24 (50.0%) 21 (41.2%)  
3 20 (41.7%) 20 (39.2%)  
4 4 (8.3%) 2 (3.9%)  
CRM +ve 2 (4.2%) 0 (0.0%) 0.15 
Tumour Perforation 4 (8.3%) 4 (7.8%) 0.98 
Tumour Differentiation   0.58 
Poor 5 (10.4%) 6 (11.8%)  
Moderate 43 (89.6%) 44 (86.3%)  
Well 0 (0.0%) 1 (2.0%)  
Non-Restorative Operation 16 (33.3%) 22 (43.1%) 0.25 
Adjuvant Chemotherapy 25 (52.1%) 16 (31.4%) 0.055 
Systemic Recurrence 13 (27.1%) 7 (13.7%) 0.61 
Local Recurrence 3 (6.3%) 3 (5.9%) 0.98 
 
1Pearson’s Chi Square, 2Students T-Test. EMVI, Extramural Vascular Invasion; pAJCC, American Joint Cancer 




Using a multivariable logistic regression model (Table 3.5), CIMP status remained a highly 
significant predictor of EMVI status (p=0.001), independent of pAJCC staging (p=<0.001). 
When considering the development of systemic recurrence, only the presence of a perforated 
tumour was significantly associated (p=0.038).  Only EMVI positivity was associated with 
poor DFS (p=0.038), but not significantly associated with poor OS, although trend was 
observed (p=0.08) for both EMVI positivity and CIMP-I status (p=0.08) (Figure 3.6). 
 
Table 3.5 Multivariable Logistic Regression analysis of factors associated with EMVI, 
Metastatic Disease, and Overall & Disease-Free Survival:  Standard Coefficients (SC) & 
Hazard Ratios (HR). 
 Factor SC or HR (95% CI) P value 
EMVI CIMP Intermediate 1.27 (0.55-1.91) 0.001*1 
  Male Sex  -0.13 (-0.59-0.34)  0.591 
  Increasing pAJCC stage  1.17 (0.59-1.76)  <0.001*1 
  CRM positivity  0.09 (-0.32-0.50)  0.661 
  Perforated Tumour  0.21 (-0.26-0.68)  0.381 
  Non-restorative Operation  -0.27 (-0.75-0.20)  0.261 
 Systemic Recurrence  CIMP Intermediate  0.78 (-0.20-1.76)  0.121 
  Male Sex  -0.79 (-1.81-0.24)  0.131 
  Increasing pAJCC stage  -0.36 (-1.46-0.73)  0.511 
   CRM positivity  0.14 (-0.29-0.57)  0.531 
  Perforated Tumour  0.54 (0.04-1.04)  0.034*1 
  Non-restorative Operation  0.56 (-0.19-1.31)  0.141 
 Overall Survival (OS)  CIMP Intermediate  0.36 (0.12-1.12)  0.082 
  EMVI Positive  4.59 (0.85-24.69)  0.082 
  Increasing pAJCC stage   0.912 
  Perforated Tumour   0.992 
 Disease-Free Survival 
(DFS)  CIMP Intermediate  0.39 (0.13-1.18)  0.10
2 
  EMVI Positive  5.98 (1.10-32.50)  0.038*2 
  Increasing pAJCC stage   1.02 
  Perforated Tumour   1.02 
 
1Binary Logistic Regression, 2Cox Proportional Hazard. CIMP, CpG Island Methylator Phenotype, EMVI, 
Extramural Vascular Invasion; pAJCC, American Joint Cancer Committee pathological stage; CRM, 





Figure 3.7  Cox log(-log(survival)) analysis for EMVI versus DFS (a) and OS (b), 
demonstrating a significant association with poor DFS (left-shift, p=0.038), but not OS 
(insignificant but trend towards left-shift, p=0.08). 














3.4.3 Survival Analysis 
Kaplan-Meier analysis (Figure 3.7) demonstrated that overall survival (OS) and disease-free 
survival (DFS) were greater in the EMVI-negative group, but only reached statistical 
significance for DFS, although strong trend was observed for OS (p=0.012 and p=0.52 
respectively, by log-rank). This effect was however overcome by Gehan-Breslow-Wilcoxon 
method (which weighs positively for early deaths (p=0.018 and p=0.028 for DFS and OS, 
respectively).  CIMP status was not statistically related to DFS or OS, although CIMP and OS 
approached significance at p=0.08.  There was a total of 20 patients with systemic metastases 
(two of these had synchronous metastases) and six had local recurrence.  Although a 
significantly greater number of patients with EMVI-positive tumours received adjuvant 
chemotherapy (p<0.0001), this relationship was not observed for CIMP-intermediate tumours, 
although trend was observed (p=0.055). Significance was not achieved through a re-sampling 
(bootstrapping) technique. 
 




















The aim of this chapter was to investigate the methylation status of rectal cancers based upon 
CIMP and determine if there was any association with EMVI or other clinicopathological 
variables that may impact outcomes.  The findings are considered in the context of the poorer 
outcomes from rectal cancer in terms of local and systemic recurrence, and survival.  
 
A clear association was demonstrated between the presence of pEMVI and male sex, T and N 
stage, AJCC classification, and the requirement for adjuvant chemotherapy. EMVI has 
previously been shown to be an independent risk factor for systemic and local recurrence, and 
death; and is an indication for adjuvant chemotherapy276-278, 293.  This study confirms the 
association of EMVI with worse clinicopathological features, and on Kaplan-Meier analysis, 
these translated into statistically significant survival disadvantage, in keeping with the findings 
of Smith (Figure 3.3)280.  Currently, neoadjuvant therapy from rectal cancers is advised on the 
basis of threatened circumferential resection margins as demonstrated on preoperative 
radiological imaging, but tumour genetic and epigenetic analysis is not routinely part of pre-
therapeutic assessment85.  By associating CIMP epigenotype with EMVI, the possibility of 
utilising neoadjuvant therapies in patients who are not demonstrated to have locally advanced 
disease by radiological standards, but who may be judged to be at higher risk based on 
epigenetic tumour profiling, may improve outcomes.  For this reason, it is important to 
understand the role that epigenetic phenotypes may have on tumour behaviour so that they may 
be harnessed to therapeutic effect and inform clinical decision making. 
 
Although a significant relationship was demonstrated between CIMP-intermediate status and 
EMVI positivity, this was not translated in to a disease-free or overall survival disadvantage 
for CIMP-intermediate patients based on Kaplan-Meier analysis, despite EMVI-positivity 
being an independent risk-factor for disease recurrence (Cox Proportional Hazard r=5.98 (1.10-
32.50), p=0.038). These findings are in keeping with prior results in a similar cohort from our 
own unit, which indicate a positive correlation between CIMP-high status and EMVI in a series 
of 160 rectal cancers undergoing neoadjuvant treatment; although this did not translate into a 
significant relationship to survival204. There was also no significant relationship between 
KRAS or BRAF and CIMP.  More broadly, results published by Kim also demonstrated that a 
higher CIMP status was associated with worse DFS, but only for colonic tumours as opposed 
to rectal tumours based on a mixed cohort of 157 patients366. In another study, high CIMP 
epigenotype was also found to be associated with worse overall- and progression-free survival 
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in patients with metastatic colorectal cancer, although this study also included both colonic and 
rectal tumours367.  Each of these studies are contributory to the hypothesis that CIMP positivity 
is associated with more locally advanced tumour types and poorer clinical outcomes, although 
the relationship is not straightforward. In a review of 20 heterogeneous studies, Gallois 
discusses the prognostic value of EMVI in mixed cohorts of colorectal cancers, concluding that 
currently there is not sufficient evidence to support EMVI as a prognostic indicator368.  Despite 
the differences between the panels used and mixed cohorts, what is clear is that the relationship 
between CIMP status and clinical outcomes is not solely limited to the relationship to EMVI, 
else DFS and OS outcomes would be more closely aligned; pointing towards additional roles 
for methylation in processes such as response to CRT, cell death, and tumour-immunological 
interaction.   
 
The consensus molecular subtyping (CMS) of colorectal cancers has identified 4 distinct 
tumour subtypes based on molecular analysis, with CMS1 being defined as typically 
hypermethylated and associated with the serrated pathway in the proximal large bowel, rather 
than in the rectum118, 201. In the original CMS study, the frequency of CMS1 reported in the 
rectum was 3%. Considering this, the dataset in this study of 100 consecutive patients with 
rectal cancers, given exclusions, demonstrated a higher than expected proportion of CIMP-
intermediate and -high (49%) which may be considered as analogous to CMS1 tumours.  
Although the CIMP-I and CIMP-H groups were considered as one for the purposes of analysis 
(equivalent to CIMP-positive in other studies), this finding does question the assumption that 
hypermethylation is a predominantly right colonic finding associated with the serrated pathway 
and may therefore represent an under-reported subgroup of rectal cancers.  These findings must 
be considered in the context of the methodology chosen to determine CIMP (Kaneda & Yagi), 
although as previously discussed, there is no consensus on determining CIMP and the 
methodology employed in this study was chosen for its robustness and use throughout other 
contemporaneous investigations, although other methods may have returned a lower 
frequency185, 186. 
 
One reason for the discrepancy is that the cohorts examined are not alike in several ways, 
especially when considering the relatively selective cohort used in this chapter (exclusion of 
patients who had received neoadjuvant therapy, for example) compared to the inclusive nature 
of the Guinney study which was based on eighteen public and proprietary colorectal cancer 
datasets comprising 4,151 patients201.  However, although the Guinney dataset is much larger, 
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only 966 patients (23%) had extractable methylation data available for contribution to the 
subtyping algorithms, raising the possibility of this component being under-represented when 
compared to other molecular markers in the modelling.  Furthermore, the assessment of CIMP 
employed by Guinney was also atypical; relying on comparative sub-group methylation 
analysis to determine which loci would be best at discriminating between the putative 
molecular subtypes, and then augmenting the effect within the model to facilitate 
discrimination, as opposed to a standardised and blinded assessment of methylation status at 
previously identified CpG islands and thus determine CIMP status. 
 
Although patients receiving neoadjuvant therapy were excluded in our study, the relationship 
between methylation and response to CRT (neoadjuvant and adjuvant) is likely to be 
significant, as has been identified in previous studies204, 369. The benefits of neoadjuvant 
therapy in rectal cancer are clear, but it is acknowledged that a tumour’s response to 
neoadjuvant therapy is currently not predictable, and identifying significant factors that affect 
response may be beneficial in managing patients370.  Currently, mucinous tumours and poorly 
differentiated tumours have all been associated with poor response to neoadjuvant therapy, but 
the prognostic values of these measures is limited and has no clinical utility in restricting access 
to pre-surgical therapies371.  Unfortunately this means that a proportion of patients who undergo 
neoadjuvant therapy will gain no benefit, and may potentially come to harm as a result of 
systemic chemotherapy and/or local radiotherapy, and/or miss the opportunity to have a 
surgical intervention372. For these reasons there is an urgency in identifying reliable molecular 
markers of tumour response, including exploration of the methylome for significant 
relationships373-375. One successful example of this approach is the utilisation of a single 
nucleotide mutation in the KRAS gene in predicting the response of patients to adjuvant 
therapy using epidermal growth factor receptor (EGFR) inhibitors; which are increasingly 
utilised in order to increase the effectiveness of treatment376.  With regards methylation, Yokoi 
reported that DNA methylation may play an important role in affecting response to 
radiotherapy in an in vitro colorectal cell line model377. This process was dependent on 
methylation-controlled expression of cellular retinol binding protein 1; cellular response to 
radiotherapy being strongly related to expression. In our study, CIMP-intermediate was 
associated with a trend towards requirement for adjuvant chemotherapy (p=0.055), although it 
did not reach significance and was not an independent risk factor for DFS or OS.  Studies 
examining the correlation between CIMP status and response to CRT have shown some 
promise, although the results have been inconsistent and are plagued by methodological 
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inconsistencies378-380. Further studies have identified methylation to be important in the 
response of tumours to chemoradiotherapy in other organ systems, including lung, breast, 
glioma, and others; and is a field that warrants further investigation in the context of rectal 
cancers381-386. The response of tumours to neoadjuvant therapy is especially important when 
considering the challenges of predicting EMVI on pre-operative imaging.  MRI has been shown 
to be accurate in the local staging rectal tumours and indicating where circumferential resection 
margins are threatened, thus indicating the need for neoadjuvant therapy, but there is an 
acknowledged shortcoming in the sensitivity and specificity of MRI-detected EMVI, especially 
where EMVI is present in vessels smaller than 3mm or when EMVI volume is low 281, 282, 387,.  
If the prognostic validity of CIMP status could be established based on biopsy, it may open the 
opportunity to intervene on radiologically EMVI-negative but CIMP-intermediate/-high and 




A clear relationship was demonstrated between CIMP-positive (pooled CIMP-intermediate and 
-high) and EMVI. The CIMP-positive pool may be considered as analogous to CMS1, although 
the number of cases reported in our series was significantly higher than that expected given the 
frequency of CMS1 in the previously published data. EMVI-positive tumours demonstrated 
worse DFS and OS, and were associated with poorer clinicopathological features, although this 
disadvantage was not conferred to CIMP-positive tumours, suggesting a more complex 
relationship between EMVI, CIMP, and outcomes. A better understanding of the biological 
mechanisms underlying CIMP and EMVI may help illuminate the clinicopathological 
relationship between EMVI and CIMP and prove useful in stratifying and guiding disease 
management.  This may be especially important for determining patients who may be at risk 
of developing early local or distant disease recurrence and therefore benefit from systemic 






The Biological Effects of Demethylation on 
Colorectal Cancer Cells In Vitro. 
 
4.1 Introduction 
Methylation is emerging as an important factor in carcinogenesis of colorectal cancer, as well 
as other cancers309, 388, 389.  Human tissue studies have identified specific epigenetic changes in 
colorectal cancers, many of which have putative cellular effects that may be directly 
contributory to the carcinogenic process; such as the hypermethylation events identified in the 
adenoma-to-carcinoma model and the Wnt pathway307, 309.  Other methylation markers 
identified in colorectal cancer are less obviously linked to carcinogenesis but may act as proxies 
for assessing the overall methylation status of DNA in healthy and diseased states.  Assessment 
of methylation is important in understanding colorectal cancer pathogenesis and in classifying 
colorectal cancers; demonstrated by methylation being an integral part of the classification 
systems employed to characterise colorectal cancer118, 161, 185.  As DNA methylation is an active 
and dynamic cellular process, important in the normal homeostasis of cells and phenotypic 
differentiation, it is open to modification in vitro and in vivo for experimental and, potentially, 
therapeutic purposes. 
 
4.1.1 In Vitro Studies of Colorectal Cancer 
The systematic investigation of colorectal cancer in the laboratory can be dated to at least 1940, 
when mice were fed diets containing potential carcinogens and the effects on the 
gastrointestinal mucosa examined at vivisection390.  This work was succeeded by further 
studies in animals until experimental techniques in in vitro cell culture began to be developed 
in the 1960’s, based first on cells extracted from viable tumours, and then on immortalised cell 
lines391, 392.  Many of the themes of the current investigation of colorectal carcinogenesis were 
being explored in relatively early work during the 1970s, including the colonic microbiome, 
the role of dietary fibre and fats, and even the niche field of DNA alkylating agents derived 
from rocket propellants393, 394!  It wasn’t until the 1980s, however, that the culture of colorectal 
cell lines (healthy, adenomatous, & cancerous) became a viable and widespread technique, 
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partially due to the relative ease with which colorectal cancer cell lines may be propagated, 
compared to other cancer types395-397.  The widespread adoption of cancer cell culture has 
greatly facilitated the mechanistic understanding of carcinogenesis, as well as drug discovery.  
For instance, the NCI-60 cancer cell line panel is a cohort of cell lines employed by the National 
Cancer Institute (USA) for high-volume screening of potential anti-cancer drugs against well 
established and characterised cell lines, including multiple colon cancers (original colon set: 
COLO 205, HCC-2998, HCT116, HCT-15, HT-29, KM12, SW-620; latter additions: DLD-1, 
KM20L2), and has aided in drug discovery (and arguably in early abandonment of futile 
investigation)398.   
 
Despite advances, there are however many shortcomings in in vitro modelling of colorectal 
cancer that limit its utility and possibly account for some of the failings in translating bench-
top science into the clinic.  New strategies are required to overcome these dilemmas.  
Specifically, regarding the investigation of rectal cancer as an individual disease entity separate 
from colorectal cancer, there is currently no commercially available rectal cancer-specific 
immortalised cell line available to investigators.  This shortcoming, however, must be balanced 
against the consideration that within the cohort of rectal cancers are found many epigenotypes, 
genotypes, and phenotypes; as demonstrated by the consensus molecular subtyping systems, 
limiting the utility of a single rectum-derived cell line.  Additionally, single-cell culture models 
of this manner do not account for the intratumoral heterogeneity displayed in rectal and other 
cancers399.  Monoculture and 2D-culture are also limited in their modelling of in vivo cancers 
in that they fail to provide the complex inter-cell interactions and tumour microenvironmental 
factors at play in in situ tumours.  This is particularly important when considering the important 
emerging role of immune responses to colorectal cancer, and the hypoxic conditions involved 
in cellular redox reactions400.  Latterly, these challenges have been met with developments in 
tissue organoid culture (3D culture) and co-culture techniques in tissue engineering401, 402.  
Spheroid cell culture has been proposed as one model for better modelling tumour 
microenvironments and cellular interactions in colorectal cancer and has been performed with 
success in a number of cell lines.  However, as a relatively novel method of tissue culture, new 
challenges such as divergent differentiation dependent on location within the spheroid and 
changes in cell behaviour when compared to 2D culture (e.g. propensity to invade) have 
emerged403.   Despite its limitations and technical challenges, cell culture, whether 2D or 3D, 
is still well placed to facilitate the understanding of colorectal carcinogenesis and aid in 
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developing therapeutic strategies, especially when coupled to modern technologies in 
translational research404. 
 
4.1.2 Migration & Invasion Assays 
4.1.2.1 Introduction 
Cellular invasion and migration are two inter-related processes that are crucial in the 
pathogenesis of colorectal cancer, and are similarly rooted in the cellular events that facilitate 
epithelial-mesenchymal transition (EMT)405. EMT describes the process by which epithelial 
cells lose their polarity and cell-to-cell adhesion and become migratory through the basement 
membrane, whereupon they may differentiate into other tissue types and move from location 
to location.  Once migrated, cells having undergone EMT may reverse the process to terminally 
differentiate in a new location by a process of mesenchymal-epithelial transition (MET)406.  
This process is crucial during embryological development and has been demonstrated to be 
critically related to healthy organogenesis and to congenital malformation407.  EMT is also 
important in wound healing, where epidermal keratinocytes undergo an EMT-like process to 
re-epithelialise damaged tissues408.  Beyond normal tissue remodelling, EMT has a 
pathological role in carcinogenesis; where dysplastic epithelial cells undergo invasive 
transformation to become invasive cancers409.  Indeed, the definition of colorectal carcinoma 
(T1+), as separate from adenomas with dysplasia or carcinomas in situ (Tis: AJCC 0), is 
characterised by cellular invasion through the basement membrane and muscularis mucosae 
into the submucosa30, 410.  Metastatic seeding may be considered as an analogous process to 
MET411.  It is therefore important to gain an understanding of the processes that govern tumour 
cell migration and invasion so that the disease process may be better understood and combatted. 
 
In in vitro studies of tumour behaviour, migration and invasion are considered as two separate 
entities defined and limited by the experimental design, although in vivo the two are considered 
to a large degree as part of the same EMT process412.  Migration specifically refers to the ability 
of cells to move in two dimensions over a surface, which may be the inside of a plastic well or 
flask, an extracellular matrix (ECM) laid down in a plate, a glass slide, or any other flat 
substrate free of barriers.  Invasion refers to the movement of cells through a matrix of 
substrate, necessitating remodelling of the substrate (such as an ECM) and modification of 
cellular architecture, cell-cell adhesion, polarity, and expression of proteins required for these 
processes.  Invasion almost exclusively occurs in three dimensions, although there are some 
experiments that utilise a three-dimensional migration model where cells pass through pores in 
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a substrate without the need for ECM remodelling, and should be considered as a separate 
process. Although different methods of cellular motility may be found throughout biology, 
well-differentiated cancer cells migrate and invade primarily by mesenchymal migration in the 
manner of fibroblasts; relying on a strong interaction with the ECM, cytoskeletal contraction, 
and extensive spindle-like remodelling of the cell body413.  A smaller proportion of cancer cells 
may migrate or invade by amoeboid movement, although this tends to be limited to melanoma 
and other irregularly migratory cancer types414. 
 
4.1.2.2 Wound Healing (Scratch) Assay 
Scratch assays are a basic model of cell migration that utilises a “wounding” to a uniformly 
confluent sheet of cells growing on a two-dimensional substrate.  The method can be as simple 
as performing a standard cell culture on a plastic well and scratching the confluent sheet with 
a pipette tip, although additional experimental complexity can be introduced by culturing cells 
on different substrates (collagen, ECM, etc), or by modifying other experimental variables.  
The time taken to restore confluence is usually taken as the primary end-point of the 
experiment, although as a measure of migration this is best estimated in short culture protocol 
(<24hrs) as longer culture times increase the proportion of confluence that is reached by 
proliferation rather than migration415.   Generally, the technique is quick, cheap, and easily 
reproducible.  Drawbacks include the unevenness of the scratch when performed with a pipette 
tip and the possibility that cells scratched from the sheet accumulate at the edge of the wound 
and may re-attach, artificially closing the wound.  Investigators have attempted to control for 
these inaccuracies by electro-scratching the sheet of cells and assessing wound-closure by 
measuring electrical impedance, although these techniques have not been broadly adopted416, 
417. 
 
4.1.2.3 Cell Exclusion Assay 
Another method of performing a migration scratch-type wound healing assay is to construct a 
barrier to cell attachment at the time of seeding, a process referred to as micro-stencilling418.  
This may be performed by use of an electrical-fence, but more commonly by use of a gel-insert 
that is well-enough attached to the culture substrate that cells cannot adhere to the area below 
it following seeding.  One of the more popular commercially available assays is the Ibidi 
Culture-InsertÒ system of re-usable silicone 2-well inserts with a 500µm cell-free exclusion 
zone (Figure 4.1)419.  This, and other similar systems, has the advantage of producing a sharp 
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edged and reproducible cell-free zone, as well as minimising cell damage and reducing 
detached cells at the wound margin. 
 
Figure 4.1 Ibidi Culture-Insert 2 Well System419. 
 
 
4.1.2.4 Boyden Chambers & TranswellÒ Systems 
Both scratch and cell exclusion assays are only suitable for assessing cell migration as they are 
performed in two dimensions and do not involve active remodelling of the ECM.  Boyden 
chambers, however, present the opportunity to assess cell migration and invasion in three 
dimensions by use of a suspended culture chamber with pores to allow cellular movement420.  
The base of the chamber can either be un-treated and inert to facilitate migration without 
invasion or be pre-treated with a layer of ECM through which cells must invade421, 422.  
Typically, a gradient between the top and bottom chambers is provided to induce cellular 
migration or invasion (such as a serum gradient or chemoattractant), and pore size chosen 
dependent on the size and characteristics of the cell line being studies.  Typically pore sizes are 
between 3-12µm but must be smaller than the cells being examined to prevent “dropping”.  It 
is also important to consider the seeding density, port density, and two-dimensional migration 
speed of seeded cells, as low-density slow-to-migrate cells will increase the overall three-
dimensional migration/invasion time during migration to a pore.  Following culture, cells that 
have moved to the distant side of the membrane can either be fixed, stained, and counted 
directly (after removal of non-migrated cells from the top), or be detached and counted by a 
fluorescence counter following tagging.  Boyden chamber systems have the advantages of 
being tailorable to different cell types and culture conditions, including co-culture, but require 
individual calibration for each cell type.  They are generally more expensive than scratch or 




TranswellÒ systems exploit the physical set-up of the Boyden chamber but occlude the pores 
in the membrane by application of ECM, thus preventing the migration of non-invasive cells 
(Figure 4.2).  Invading cells must degrade the ECM on the membrane before passing to the 
distant side of the membrane, induced by a gradient as previously discussed423.   The most 
commonly used ECM is MatrigelÒ (Corning, New York, USA), a solubilised basement 
membrane extracted from Engbreth-Holm-Swarm (EHS) mouse sarcoma that has a high 
proportion of ECM proteins such as laminin, collagen IV, heparin sulfate proteoglycans, and 
others424.  Matrigel is a good model for invasion through the ECM as it has characteristics that 
are highly similar to the protein and growth factor profile found in naturally occurring basement 
membrane425-427.  As previously discussed, invasion of the basement membrane is the defining 
feature of invasive cancer, including CRC, and ECM remodelling has been observed in the 
invasive-front microenvironment410, 428, 429.  TranswellÒ  systems are available pre-treated with 
ECM in a variety of pore sizes, although modifications are feasible by purchasing individual 
components, and are very widely used in cancer research.  
 
Figure 4.2.  TranswellÒ System.  An ECM such as Matrigel may be placed on top of the 




4.1.2.5. Other Migration & Invasion Models 
As well as the three models already described a number of other techniques for estimating 
cellular migration and invasion exist, although they are less popular.  Fence assays utilise a 
reverse methodology to scratch and exclusion assays by introducing small areas of cells at 
confluence to larger areas of naïve substrate and observe outgrowth from the pool, rather than 
closure of a wound.  Carrier-bead and spheroid migration assays take this principle further by 
introducing beads coated with confluent cells or spheroids to naïve substrate and observing 
outgrowth (akin to bacterial or fungal seeding on growth substrates for antimicrobial/fungal 
assessment).  More complex invasion assays may be performed by constructing a platypus 
assay, where cells are sequentially sandwiched between two layers of ECM with an acellular 
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void in a proportion of the plate (created by exclusion), into which cells might invade laterally 
rather than through a porous membrane.  Similarly, cells and spheroid may be introduced to 
larger blocks of gelatinised ECM and their free migration through or outward extension into 
the matrix may be observed like veins running through a block of blue cheese.  Co-culture 
models of spheroid invasion (spheroid confrontation assay) may also be constructed in three-
dimensional ECM blocks to introduce a further degree of three-dimensional and tissue 
microenvironmental complexity.  Although the techniques and technology required for each of 
these assays is not advanced or expensive, they are time-consuming and prone to error, making 
them unsuitable for high-throughput screening or baseline biologic investigation, but may be 
appropriate in specific circumstances where a more elegant model is required412.  
 
4.1.3 In Vitro Demethylation in Colorectal Cancer Models 
Epigenetic aberrations, including DNA hypermethylation, have been established as important 
factors in the molecular classification of CRC, although the pathogenic role is less well 
understood118, 430.   In vitro studies of methylation in colorectal cancer have demonstrated that 
10-day treatment with AZA at sub-cytotoxic doses can reactivate previously transcriptionally 
silenced genes, although the patterns of demethylation at specific promotor regions did not 
uniformly match gene reactivation431.  However, in another study based on array analysis of 
14,000 gene promotors in HCT116 cells, AZA treatment was demonstrated to produce specific 
and reproducible patterns of demethylation as well as conserved loci that were never 
demethylated432.  A more recent study has found that demethylation of SW480 cells by AZA 
reactivates tumour suppressor NDN and potentially down-regulates Wnt signalling433.  A 
further study examined the effects of AZA derivatives and 5-FU co-therapy on cell lines SW48 
and HT-29, finding that there was potentially a synergistic effect with dual therapy434.   
 
4.1.4 In Vivo Demethylation in Colorectal Cancer Trials 
The suggestion of synergy between AZA derivatives and other chemotherapy agents has led to 
a number of limited clinical trials in treatment-exhausted metastatic colorectal cancers, 
although results have so far been disappointing.  A recently published phase II study of AZA 
with histone deacetylase inhibitor entinostat against multiply-treated metastatic colorectal 
cancer demonstrated no benefit233.  A similarly disappointing outcome was found in a phase 
I/II trial of AZA with CAPOX in refractory CIMP-high metastatic colorectal cancer232. This 
study’s methodology of determining CIMP-H was not well described and a tenuous focus on 
serum and stool vimentin hypermethylation as a proxy goes some way to undermining their 
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classification of CIMP-H, although their clinical outcomes were robust.  However, another in 
vitro co-therapy study demonstrated that AZA acted synergistically with irinotecan to improve 
survival and improve tumour response in HCT116 CRC cell xenografted into mice, and has 
led to Phase I/II trials examining the efficacy of another DNMT inhibitor (Guadecitabine, SGI-




4.2 Aims and Objectives 
This chapter will examine the effects of demethylation on colorectal cell lines in vitro.  
Established methods of assessing locus-specific methylation (those already employed in 
Chapter 3) will be utilised for internal and external validity and consistency, as well as 
additional assessments of global methylation for broader perspective.  Both a two-dimensional 
model of migration and three-dimensional models of invasion will be employed to determine 
the effects of demethylation in increasingly complex models that might provide an insight into 
and EMT/MET processes.  Established (AZA) and putative (RRx-001) demethylating agents 
will be employed to investigate their comparative effects, following baseline assessments of 




4.3.1 Cell Culture, Treatment, & Cytotoxicity 
4.3.1.1 Cell Culture 
Maintenance and control culture of DLD-1 cells was performed as outlined in Section 2.3 and 
modified as described below for experimental purposes.   
 
4.3.1.2 Treatment with Demethylating Agents 
Both AZA and RRx-001 are stable in powdered form at -20°C and room temperature, 
respectively, but degrade when in solution.  Although the rate of degradation for AZA is known 
(half-life dissolved in dH2O or DMSO at room temperature at treatment concentrations (0.25-
5.0 uM) is approximately 10-15hrs), the degradation of RRx-001 in solution and subsequent 
loss of biological activity is not known, although in vitro studies indicate it to be rapidly 
reactive with blood components and biologically effectively consumed almost immediately 
following initial administration235, 239.  For the purposes of this study, a trial of the stability (in 
terms of biological efficacy) of each agent was undertaken by assessing cytotoxicity and 
demethylating ability of each agent following fresh preparation and storage at -80°C in stock 
concentration of 100 uM.  Stored reagents were trialled alongside fresh-preparations, negative 
controls, and solvent controls to assess biological activity (molecular chemistry & 
pharmacokinetics of each compound was beyond the remit of this study).  Both AZA and RRx-
001 were found to be soluble in H2O/DMSO at stock and working concentrations and stable at 
-80°C for at least one week, which was the maximum period these reagents were stored for 
when used in experimental models. 
 
Each cell-culture experiment was conducted in multiple technical and biological replicates in 
order to assess and reduce sources of variation, and with negative, solvent, and where 
applicable positive controls (AZA acted as positive control for RRx-001)436.  AZA and RRx-
001 were presented across a dose-curve of 0.10, 0.25, 0.5, 1.0, 2.0, and 5.0 uM for initial 
screening of cytotoxicity and biological activity, and then the dose-curve rationalised for 
further experiments based on results.  Doses were calculated and solutions of drug created by 
a serial dilution technique.  This was to ensure the adequate mixing of drug in solution, and the 
accuracy and control between replicates of doses, especially at lower concentrations (versus 




The number of cells observed in a population exposed to any particular treatment is the product 
of a number of factors, specifically; time, the starting population, rate of cell division 
(proliferation), and rate of cell death (natural apoptosis & toxicity).  Each of these factors must 
be accounted for when assessing the effects of a chemical on a biological process so that effects 
on outcomes such as cell migration and invasion are not confounded by co-factors related to 
toxicity.  As such, a baseline assessment of cytotoxicity and cytostasis must be made prior to 
experimetation437.  The OECD Guidelines for the Testing of Chemicals (In Vitro Mammalian 
Cell Micronucleus Test) sets out the standards for assessing the cytotoxicity of a compound 
whether or not the investigator is employing actin polymerisation inhibitor cytochalasin B 
(cytoB); recommending that Relative Population Doubling (RPD) or Relative Increase in Cell 
Count (RICC) be used to assess cytotoxicity and cytostasis when cytoB is not used438.  
Cytotoxicity should be assessed across a treatment gradient and in biological and technical 
replicate.  The maximum cytotoxic effect used in biological modelling should be based upon a 
reduction of RPD of 55% +/- 5% at the maximum dose, although care should be taken when 
assessing outcomes at doses approaching this threshold.  Additional tests examining endpoints 
such as cell integrity, apoptosis, necrosis, etc, can also be employed but should not substitute 
RPD or RICC439, 440.  For the purposes of this research, a limit of 50% reduction in RPD will 
be set. 
 
Assessment of RPD was made by culture of DLD-1 cells in control, solvent control, and 
treatment media and a dose-curve was employed to examine the cytotoxic effects of each 
compound.  DLD-1 cells were grown until approximately 70% confluent according to standard 
culture conditions and then trypsinised and 5mls of cell suspension transferred to 25cm plastic 
cell culture flasks at a concentration of 3x104 cells ml-1 (coulter counter assessment).  Cells 
were allowed to adhere for a minimum of 8 and maximum of 12 hours (usually overnight) and 
then treated daily with AZA or RRx-001 (or control or solvent control) for a further 72hrs at 
0.10, 0.25, 0.5, 1.0, 2.0, and 5.0 uM dose concentration.  At the end of the 72hr period cells 
were trypsinised, washed, and re-suspended in 10ml PBS and counted on a haemocytometer or 
on the coulter counter.   
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RPD was calculated using the formula below. 
 
Population Doubling (PD) = Log (cell count after treatment  / cell count in control) 
Log2 
 
 Relative Population Doubling (RPD) = Number of population doublings in treatment        x100 
            Number of population doublings in control 
 
In addition to RPD, trypan blue, a commonly used stain that penetrates the membranes of dead 
but not viable cells, will be used for an additional assessment of cytotoxicity441.  DLD-1 cells 
were cultured and treated as per the protocol for RPD testing.  At the point at which cells were 
re-suspended in PBS for counting, cells were instead treated with 0.4% Trypan Blue solution 
(Sigma-Aldrich (Merck), USA) and incubated at room temperature for 5 minutes.  Cells were 
then counted on a haemocytometer and a crude ratio of viable (unstained) cells versus dead 
cells (stained) was calculated. 
 
4.3.2 Wound Healing Assay 
An exclusion-zone assay was used as this provide the most easily reproducible and controllable 
method of assessing two-dimensional cell migration.  The system employed was the Ibidi 
Culture-Insert 2 Well System as outlined above419.  This provided a consistent 500µm “scratch” 
across which cells migrate on the base of a standard plastic cell culture well.   
 
DLD-1 cells were grown until approximately 70% confluent according to standard culture 
conditions and then trypsinised and transferred to 25cm plastic cell culture flasks at a 
concentration of 3x104 cells ml-1 (coulter counter assessment) and allowed to adhere for a 
minimum of 8 and maximum of 12 hours (usually overnight).  Cells were then cultured for a 
further 72hrs in control, solvent control, or treatment (AZA or RRx-001) medium at a 
concentration based on cytotoxicity studies.  Control or treatment media was refreshed daily.   
 
After a full 72hrs of culture, treated (or control) cells were again trypsinised, washed, and 
diluted to a concentration of 5x105 cells ml-1 in fresh culture medium.  Ibidi cell culture inserts 
were applied to the base of 12-well culture plates and 70µl of suspended cells applied to each 
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side of the insert (either side of the exclusion zone).  700ml of suspended cells were applied to 
the well outside of the insert.  After a period of 24hrs during which cell adherence to the base 
of the plate occurred, the insert was removed with sterilised forceps leaving a cell-free 500µm 
“scratch” in the adherent cell monolayer.  A further 700ml of fresh culture media was added at 
this point to prevent dehydration during undisturbed culture during time-lapse microscopy.  
 
12-well plates were then monitored by time-lapse light wide-field microscopy (frame capture 
once every 10 minutes) using the etaluma 560 Inverted Live-Cell Microscope platform.  Time-
to-convergence was measured by the clock starting when the Ibidi cell culture insert was 
removed and stopped when “first contact” was made between cells from either side of the cell-
free exclusion zone.  First contact was chosen as an endpoint as it favours cell migration as the 
predominant biological process (over cell proliferation), although wound-width, given by the 
formula below, was also employed an alternative endpoint (using Image J software)442, 443.  
Techniques to inhibit cell proliferation, such a mitomycin C, were not employed444. 
 
Formula for calculating Rate of Cell Migration. 
 
In addition to the method set out above, an attempt was made to use the IN Cell Analyser (GE 
Healthcare) platform to facilitate high-throughput analysis of multiple wells in the 12-well 
plate, thus negating the limitation of the single-lens non-mobile platform of the etaluma system.  
Unfortunately, after several attempts, this was abandoned due to technical and physical 
constraints (programming/software errors, demand from other research groups performing 
time-sensitive experiments, physical location in another building thus requiring culture 
transfer).  This did not affect the outcomes of the research, and in fact may have aided in 
increasing robustness through the necessity of performing multiple biological and technical 




4.3.3 Extracellular Matrix Invasion 
A model of three-dimensional cellular invasion was constructed utilising the Corning (New 
York, USA) BioCoatä TranswellÒ Boyden chamber system with a pre-loaded layer of 
Matrigel acting as the invasion matrix.  This system provides a growth area of 0.3cm2 of 
Matrigel ECM on top of a polyethylene terephthalate (PET) membrane perforated by 8-micron 
pores.  Cells in the top chamber must therefore penetrate the EMC and translocate through the 
pores to the inferior aspect of the membrane in order to satisfy the definition for invasion.  This 
system was chosen because of the likeness of the Matrigel ECM to the acellular components 
of the colorectal basement membrane and the ability of the DLD-1 cells to translocate through 
a pore of this size425-427.   
 
DLD-1 cells were cultures as per the protocol set out for wound healing assay (section 4.3.2) 
until the full period of 72hrs of treatment (or control) had been achieved.  Invasion chambers 
were removed from storage at -20°C and allowed to come to room temperature and were then 
rehydrated in 1000µL of serum-free growth medium (500µL in each of the top and bottom of 
the wells/inserts) for 2 hours in standard incubator conditions.  This rehydrating medium was 
then removed by pipetting, making sure not to damage the layer of Matrigel.  A companion 
plate of invasion chambers consisting of PET membrane with 8micron pores but containing no 
ECM was also prepared. 
 
Cells were trypsinised, washed, and made to a concentration of 3x105 cells ml-1 in serum-free 
medium.  750µL of fully composed medium (i.e. including serum) was added to the bottom 
compartment of each well and the invasion chambers (ECM & companion) carefully placed 
inside.  500µL of suspended cells was then placed in the upper portion of the invasion chambers 
atop the ECM and incubated for 24 hours.  A variation to this protocol was also performed 
where 200µg ml-1 fibronectin was added to the bottom chamber to provide an additional 
chemoattractant (invasion gradient), as it has been shown to be an important factor in 
stimulation and regulating ECM remodelling and cellular invasion in healthy and cancerous 
tissue445-447. 
 
Following incubation, invasion chambers were removed from incubation wells and inverted to 
remove growth medium.  The seeding-surface of the invasion membrane (top) was then wiped 
twice with a cotton bud to remove ECM and non-invading cells, as per manufacturers protocol.  
Invading cells on the under-surface of the invasion membrane were then fixed and stained by 
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sequential submersion in 100% methanol for two minutes and then crystal violet for two 
minutes, and then rinsed in dH2O and left to air dry.  Invading cells were then counted on a 
haemocytometer under light microscopy following removal of the invasion membrane from 
the chamber with a sharp scalpel.   
 
Invasion was calculated as a percentage and index using the following formulae: 
 
 Percentage Invasion = (Mean number of cells invading through ECM / Mean number 
of cells invading through control membrane) x 100 
 
 Invasion Index = (% invasion for test (treated) cells / % invasion for control cells) 
 
 
4.3.4 Assessment of Methylation Status 
4.3.4.1 CIMP Status 
Methylations status of control, solvent control, and treated DLD-1 cells was assessed by the 
same methodology of bisulfite-conversion and msPCR as set out in Chapter 3 (Sections 3.3.3, 
3.3.4, 3.3.5, and 3.3.6).  The only difference to these protocols was that DNA was harvested 
from cultured cells, negating the steps involving DNA extraction from FFPE slides.  Cells were 
first trypsinised, washed with PBS twice, and then vortexed to pellet and the supernatant 
discarded.  Cell pellets were then resuspended in proteinase K and Tissue and Cell Lysis 
Solution and the previously described protocol of the MasterPure Complete DNA and RNA 
purification kit (Epicentre, Illumina, Wisconsin, USA) followed. The quantity and quality of 
DNA was again measured by spectrophotometry and extracted DNA was stored at -20°C 
during active experimentation and archived at -80°C when not in use. 
 
4.3.4.2 Global DNA Methylation  
In addition to assessment by msPCR, global DNA methylation was also assessed by means of 
the MethylFlash Global DNA Methylation (5-mC) ELISA Easy Kit (Colorimetric) kit 
(Epigentek, New York, USA).  In this assay, DNA harvested from DLD-1 cells is bound to 
pre-prepared wells containing antibodies with a high affinity to DNA and then capture-
indicator antibodies specific to methylated DNA are added and the plate subjected to analysis 
by spectrophotometer, the proportion of methylated DNA being proportionate to the optical 
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density (OD).  This method was chosen as it is widely used across the methylation literature to 
provide a broad and quantitative assessment of global DNA methylation448, 449. 
 
DNA was extracted from DLD-1 cells as set out previously, its quantity and quality assessed 
by spectrophotometry, and then diluted to 50ng µL-1 in DNA & RNA-free water.  All reagents 
were prepared according to the manufacturers protocol (https://www.epigentek.com/docs/P-
1030.pdf) and 100ng of DNA added to each sample well of the plate (see Figure 4.3).  Negative 
controls and positive controls (both provided in the kit) were applied to the appropriate wells 
of the plate, including the 0.1% to 5.0% concentration gradient for the positive control that 
generates the standard curve for quantitative assessment.  DNA and control solutions were 
gently swirled in the test wells and then the whole plate was covered with parafilm and 
incubated at 37°C for 60 minutes. 
 
Detection Complex Solution (DCS) was then mixed according to supplied protocol and, after 
washing each well three times with 150µL of supplied washing buffer (WB), 50µL DCS was 
applied to each well.  The plate was then re-covered with parafilm and left to incubate for 50 
minutes at room temperature, after which the DCS was removed by pipetting and each well 
washed with 150µL WB a further five time.  100µL detection solution is then added to each 
well (vertical columns simultaneously) and the plate briefly agitated and then left for several 
minutes until the 5% PC wells turn dark blue, whereupon the stop solution is added in a similar 
fashion.  Wells with a positive detection will then turn from blue to yellow after several minutes 
and the plate is read by spectrophotometry at 450nm within 15 minutes. 
 
Percentage global DNA 5-mC can then be calculated using the formula shown below, 
following calculation of the slope from the standard curve.  (OD, optical density; NC, negative 




Figure 4.3.  Schematic of 96-well plate for MethylFlash Global DNA Methylation (5-mC) 







AZA was applied to DLD-1 cells across a dose curve as described previously.  At the end of 
the treatment period of 72hrs, cells were harvested and counted both by coulter counter and on 
a haemocytometer.  Percentage RPD is shown in Figure 4.4.1 across the dose curve, 
demonstrating a 50% reduction in RPD at between the 0.5uM and 1.0uM AZA doses.  
Averages of biologic replicates (typically 5) are represented by individual technical replicates 
RPD1-5, and an over-all average by the bold line (total replicates 25). Standard deviation (SD) 
at the 0.5uM dose is ±7.3% from a baseline of 61.0% RPD, and at no point on this series is 
³10.0%. 
 
Figure 4.4.1 %RPD Dose Curve for Azacytidine.  (Doses, where stated in uM, are for 
azacytidine (AZA), error bars indicated standard deviation). 
 
 
Trypan blue analysis demonstrated that there was an increase in non-viable cells at AZA 
concentrations of greater than 1.0uM (³30% non-viable), whereas concentrations below this 
level did not significantly affect the ratio of non-viable cells.  The discrepancy between a 







Control DMSO 0.1uM 0.25uM 0.5uM 1.0uM 2.0uM 5.0uM
RPD AZA 
Ave RPD1 RPD2 RPD3 RPD4 RPD5
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(significant effects at ³ 1.0uM) suggests biologic activity of AZA at lower concentrations that 
is not due to cell death. 
 
4.4.1.2 RRx-001 
RRx-001 was applied to DLD-1 cells across a dose curve as described previously.  At the end 
of the 72hr treatment period, cells were harvested and counted both by coulter counter and on 
a haemocytometer.  Percentage RPD is shown in Figure 4.4.2 across the dose curve. Averages 
of biologic replicates (typically 5) are represented by individual technical replicates RPD1-5, 
and an over-all average by the bold line (total replicates 25). A 50% reduction in RPD at a dose 
of approximately the 1.0uM RRx-001 is demonstrated, however, standard deviation indicates 
that there is a high degree of variability of response to treatment at this dose (SD ±35.6% from 
50% RPD), and thus an experimental dose of 0.5uM would be more appropriate (SD ±10.1% 
from 72.4% RPD). 
 
Figure 4.4.2 %RPD Dose Curve for RRx-001.  (Doses, where stated in uM, are for RRx-001, 
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Figure 4.4.2 also indicates that at doses of ³5.0uM, and more variably at 2.0uM, the RPD 
becomes negative, indicating a population decline compared to baseline seeding, and a highly 
cytotoxic effect of RRx-001.  This was reflected in the trypan blue examination of RRx-
001where there was a lower ratio of viable cells (£70%) at doses of 1uM and above (<20% at 
5.0uM).  Viable cell ratios were however acceptable at doses up to 0.5uM RRx-001. 
 
4.4.2 Two-Dimensional Migration (Scratch) Assay 
Given the results of the cytotoxicity assays (RPD and trypan blue), a maximum experimental 
dose of 0.5uM over a 72hr exposure period (daily treatments) of both AZA and RRx-001 was 
employed as a baseline for wound healing and invasion assays.   
 
Using the Ibidi culture system, untreated control and solvent control (DMSO) exposed DLD-1 
cells took a mean time of 38 hours (SD ±1.5) and 41 hours (SD ±3.0), respectively, to converge 
(reach first contact) across the 500µm cell-free zone.  Prior treatment for three days with either 
0.25uM or 0.5uM AZA resulted in a mean convergence time of 37.5 (SD ±2.0) and 48.0 (SD 
±4.5) hours, respectively. Prior treatment for three days with either 0.25uM or 0.5uM RRx-001 
resulted in a mean convergence time of 38.5 (SD ±3.0) and 58.5 (SD ±4.5) hours, respectively.  
The difference of the means between the control and 0.5uM treatments with both AZA and 
RRx-001 were highly significant based on students t-test (p<0.001), but not for DMSO or the 
lower doses of 0.25uM of either compound.  These results are shown in Figure 4.4.3. 
 
Figure 4.4.4 demonstrates the process of cell migration across the void using the Ibidi cell 
system, and the measured endpoints for illustrative purposes.  Image a. demonstrates the 
starting position of the cells in culture at timepoint 0, with the gel insert only just removed. 
Image b. demonstrates the point of first convergence PoC, where cells from either side of the 
void make physical contact and stop the clock (time to convergence, TtC).  Image c. 
demonstrates a greater degree of convergence although complete exclusion of the void is yet 
to occur.  Images a. and b. have also been marked-up to demonstrate the area that remains to 
be filled-in by cells that forms the final width metric that could be used to calculate the Rate of 
Cell Migration, although this was only applied when cells reached PoC as demonstrated in 
image b as this is the least subjective time-point for assessing convergence. Image d. illustrates 
almost complete occlusion of the void and proliferative overgrowth away from the original 
cell-free zone. 
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Control 38.5 hrs 37.0 – 40.0 hrs ±1.5 hrs - 
Solvent Control (DMSO) 41.5 hrs 38.0 – 44.0 hrs ±3.0 hrs NS 
AZA 0.25uM 37.5 hrs 36.5 – 40.5 hrs ±2.0 hrs NS 
AZA 0.50uM 48.0 hrs 43.0 – 52.0 hrs ±4.5 hrs <0.001 
RRx-001 0.25uM 38.5 hrs 36.0 – 42.5 hrs ±3.0 hrs NS 














Figure 4.4.4 Etaluma light microscopy images demonstrating stages in cell migration during 









DLD-1 cells at time point 0 immediately 
after the gel insert has been removed.  Note 
the 500µM cell-free void (scratch) between 
the relatively confluent cell fronts. 
DLD-1 cells at the point of convergence 
(PoC), representing the ‘clock-stop’ for 
Time to Convergence.  Note cell-free 
shaded area that forms the basis of the 
width (area) metric. 
DLD-1 cells at beyond PoC.  There are still 
a few cell-free voids but >70% confluence 
has been reached and the cells behind the 
convergent zone are crowded, 
demonstrating a proliferative process away 
from the original cell-free zone. 
DLD-1 cells beyond the PoC but with some 
cell-free void remaining.  Note the cell 
morphology along the convergent zone; 
elongated cells have bridged the void, 
suggesting a cell-migratory process, rather 
than proliferative. 
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The Rate of Cell Migration metric Rm was found to be unreliable.  Firstly, for the formula set 
out in Section 4.3.2, Rm is defined as the initial width, minus the residual width, divided by 
time.  Employing the PoC definition as described (the residual width being 0), the only 
independent variable is time, and therefore the metric Rm = 500µM / TtC and is not a better 
discriminator over TtC alone, when examining the effects of AZA and RRx-001 on migration.  
Secondly, if the metric Rm is modified to replace initial width and residual width with initial 
area and residual area, as demonstrated by the shaded areas on Figure 4.4.5 a. – c., no 
advantage was found over TtC alone, nor was a statistically significant difference in mean cell-
free area at PoC evident.   
 







Control DLD-1 cells at PoC.  The shaded 
cell-free area is measured at 154,000µM2. 
DLD-1 cells exposed to 0.5uM RRx-001 at 
PoC.  The shaded cell-free area is measured 
at 145,500µM2. Students-t test for 
significant difference between mean area 




DLD-1 cells exposed to 0.5uM AZA at 
PoC.  The shaded cell-free area is measured 
at 149,000µM2.  Students-t test for 
significant difference between mean area 
in treated vs control cells was non-
significant. 
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4.4.3 Three-Dimensional Invasion Assay 
Given the results of the cytotoxicity assay, a maximum experimental dose of 0.5uM of both 
AZA and RRx-001 was employed in invasion assays over a 72hr exposure period with a daily 
dosing regime. 
 
After 24 hours incubation there was no difference in the mean percentage invasion (PI) between 
control and solvent control (DMSO) exposed DLD-1 cells (100% and 97-98%, respectively), 
with a mean invasion index (II) of 77 and 75, respectively.  Prior treatment for three days with 
either 0.25uM or 0.5uM AZA resulted in a mean PI of 50.0% (SD ±3.4%) and 31.1% (SD 
±3.1%), and II of 42 and 27, respectively. Prior treatment for three days with either 0.25uM or 
0.5uM RRx-001 resulted in a mean PI of 49.5% (SD ±2.6%) and 33.10% (SD ±2.4%), and II 
of 41 and 28.5, respectively.  The difference between the mean PI of the control DLD-1 and 
DLD-1 exposed to either 0.25uM or 0.5uM treatments with either AZA and RRx-001 were 
highly significant based on students t-test (p<0.001), but not for DMSO. The addition of 200µg 
ml-1 fibronectin, an established chemoattractant, resulted in an increase in the baseline 
percentage invasion, PI, at control and solvent control (mean increase PI =11) and was 
maintained across the experimental arms with both compound at all doses.  This increase did 
not however cause a significant change to the invasion index, II, as it affected controls and 




Figure 4.4.6. Light microscopy demonstrating haemocytometer counts of invading DLD-1 
cells on the underside of the invasion well.  Note the 8micron pores in the film.  Cells have 
been fixed with 100% methanol and crystal violet. Image a – control; b – control + fibronectin; 





























Figure 4.4.7 DLD-1 invasion through Matrigel ECM expressed as Percentage Invasion (PI) 
and Invasion Index (II). 
a.  DLD-1 PI & II versus AZA 
 
 








Control DMSO 0.25uM 0.50uM
ECM Invasion AZA
Mean %Inv Mean %Inv + Fib Rep1 Rep2







Control DMSO 0.25uM 0.50uM
ECM Invasion RRx-001
Mean %Inv Mean %Inv + Fib Rep1 Rep2
Rep3 Rep4 Mean InvIdx Mean InvIdx + Fib
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4.4.4. Demethylating Effects of Azacytidine and RRx-001 
4.4.4.1 CIMP Status 
Methylation status of control, solvent control, and treated DLD-1 cells was assessed by the 
same methodology of bisulfite-conversion and msPCR as set out in Chapter 3 (Sections 3.3.3, 
3.3.4, 3.3.5, and 3.3.6).  Cells were first cultured for three days and exposed to AZA 0.50uM 
or RRx-001 0.50uM according to the protocol employed for cytotoxicity and migration / 
invasion assays in Section 4.3.1 onwards.   
 
The baseline methylation status of DLD-1 cells is pan-methylated at each of the loci employed 
in the experimental panel, evidenced by strong amplification of DNA by the methylated-
specific primers in the control and solvent control datasets.  There was, however, a minor 
degree of amplification of non-methylated DNA for both SOCS and IGFBP, although this did 
not reach the 10% image density saturation (Gel Doc XR (Bio-Rad) system, Quantity One 
software) threshold for non-anomaly when analysed against the control bands.  
 
Following exposure to 0.50uM AZA, DLD-1 cell DNA demonstrated significant de-novo 
demethylation at five out of eight loci; MINT, HAND, ADAMTS1, NEUROG, and THBD.  
This effect, however, was not universal across the entire cell population, as DNA was extracted 
which also amplified against the methylated primers, although non-methylated amplification 
was well above the 10% threshold, indicating substantial demethylation.  The previous patterns 
of methylation for the other three loci (hMLH, SOCS, and IGFBP) remained unchanged. 
 
Following exposure to 0.50uM RRx-001, DLD-1 cell DNA demonstrated significant de-novo 
demethylation at four out of eight loci; MINT, HAND, NEUROG, and THBD.  Again, 
demethylation at these loci was incomplete across the extracted DNA and therefore the cell 
population, as DNA was also amplified against methylated primers at these loci. Subjectively, 
the bands representing amplification of unmethylated DNA at the HAND, NEUROG, and 
THBD loci were weaker than that observed following exposure to AZA, suggesting a lesser 
degree of demethylation.  The methods used in the assay were not, however, quantitative, and 
thus this result should be considered as qualitative only. The previous patterns of methylation 
for the other three loci (hMLH, SOCS, ADAMTS1, and IGFBP) remained unchanged. 
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According to the epigenotype classification described in Section 1.3.6, DLD-1 cells are CIMP-
H at baseline and remain so despite demethylation (with either AZA or RRx-001) of MINT 
and the Group 2 Markers185.  The above results are summarised in Table 4.1. 
 
Table 4.1 Methylation status of selected individual genes and CIMP Status of DLD-1 cells 
after exposure to AZA and RRx-001.  M = methylated, U = unmethylated, + = strong, - = weak, 








































Control M M M M M M M M H 
AZA M U M U- U U M U H 
RRx-001 M U+ M U- M U- M U- H 
 
4.4.4.2 Global Methylation  
The MethylFlash Global DNA Methylation (5-mC) ELISA Easy Kit (Colorimetric) kit 
measured at 450nm was used to assess global DNA methylation (global 5-mC) in control DLD-
1 cells and in cells exposed to AZA and RRx-001. As this method allows global quantitative 
assessment of DNA methylation, a dose curve methodology was applied. 
 
A standard curve for analysis of methylation at £1% global 5-mC was constructed using the 
controls provided in the kit and a linear regression model, yielding an R2 = 0.8136, which was 
improved to R2 = 0.9542 if the upper limit was set at £0.5% global 5-mC, and delivering a 
slope of b = 0.414 (Figure 4.4.8 a.).  This is in accordance with the manufacturer’s 
recommendation for the use of 4 data points (0%, 0.1%, 0.2%, and 0.5%) to attain a slope at 
the most linear section of the curve.   
 
Both AZA and RRx-001 effectively demethylated DLD-1 cells, as demonstrated in Figure 
4.4.8 b. The total percentage of methylated cytosines within DNA of control DLD-1 cells was 
0.05676% (0.27% global cytosine - GC), which fell to 0.00008% (0.0004% GC) in cells treated 
with 0.5uM AZA and to 0.02093% (0.0996% GC) in cell treated with 0.50uM RRx-001.  









Control 0.25 uM 0.5 uM 0.75 uM 1.0 uM 1.5 uM
Global 5-mC%
AZA RRX
doses, whereas the demethylation demonstrated by RRx-001 was dose-dependent up to 1.0uM.  
Above doses of >1.0uM of both agents a paradoxical rebound in global 5-mC was observed. 
 
Figure 4.4.9 also demonstrates the global demethylation produced by both AZA and RRx-001 
at a macro level by showing the ELISA plate colorimetric output.  Note the both the precipitous 
decline in the proportion of 5-mC with AZA, and the dose dependent relationship with RRx-
001, as well as the paradoxical increase in 5-mC at the 1.5uM dose of each agent. 
 
Figure 4.4.8 a. Standard curve for analysis of global 5-mC ELISA & b. global methylation in 





























Figure 4.4.9 Resolved MethylFlash Global DNA Methylation (5-mC) ELISA plate 






This chapter’s aims were to examine the effects of demethylation on a colorectal cell line in 
vitro, and to set parameters for the further investigation of demethylating agents in a model of 
colorectal cancer epithelial-mesenchymal and mesenchymal-epithelial transition (EMT/MET).  
To this end, the first element of this chapter was to establish the baseline cytotoxicity of AZA 
and RRx-001 in DLD-1 cells so that any effects observed in subsequent experiments cannot be 
confounded by toxicity.  The second element of this chapter was to examine the in vitro 
biologic effects of AZA and RRx-001 at sub-cytotoxic doses on DLD-1 cells in models of 
EMT & MET.  The third element was to establish the demethylating effects of AZA and RRx-
001 at sub-cytotoxic and biologically effective doses, both in terms of the locus-specific 
methylation status employed by the Kaneda & Yagi CIMP panel, and global methylation185.  
By these means the overarching aim was to establish a three-way-look at the investigation of 
an association between the methylation status of DLD-1 cells the biologic activity that is 
dependent on their methylation status. 
 
4.5.1 Cytotoxicity of Azacytidine and RRx-001 
An appropriate upper-limit for cytotoxicity is important when selecting doses of potentially 
biologically active or mutagenic compounds since excessive cytotoxicity is a well-established 
source of misleading positive results439, 450.  Population-doubling (RPD) is advocated by many 
authors as a reliable method of excluding cytotoxicity as a result of disruption to off-target 
cellular physiological processes and is supported by the OECD and other regulatory 
authorities437, 438, 451.  Based on this guidance an upper limit of 55±5% RPD was set as a cut-
off for both AZA and RRx-001; doses above this being considered cytotoxic and doses below 
being considered non-cytotoxic.  Exposure times were informed partly on the basis of prior 
experimentation within our own department, and also in accordance with other authors’ 
protocols452.  For both compounds, 55±5% RPD was reached between 0.50uM and 1.00uM, 
with 0.50uM of AZA and RRx-001 being considered as a reliably sub-cytotoxic dose (see 
Section 4.4.1 for full results).  These finding are broadly in keeping with those previously 
published by other authors investigating the in vitro effects of AZA on a variety of cell lines, 
although both higher and lower concentration tolerances have been reported209, 453.  
Interestingly, Juttermann and colleagues suggest that the cytotoxic effects of AZA observed at 
higher concentrations (³0.50uM in their investigation) are caused by an irreversible covalent 
trapping of DNMT to DNA, rather than the effects of demethylation itself, underlining the 
significance of establishing sub-cytotoxicity when investigating the specific effects of 
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demethyltion213.  As RRx-001 is a novel compound, there is little published evidence on its 
biologic effects and cytotoxicity in vitro, although doses of between 0.5uM and 5.0uM have 
been found to be sub-cytotoxic (and demethylating) in squamous cell carcinoma (SSC VII) 
cells243.  Furthermore, the same study examined the comparative global demethylating effects 
of RRx-001 against AZA at doses of between 0.5uM and 2.0uM, finding a comparative 
epigenetic effect.  This is consistent with another in vitro study, where RRx-001 was found to 
modulate DNMT1 and DNMT3a activity by increasing free oxygen and nitrogen radicals, 
reducing the abundance of methylation substrates and thus causing demethylation454.  The 
establishment of sub-cytotoxic doses of both AZA and RRx-001 at £0.50uM concentrations 
was also supported by the favourable results of the trypan blue assays. Furthermore, as RPD is 
a more sensitive measure of early toxicity, effects observed inviable cells following protracted 
treatment are likely to represent biologic effects rather than toxicity. 
 
4.5.2. The in vitro biologic effects of AZA and RRx-001 
Wound healing (scratch) and Boyden chamber-type assays are established methods of 
investigating cell migration and invasion419, 420.  Increasing elements of complexity may be 
added to the basic experimental design to create cellular environments more comparable to 
those that are key in the EMT and MET processes422, 423.  The results of the scratch assay 
(Section 4.4.2) demonstrated that, at sub-cytotoxic doses, both AZA and RRx-001 significantly 
increased the time taken for DLD-1 cell to migrate across the cell-free zone (p<0.001 for both 
compounds).  Similarly, AZA and RRx-001 at the same sub-cytotoxic doses reduced the ability 
of DLD-1 cells to invade through the ECM and migrate through the porous membrane of the 
TranswellÒ Boyden chamber system (p<0.001 for both compounds) (Section 4.4.3).  These 
results suggest that both compounds reduce the migratory and invasive propensity of DLD-1 
cells in in vitro models of EMT and MET, therefore suggesting that hyper-methylation could 
increase motility and invasion in the carcinogenic process. 
 
The results of this section are in keeping with the findings of other investigators, who have 
reported that other colorectal cell lines (HCT-116) were less able to migrate across and invade 
through a control and ECM treated Transwell system, respectively, following treatment with 
AZA452.  Another similar study, this time employing different colorectal cancer cell lines 
(SW480 and SW620) and decitabine (an AZA derivative), also demonstrated a reduced 
propensity for CRC cell to migrate and invade following treatment with a demethylating 
agent455.  Despite the different cell types and demethylating agents used in these studies, the 
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alignment with the findings from this investigation suggest a consistency in the application of 
demethylating agents to CRC cell lines and the reduction in the ability of cells to invade.  This 
is particularly interesting when considering the EMT/MET process, especially in the case of 
SW620 which is a lymph node metastasis derived colorectal cancer cell line. 
 
Similar findings have also been reported for other tumour types, including oesophageal 
squamous cell carcinomas and adenocarcinomas, renal cell carcinomas, gastric carcinomas, 
and laryngeal squamous carcinomas456-459.  In a study of multiple oesophageal tumour cell 
types, treatment with AZA (and/or decitabine) resulted in a reduced ability of tumour cells to 
migrate and invade, but only when dual therapy with other epigenetic modifiers was applied; 
specifically, histone deacetylases (HDACs)456.  These findings were echoed in another study 
examining the effects of dual treatment with the HDAC valproic acid in conjunction with AZA 
on renal cell carcinomas (786-O and 769-P) in vitro457.  These studies suggest that there is a 
synergistic effect between demethylating agents such as AZA with other epigenetic modifiers, 
and that the biological effects may only be observed when the two are applied in tandem, 
counter to the findings in this chapter.  However, as well as the previously discussed studies 
on colorectal cancer cell lines, other authors have also found that monotherapy with AZA 
effectively reduces the ability of cancer cell lines to migrate and invade.  This is demonstrated 
by the study on gastric cancer (AGS cells) by Zuo and colleagues, who demonstrated reduced 
migration and invasion with AZA monotherapy458.  Lui also found that AZA monotherapy 
reduced the ability of laryngeal squamous cells (HEp-2) to migrate and invade, based on 
scratch and Transwell assays459. 
 
No previous study has examined the biologic effects of RRx-001 in terms of the propensity of 
treated cells to migrate or invade.  The results in this chapter indicate that, at sub-cytotoxic 
doses, RRx-001 significantly reduces the ability of DLD-1 cells to migrate in two-dimensions 
in a wound healing assay, and to invade in three-dimensions through the ECM components of 
Matrigel in a Transwell Boyden-chamber assay. This was demonstrated by the reduced 
percentage invasion (PI) and invasion index (II) with increasing doses of RRx-001 when 
compared to control and was statistically significant (p<0.001).  The reduction in invasion was 
comparable to that observed with the same doses of AZA. The addition of fibronectin to the 
bottom chamber increased the percentage invasion by 10-15% at each dose-point for both AZA 
and RRx-001 but did not increase the II as it also proportionately increased the denominator. 
 
 129 
4.5.3. Assessment of Methylation Status 
At baseline, DLD-1 cell were found to be CIMP-high based upon the two-panel classification 
system described in by Kaneda and Yagi, and summarised in Section 1.3.6185.  Each of the 
eight loci was found to be methylated; each demonstrating strong amplification at the specific 
CpG islands against the methylation specific-primers.  A minor degree of amplification was 
evident for both SOCS and IGFBP, although this did not reach the 10% threshold for significant 
heterogeneity. 
 
Following treatment with AZA at 0.50uM concentration, DLD-1 demonstrated significant but 
incomplete demethylation of five out of eight loci; MINT, HAND, ADAMTS1, NEUROG, 
and THBD. Although incomplete, demethylation of these loci was significant as the 
demethylated bands for these sites was stronger than the methylated bands, which is converse 
to the baseline methylation status.  The finding that AZA is an effective demethylator of human 
DNA is not unexpected, as it is a well-established demethylating agent with widespread 
laboratory and some clinical applications (see Section 2.2.3 of General Methodology).  The 
previous patterns of methylation for the other three loci (hMLH, SOCS, and IGFBP) remained 
unchanged.  Despite demethylation at five of the eight loci, the CIMP status of DLD-1 cells 
exposed to AZA remains CIMP-high, as two of the Group 1 markers remain methylated 
(hMLH and SOCS). 
 
AZA also produced a dramatic decline in global 5-mC, as demonstrated by the ELISA.  At 
0.50uM dose of AZA, global 5-mC was reduced by a factor of over 700, from 0.05676% of 
global DNA to 0.00008%.  The figure of just over a twentieth of 1% for baseline 5-mC is 
objectively very low, with expected levels of methylated cytosine in human DNA typically 
being approximately 1%, dependent on the tissue460, 461.  Indeed, Donoghue reports 62% 
methylation at CCGG sites throughout DLD-1 DNA, suggesting a much higher percentage of 
global 5-mC462. These findings do not however take account of the stochastic variations in 
DNA methylation observed in cancer cells, or the acknowledged pan-hypomethylation across 
the entire epigenome despite the locus-specific hypermethylation observed in CIMP-high 
tumours463. Additionally, although there are multiple methods of determining global DNA 
methylation, the ELISA-based method employed in this chapter is considered reliable and 
validated against human and non-human DNA and in a variety of disease states, including 
cancers448, 464, 465.  Despite the low absolute figures, what is clear from the global 5-mC ELISA 
 130 
is that the relative proportion of methylated cytosine has fallen dramatically following AZA 
treatment, and was controlled against a well-fitting standard curve (R2=0.9542). 
 
Following treatment with 0.50uM RRx-001, four of eight loci were effectively demethylated; 
MINT, HAND, NEUROG, and THBD.  Patterns of methylation at the remaining four loci 
remained unchanged.  As was the case with demethylation with AZA, the CIMP status of DLD-
1 cells treated with RRx-001 did not change, remaining HIMP-high, as hMLH and SOCS were 
again resistant to demethylation.  Although essentially a binary test, subjectively the 
demethylated bands observed for HAND, NEUROG, and THBD were weaker than they were 
for AZA, suggesting a less efficient demethylation at these loci at an equal dose.  Note that the 
methodology employed is not quantitative, and thus this is a qualitative observation.   
 
This finding of potentially less efficient demethylation fits with the findings of the ELISA, 
where although RRx-001 did produce a demonstrable global decline in the proportion of 5-
mC, it was not such a precipitous drop as that observed with AZA.  At 0.50uM RRx-001 
demethylation was only approximately half that of observed with the same dose of AZA, and 
equivalence was only reached at a dose of 0.75uM RRx-001 (just above the cytotoxic 
threshold). This is consistent with a previous in vitro study where RRx-001 was found to 
modulate DNMT1 and DNMT3a activity by increasing free oxygen and nitrogen radicals, thus 
reducing the abundance of methylation substrates in a dose dependent but dynamic manner454. 
This is opposed to the permanent sequestration of DNMT1 and thus failure of de-novo 
methylation during cell division brought about by AZA. 
 
The observation that high doses of either compound cause a paradoxical rebound in global 
methylation must disregarded as an anomaly, primarily because these doses (>1.0uM AZA and 
RRx-001) are well above the cytotoxic threshold.  Additionally, because the level of 
methylation that might be expected if the agents are acting in a targeted manner would be so 
low, the efficiency and therefore results of the ELISA cannot be relied upon. Furthermore, 
there may also be direct chemical interference with the colorimetric assay at higher doses, 





The results of this chapter demonstrate that DLD-1 colorectal cancer cells are CIMP-high at 
baseline, despite the absolute proportion of 5-mC being lower than expected based on the 
ELISA employed.  Both AZA and RRx-001 were found to be effective demethylators of DLD-
1 cells, both at locus specific CpG islands that form the CIMP classification system and at a 
global methylation level.  AZA was a much more efficient demethylator than RRx-001 based 
on ELISA, but both agents effectively demethylated at least half of the loci associated with 
CIMP status; AZA demethylating 5/8 loci, RRx-001 4/8 loci, based on methylation-specific 
PCR.  Despite locus specific demethylation, neither agent changed the CIMP status of DLD-1 
cells as 2/3 Group 1 genes remained methylated (hMLH and SOCS). 
 
When DLD-1 cells were exposed to the same doses of AZA and RRx-001 that resulted in 
effective demethylation, their ability to migrate in two-dimensions and invade in three-
dimensions through and ECM-like substrate were significantly restricted.  These effects 
occurred at doses that had previously been demonstrated to be sub-cytotoxic.  We can therefore 
infer that demethylation results in a reduced ability of DLD-1 cells to migrate and invade in a 
manner akin to the EMT and MET processes of in vivo colorectal cancers, and that this 
pathological process may be driven by aberrant locus specific hypermethylation.  The next 
chapter of this thesis will therefore investigate locus specific hypermethylation as a potential 







Methylation Dependent Gene Expression and the 




5.1.1 The Epithelial-Mesenchymal & Mesenchymal-Epithelial Transitions 
The epithelial to mesenchymal transition (EMT) is a normal physiological process whereby 
cells of the epithelium undergo multiple phenotypic changes to become mesenchymal-type 
cells; typically losing their polarity and normal cell-cell adhesions and thus allowing them to 
become migratory and invasive466, 467.  During embryological development this process is key 
to normal tissue differentiation and organ development, and malfunction in this process can 
lead to abortion or congenital abnormality407.  Cells that have undergone EMT are also more 
resistant to apoptosis and senescence and have a role in localised immunosuppression. EMT is 
also an important process in wound healing and tissue fibrosis outside of embryological 
development, and dysfunction may underlie pathological healing (scarring) in adult tissues468.  
The reverse process, mesenchymal to epithelial transition (MET), is also a fundamental normal 
physiological process that describes the migration and terminal differentiation of mesenchymal 
cells to polarised epithelial cells469.  Cells undergoing EMT or MET progress through a number 
of stages characterised by differential expression of intracellular proteins, cytoskeletal changes, 
and expression of cell-surface receptors and junctional complexes (Figure 5.1).  These 
phenomena are also observed in carcinoma, and thus the normal processes of EMT and MET 
are thought to be integral to the development of cancers470, 471. This is particularly important 
when considering the processes necessary for tumours of epithelial cell origin to first become 
invasive through the basement membrane, to penetrate vasculature and lymphatics, and then to 
seed as metastasis; as these stages of tumour progression share many similarities with the EMT 








When considering EMT-like progression in early cancers, including CRC, it is important to 
recognise that the process of tumourigenesis shows plasticity from a cellular and heterogeneous 
from a population perspective470.  Based on a model of early skin squamous cell carcinoma, 
Pastushenko and colleagues describe how induced EMT-like tumourigenesis resulted in a 
significant increase in the heterogeneity of expressed cell surface markers.  By characterising 
these markers as either epithelial-associated of mesenchymal-associated the degree of EMT-
progress was able to be characterised, revealing sub-populations of tumour cells displaying 
differing degrees of transition, described as degrees of stemness.  This concept has been 
previously reported by authors when investigating the heterogeneity of early invasive tumours 
and the observation that some cells undergoing an EMT-like transformation are able to transit 
between different states475. Even when tumours have become well established (by size criteria), 
solid-type (non-diffuse) tumours, such as colorectal adenocarcinoma, display localised 
heterogeneity within the tumour mass; cells at the invasive front displaying phenotypic 
differentiation to those at the centre of the tumour mass476. This is also evident at a genetic and 
epigenetic level477.   
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Due to the levels of observed heterogeneity, some authors have advocated a classification 
system for the degree of EMT-like phenotypes in carcinoma based on characteristic such as 
cell polarity, cell-cell adhesion, loss of keratin expression, and upregulation of vimentin474.  
This system is based on EMT-like phenotypic changes that are conserved across different 
tumour types (including colorectal adenocarcinoma, lobular breast carcinoma, melanoma, and 
sarcomas) and may serve as an exercise in classifying tumour from an academic perspective.  
However, there is currently no clinical application for this system, and no clinicopathological 
correlation has been attempted, although the conservation of some phenotypic features serves 
as a starting point for understanding some of the genetic and cellular events that underlie the 
process. 
 
In healthy tissues, the adhesion between epithelial cells is predominated by E-cadherin, which 
is itself linked to the actin component of the cytoskeleton via its intracellular domain and 
associated proteins b- & a-catenin.  During physiological and cancer-related EMT, loss of E-
cadherin cell-cell interaction is regarded as a critical step, and E-cadherin as a “master 
regulator” of the loss-of-adhesion component of the EMT process472. Normal regulation of E-
cadherin relies on a highly complex set of interactions between canonical intracellular 
signalling pathways, although b-catenin, RAS, and src are thought to play a central role478. As 
previously discussed in Section 1.3.2, activation of the APC/b-catenin pathway through 
mutation and pathological RAS signalling are regarded as key early steps in the classical 
adenoma-carcinoma pathway of CRC, and may result in loss of E-cadherin function.  Of note, 
very few cancers are thought to originate with a primary mutation in E-cadherin itself, although 
some diffuse-type cancers (notably lobular breast carcinoma) have been associated with 
heterogeneous methylation of CpG island associated with E-cadherin gene CDH1 on the long 
arm of chromosome 16479. 
 
As well as loss of E-cadherin, EMT/invasive changes are induced in response to growth factor 
signalling, specifically at receptor tyrosine kinases in response to insulin-like growth factor 
(IGF) or transforming-growth factor b (TGF-b)480.  Response to IGF is thought to dominate 
the normal EMT process by activation of the RAS/MAPK, PIK3AK/AKT, and src pathways, 
although pathological carcinoma invasion in response to IGF is primarily mediated through a 
b-catenin pathway. As well as disrupting cell-cell adhesion by effects on E-cadherin, IGF-II is 
able to induce EMT by upregulation of b-catenin/TCF-3 target genes including cyclin-D1 and 
c-myc; which themselves are a cell-cycle protein important at G1 (associated with VEGF 
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mediated angiogenesis in tumours) and a transcription factor (proto-oncogene associated with 
cell proliferation in cancers), respectively481.  TGF-bs are regulatory growth factors secreted 
by stromal cells and are essential to healthy EMT (intrauterine global loss of TGF-bs is fatal) 
and contribute to normal crypt architecture in the small bowel and colon482. In healthy colon 
the TGF-b family of signalling ligands normally act on epithelial cells to suppress cell 
proliferation and tumour development via their effects on SMAD expression and reciprocal b-
catenin suppression, and by the activation of cyclin-dependent kinase inhibitors483.  However, 
in the context of early tumours undergoing and EMT-like progression, TGF-bs can act 
conversely to suppress the stromal anti-tumoural inflammatory response mediated by immune 
cells, thus facilitating invasion484, 485.  
 
During EMT-like invasion, cancerous cells must change their cytoskeletal structure to facilitate 
migration through the ECM.  Although also integral to the E-cadherin regulated cell-cell 
adhesion, cytoskeletal components such as cytokeratins (intermediate filaments: IF) are critical 
to cell division & migration during EMT and are highly conserved across tissue and tumour 
types486, 487. The IFs themselves are a huge family of highly conserved proteins that are 
differentially expressed in different tissue types and are typically sub-divided into groups.  
Groups I and II are typically found in epithelial cells and the expression of specific cytokeratins 
in this group has aided in the characterisation of cancers, especially when identifying the source 
of metastasis488. However, group III IFs such as desmin and vimentin are more typically 
expressed in stromal cells such as fibroblasts but have been found to be over-expressed in a 
variety of epithelial-type cancers such as bladder and colorectal cancer, particularly following 
metastasis489, 490. The increased expression of stromal cytoskeletal proteins is another 
indication that cells undergoing malignant transformation initially progress through an EMT-
like process.  In colorectal cancer, EMT-like induction of cytoskeletal changes is again 
primarily mediated via the TGF-b pathway and is downstream effects on the SMAD3 and 
SMAD4 transcription factors, and the wnt/b-catenin pathway and downstream effects on 
SLUG and SNAIL490.  Despite increases in expression of group III IFs in epithelial cancers, 
the use of proteins such as vimentin as biomarkers in colorectal cancer had not been adopted, 
largely due to poor sensitivity during early disease stages and lack of superiority in stage IV 
disease over traditional markers such as CEA491, 492. 
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As well as loss of normal cell-cell adhesion and changes to the cytoskeleton, cells undergoing 
physiological and pathological EMT demonstrate loss of normal cell polarity.  Cell polarity is 
normally maintained by polarity regulator complexes (PRCs) such as Bazooka, Crumbs, and 
Scribble, which are not only highly conserved across cell types but also between species493. As 
well as maintaining basal-apical polarity, these complexes also have an important role in cell 
migration and proliferation, both in EMT and in carcinogenesis. Under normal physiological 
conditions, polarity is maintained by the interaction of PRCs with components of the basement 
membrane and stroma such as laminin, collagens I-IV, and other integrins. Changes to the 
cellular microenvironment can, however, induce EMT in a number of epithelial call types in a 
process mirrored by early cancer transformation494. This is demonstrated by the observation 
that blockade of normal b1 integrin binding stimulates expression of the malignant phenotype 
in some pre-malignant epithelial cancers495. In colorectal cancer, PRC apical protein kinase C 
(aPKC) may be found to be over-expressed as a result of RAS mutation, and has been found to 
be a critical factor in regulating EMT496, 497.  The relationship between aPKC over-expression 
and dysfunction of PRCs such as Scribble seem to be key to this element of early cancer 
development, and may act via a common pathway of ErbB2 transcription and subsequent 
HER2 expression, leading to downstream effects on MAPK and PIK3AK signal transduction 
pathways498.  The central role of HER2 in CRC may be reflected in HER2 expression being a 
factor in predicting loss of treatment response to anti-EGFR therapies, and may itself be a 
future therapeutic target499. 
 
The reverse process of MET is less well characterised than EMT, and the genetic and cellular 
events that underlie the observed phenotypic changes are not well understood. It should also 
be noted that when considering healthy physiological MET the original mesenchymal cells 
become terminally differentiated epithelial cells, whereas the cells of a tumour metastasis 
remain abnormally differentiated500. There is, however, an acceptance that tumour cells that 
have successfully metastasised have adhered to and penetrated the host tissue vascular or 
lymphatic wall, migrated to the parenchyma, and seeded in their metastatic niche, after which 
they must proliferate to form a metastasis. The limiting factor in this process is deemed to be 
the ability of the micrometastasis to induce angiogenesis (Figure 5.2)501.  This phenotypic 
change may occur after a long period of tumour cell dormancy, sometimes many years after 
the primary tumour has been treated.  The complexity of this process perhaps underlies the 
estimation that only 0.01% of circulating tumour cells form a secondary tumour502. 
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Figure 5.1.2 The Metastatic Process (adapted from Chambers, et.al.)502. 
 
 
Once epithelial cells have undergone the EMT-like process of loss of normal cell-cell adhesion, 
loss of polarity, and changed their cytoskeletal architecture they are more able to negotiate the 
basement membrane and stromal layers.  Fundamentally this is the process that facilitates 
colorectal cancers to progress form tumourous cells in situ (Tis) to more advanced tumours of 
the bowel wall (T1-4), to invade blood vessels and lymphatic, and eventually metastasise to 
local lymph nodes and more distant sites.  Another requirement for tumours progress on this 
pathway is the ability to degrade the extracellular matrix.  
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5.1.2 Metalloproteinases & Cancer 
The metalloproteinases (MMPs) are a large group of proteolytic enzymes capable of degrading 
all of the protein components of the extracellular matrix (ECM), as well as some growth factors.  
This large family is sub-divided into groups dependent on the preferred target substrate of each 
MMP, such as the collagenases (MMP1, -8, -13) or the gelatinases (MMP2, -9)503.  Throughout 
the body of scientific literature, MMPs are referred to variably by their MMP assignment, their 
substrate assignment, or common names, leading to significant potential for confusion. One 
such example is collagen-IV-specific MMP2, which is variably also known as Gelatinase-A or 
72kDa Type-IV collagenase.  For the purpose of this thesis each MMP will be referred to by 
its MMP assignment (e.g. MMP2, MMP9, etc). MMPs are summarised in Figure 5.3. Most 
MMPs are released into the ECM, often in the form of an inactive pro-enzyme (zymogen), after 
which they are activated and free to act upon the surrounding substrate.  However, some sub-
groups of MMP can be found attached to the cell surface (the GPI-anchored MMPs) or as 
transmembrane proteins (the transmembrane-type MMPs)504. 
 
Figure 5.1.3 Matrix Metalloproteinases (MMPs) (adapted from Stamenkovic)505. 
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The role of MMPs is to modulate the structural components of the ECM; predominantly, 
collagens and gelatins. This is an important part of healthy embryological development and 
organogenesis, as well as tissue homeostasis, remodelling, and repair in mature tissues506. This 
is particularly pertinent when considering wound healing and the migration and invasion of 
mesenchymal cells through he ECM, although most cells in their base state do not express 
MMPs strongly.  Transcriptomal control of MMPs is partially mediated by growth factors, 
hormones, cytokines, and cellular transformation, including soluble suppressive factors such 
as TGF-b, retinoic acid, and glucocorticoids. However, the primary induction of MMP 
expression is mediated by integrins or cell-cell interactions; particularly cells of the immune 
system507, 508. The extracellular action of MMPs further regulated by the balance of inhibitory 
factors; specifically, a-macroglobulins and MMP-specific tissue-inhibitors of 
metalloproteinases (TIMPs)509.   
 
In addition to their roles is healthy tissue maintenance, MMPs also have a long-established role 
in carcinogenesis505. In relation to epithelial-derived tumours, such as CRC, the first stage of 
tumour invasion is through the basement membrane, which itself is primarily composed of 
type-IV collagen, and thus much interest has been directed towards MMP2 and MMP9510. The 
role of MMP2 has been investigated specifically in relation to colorectal cancer, where 
increased expression has previously been associated with worse Duke’s stage511. Similarly, 
TIMP2, the specific inhibitor of MMP2, has been associated with increased likelihood of 
localised disease spread in colorectal cancer, although MMP2 and MMP9 were not found to 
be significant512. At best, the role and significance of increased MMP2 and MMP9 expression 
in solid cancers, or their respective inhibitors, is not consistent.  Several tumour types have 
shown association between worsening stage and/or tumour biology associated with increased 
MMP2 expression, although MMP2 has failed to be reliable as a diagnostic tumour marker or 
in stratifying clinical outcomes513. 
 
A more recent perspective on the role of collagen-IV specific MMPs in colorectal cancer has 
examined the failures to translate laboratory models of CRC and MMP activity to observations 
made in vivo514. Mook and colleagues consider that MMPs and early invasive CRC are 
interacting with a complex stromal environment in vivo, and that the previous modelling of 
CRC (specifically in the application of MMP-blocking agents as potential therapy) has been 
inadequate in accounting for the complex cell-cell and cell-stromal interactions that partially 
determine MMP activity. One hypothesis suggested is that MMP inhibition may actually 
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contribute to carcinogenesis by preventing MMPs degrading angiogenic growth factors and 
cytokines. Furthermore, selective inhibition of MMP2 and MMP9 may also contribute to 
carcinogenesis in CRC by preventing macrophage and other inflammatory cell migration to 
early tumours, thus reducing anti-tumoural response. The failure of MMP inhibitors as anti-
cancer therapies, and a growing appreciating that these failures may be due to a poor 
appreciation of the role of these proteinases in the immune response, have subsequently 
prompted investigators to examine whether MMP inhibitors may have a role in inflammatory 
diseases such as rheumatoid arthritis515.  
 
Surprisingly, there has been little investigation of methylation of MMPs and TIMPs relating to 
any type of cancer, and almost none relating to colorectal cancer.  A single study identified 
relative hypermethylation and subsequent silencing of MMP16 (a transmembrane MMP) in in 
vitro colorectal cancers and in colorectal cancer cell lines (SW480, DLD-1, and LoVo)516. 
Treatment with AZA restored expression of MMP16 following demonstrable locus-specific 
demethylation. Further studies have highlighted a potential role for epigenetic mechanisms 
(including methylation and chromatic restructuring) in the regulation if MMPs in other 





5.1.3 Differential Gene Expression 
Phenotypic changes in epithelial cells undergoing EMT-like progression to early invasive 
cancers will change the expression of genes required to effect this transformation.  As this 
process defines a malignant transformation, the genetic factors that bring about the change in 
gene expression can thus be assumed to carcinogenic; whether chromosomal, mutational, or 
epigenetic. However, due to the high-level of interlinkage between canonical intracellular 
signalling pathways, care must be taken when interpreting expressional changes associated 
with signalling, and thus end-effect changes in expression (such as those that define EMT or 
the relationship to the ECM) may provide better indicators of invasive transformation520. 
 
One method of examining differential gene expression is to examine messenger RNA (mRNA) 
profiles; relative increases or decreases in specific gene mRNA provide an insight into biologic 
mechanisms, and may be attributable to specific genetic events, exposure to genotoxic agents, 
or therapies. This methodology is widely applied in toxicogenomics, where cells are exposed 
to putative genotoxins and expressional changes associated with exposure can therefore 
indicate a mechanism of carcinogenic action521. The process may also be applied in reverse, 
where exposure to a potentially therapeutic agent may result in differential gene expression 
that may be regarded as effecting an anti-tumoural phenotypic change or cell death. The 
combination of these molecular techniques with chemo- and bioinformatics can also reveal 
expressional changes associated with therapeutic agents that are not evident at a phenotypic 
level522, 523.   
 
When screening for expressional changes, a high-throughput wide-net approach is usually 
employed in the first instance to capture a potentially relevant expressional event, which can 
then be focused-down upon by more targeted methods. One such method of initial screening 
is through microarrays524.  Microarrays exploit the relative binding saturation of fluorescently 
labelled target RNA to specific pre-loaded oligonucleotide primers on rigid surfaces, causing 
differential fluorescence to indicate relative expression. In this format microarrays are 
commonly known as gene chips and have the ability to screen multiple genes (from the tens to 
the many hundreds, depending on the platform). Once differential expression has been 
examined, clustering techniques (supervised or unsupervised data analysis) may be used to 
identify genes with a similar response to stimulus, or which genes best indicate the application 
of specific stimuli525. 
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This process has been refined further to incorporate quantitative real-time PCR (qRT-PCR) 
techniques to the basic array format and is now considered the gold-standard in quantitative 
assay screening for expressional change526, 527. This process relies upon real-time observation 
of relative fluorescence during exponential amplification of complimentary cDNA, and thus 
both an internal and external control for expression must be employed, as well as a pre-
amplification stage of cDNA synthesis from mRNA. Despite the additional complexity, qRT-
PCR has been shown to be an accurate and precise method of assessing gene expression528. If 
a biologic process is suspected, pathway-specific microarrays based upon genes known to be 
important to that processes may facilitate in the initial screening by narrowing the target 
spectrum of genes, increasing efficiency.  
 
qRT-PCR can also be used to validate the array data once it has suggested specific target genes 
of interest and may also demonstrate dose-dependent expressional change when examining the 
effects of genotoxic of therapeutic agents.  The selection of target genes for qRT-PCR is based 
upon array data, but also consideration of the biologic process being investigated and the 
complexity of cellular signalling; thus, differential extracellular enzyme expression may 
provide more illuminating to phenotypic changes than, for instance, a canonical signalling 
protein with multiple downstream effects.  The expressional changes that may be observed in 
array and specific qRT-PCR may be confirmed further by standard quantitative protein 
techniques, such as Western blotting. 
 
For the purposes of this study, the Qiagen RT2 Profiler PCR Array for Human Tumour 
Metastasis was chosen as the PCR array527.  There were several factors influencing the choice 
of this array, especially considering there are EMT-specific arrays provided by the same 
manufacturer that might have provided a more specific insight into the expressional events that 
underlie EMT-like transformation of an early cancer.  However, the overarching narrative of 
this thesis is to examine specifically the biological processes that underlie extramural vascular 
invasion in rectal cancer, particularly in the context of locally advanced disease.  These 
processes depend not just on and EMT-like process enabling invasion of the submucosa, but 
also invasion of other tissues, including blood vessels and lymph nodes.  A decision was made, 
therefore, to look more closely at the extracellular remodelling, locally invasive, and locally 
metastatic abilities of DLD-1 cells (derived from a Dukes C adenocarcinoma), as opposed to 
early EMT-like changes such as loss of cell polarity and cell-cell adhesion.  Clearly there is a 
high degree of overlap between EMT and local invasion from the point of view of underlying 
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biologic process, and thus some of the same genes are examined on the corresponding EMT 
and metastatic arrays.  However, on balance, the coverage of likely genes of interest was more 
appropriate on the human tumour metastasis array than the EMT array.  This was particularly 
the case for MMPs and TIMPs, with only MMP2, -3, & -9, and TIMP1 being examined on the 
EMT array, whilst MMP7, -10, -11, & -13, and TIMPs -2, -3, & -4 are all examined on the 
metastasis array in addition to those examined on the EMT array.  Additionally, the APC, 
KRAS, and SMAD genes are also examined on the metastasis array but are absent on the EMT 
panel.  Cadherins and Type IV collagen are present on both.  A full list of gene targets on the 
Qiagen RT2 Profiler PCR Array for Human Tumour Metastasis focused array is presented in 
Figure 5.1.4. 
 







5.2 Aims & Objectives 
This chapter will examine the gene-expressional effects of demethylation of colorectal cell 
lines in vitro by AZA and RRx-001.  Firstly, a gene qRT-PCR array will be employed to 
identify genes of interest, with a focus on those genes important in the EMT and locally 
invasive processes.  Secondly, a more in-depth investigation of differential expression of genes 
identified by the array will be performed to confirm array results, and to examine for any 





DLD-1 cells were cultured in control conditions or exposed to AZA and RRx-001 according 
to the protocols described in Sections 2.3 and 4.3.1.2.  Treatment arm doses of AZA and RRx-
001 were 0.50uM.  For the purposes of the array, only AZA at 0.50uM for 72hrs exposure was 
used against control, as this provided a baseline for investigation potential differential gene 
expression in a well characterised compound with a specific mode of demethylation.  For 
subsequent gene-specific qRT-PCR, RRx-001 and an additional dose-exposure of 24hrs AZA 
were employed.  The purpose of this was to examine for any temporal effect of demethylating 
agent AZA, as it relies on cell proliferation to effect demethylation.  This was the only 
modification. 
 
5.3.1 RT2 Profiler PRC Array Gene Expression 
5.3.1.1 RNA Extraction & Purification 
RNA was extracted from DLD-1 cells by employing the Qiagen RNeasy RNA kit.  There was 
no deviation from the product protocol. The maximum RNA haves from this system is 100µg 
per sample, and thus a maximum of 5x106 cells (as recommended in product literature) were 
used in each sample to prevent over-saturation of the system.  DLD-1 cells were first 
trypsinised and washed twice with PBS before undergoing RNA extraction. All reagents were 
prepared as per the kit protocol and RNA extraction was performed under clean laminar-flow 
conditions using standard precautions to prevent cross-contamination / fouling of reaction.   
 
Firstly, 600uL of Buffer RLT was added to cell pellets in a microcentrifuge eppendorf 
containing pelleted cells and vortexed thoroughly until no cell clumps were visible and until 
fully homogenized (approximately 3 minutes).  Following homogenization, 600uL of 70% 
ethanol was then added and the suspension mixed thoroughly by pipetting.  Of the resulting 
suspension, 700uL of was then transferred to spin columns placed in a 2ml collection tube and 
centrifuged at 10,000rpm for 15 seconds.  The flow-through was discarded. 700uL of Buffer 
RW1 was added to the spin column (replaced in the emptied collection tube) and was 
centrifuged again at 10,000rpm for 15 seconds.  The flow-through was discarded. 500uL of 
Buffer RPE was then added to the spin column and centrifuged at 10,000rpm for 15 seconds.  
The flow-through was discarded. A further 500uL of Buffer RPE was added to the spin column 
but this time centrifugation at 10,000rpm was for 2 minutes to ensure drying of the RNA 
collection membrane and full elimination of any residual ethanol. Spin columns were then 
transferred to a fresh 1.5ml collection tube and 50uL of nuclease-free water (DEPC-free) was 
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added directly to the spin column membrane.  Spin columns were centrifuged at 10,000rpm for 
1 minute to elute the RNA.  Harvested RNA was then quantified and its purity checked by 
spectrophotometery (Nanodrop) at 260 nm. RNA was stored at -20oC. 
 
5.3.1.2 cDNA Synthesis 
The Qiagen RT2 First Strand Kit was used to generate cDNA from mRNA as it is the validated 
kit for use in conjunction with the RT2 Profiler Array. There was no deviation from the 
published product protocol. 0.5ug of total RNA was used for each sample as recommended by 
the product literature, and thus input of total RNA was standardised based on the quantified 
RNA harvest as specified above. Reagents were prepared as specified in the protocol.   
 
The gDNA elimination cocktail was made by the combination of 5ug RNA with 2uL of Buffer 
GE and a variable amount of nuclease-free water in a clean eppendorf to make a total volume 
of 10uL.  The mixture was mixed by pipetting and then incubated for 5 minutes at 42oC, and 
then transferred to ice for 1 minute.  10uL of reverse-transcription cocktail was then added to 
each gDNA elimination cocktail and mixed by pipetting. This mix was then incubated at 42oC 
for 15 minutes to facilitate cDNA synthesis and then the reaction stopped by incubation at 95oC 
for 5 minutes. 91uL nuclease-free water was then added to each sample, mixed, and the sample 
kept on ice before proceeding directly to the RT2 protocol. 
 
5.3.1.3 RT2 Profiler Array 
The Qiagen RT2 Profiler PCR Array for Human Tumour Metastasis (cat. no. 330231 PAHS-
028ZA) was employed for expressional analysis.  There was no deviation from the published 
product protocol. Reagents were prepared as specified in the protocol. RT2 SYBR Green 
Mastermix (containing HotStart DNA Taq Polymerase) was employed to ensure accurate 
results. As the chosen array is a 96-well format plate all volumes were calculated 
correspondingly. 
 
The PCR components were mixed to a total volume of 2700uL in a 5ml tube accordingly; 2x 
RT2 SYBR Green Mastermix 1350uL, cDNA product 102uL, nuclease-free water 1248uL. 
25uL of the PCR components was then added to each well of the profiler array using an 8-
channel pipettor, ensuring fresh tips for each well to avoid cross-contamination of well 
contents. The array wells were then sealed with the supplies Optical Thin-Wall 8-cap strips.  
The plate was then centrifuged for 1 minute at 12,000rpm and the plate examined to ensure no 
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bubbles were present at the base of the wells, and then placed on ice while the RT-PCR cycler 
was programmed. As a Bio-Rad (USA) IQ-5ä  Real-Time PCR System was employed, cycling 
conditions were set as shown in Table 5.3. Figure 5.3 demonstrates the plate layout for the 
Qiagen RT2 Profiler PCR Array for Human Tumour Metastasis. 
 
Table 5.3 Cycling conditions for qRT-PCR when employing the RT2 Profiler Array. 
Cycles Duration Temperature Comment 






Exponential amplification & fluorescence data 
collection 
 
Figure 5.3 Plate layout for Qiagen RT2 Profiler PCR Array for Human Tumour Metastasis. 
Please refer to Figure 5.1.4 for corresponding gene information.  
 
 
5.3.1.4 Data Analysis 
Baseline was set automatically by the cycler software from cycle 2 through 2 cycles.  Threshold 
CT was set manually based upon the log view of the amplification plots, specifically on the 
lower portion of the linear amplification phase.  Raw data was exported to a Microsoft Excel 
spreadsheet for use with SABioscinces PRC Array Data Analysis Template. A melting 





5.3.2 qRT-PCR of Metalloproteinases 
Metalloproteinase targets were chosen based upon the results of the Qiagen RT2 Profiler PCR 
Array for Human Tumour Metastasis; for full results see Section 5.4.1.  Four sets of qRT-PCR 
were conducted for each gene target: Control; 24hrs 0.50uM AZA; 72hrs 0.50uM AZA; 72hrs 
0.50uM RRx-001.  Each culture condition was performed in three biological replicates, each 
of which were subject to parallel technical triplicate during PCR. mRNA was extracted, 
purified, and quantified by the same methods described in Section 5.3.1.1.  A real-time one-
step RT-PCR methodology was applied employing the QuantiFast SYBR Green RT-PCR kit 
supplied by Qiagen, eliminating a separate cDNA synthesis stage. 
 
Six pairs of cDNA primers were designed for qRT-PCR targeting MMPs and TIMPs: MMP2, 
MMP9, MMP11, MMP13, TIMP2, & TIMP4. Primer design employed a dual technique of 
target sequence verification via the NCBI GenBank open source reference 
(https://www.ncbi.nlm.nih.gov/genbank/) and then oligo analysis via Beacon Designer, 
PREMIER Biosoft International (http://www.premierbiosoft.com/qpcr/index.html).  Oligos 
were also cross-referenced using Primer-BLAST open access software 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/)529. b-actin was used as a housekeeping 
gene in order to provide reference for quantitative analysis (sequence supplied and previously 
validated in-house). Primer sequences are listed in Section 2.2.5.  No primer demonstrated 
dimerization, hairpins, or other significant erroneous pairing events, and each had an efficiency 
³90% and a melting temperature Tm ³70oC. 
 
qRT-PCR reactions were set-up individually in a 96-well plate with the following components: 
2x QuantiFast SYBR Green Mastermix 12.5uL, Primer A 0.5uL, Primer B 0.5uL, QuantiFast 
RT Mix 0.25uL, template RNA variable volume to control for 100ng/reaction, nuclease-free 
water variable volume to make-up total reaction volume to 25uL. In addition to the 
experimental wells performed in triplicate, a standard curve was constructed by serial dilution 
(concentrations 1.0, 0.1, 0.001, 0.0001) for each primer and each plate.  Reagents were kept on 
ice throughout to prevent degradation of mRNA. Plates were sealed with biofilm.  The plate 
was then centrifuged for 1 minute at 12,000rpm and the plate examined to ensure no bubbles 
were present at the base of the wells, and then placed on ice while the RT-PCR cycler was 
programmed. As a Bio-Rad (USA) IQ-5ä  Real-Time PCR System was employed, cycling 
conditions were set as shown in Table 5.4.  
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Table 5.4 Cycling conditions for qRT-PCR when employing the QuantiFast SYBR Green RT-
PCR kit and gene-specific cDNA primers. 
Cycles Duration Temperature Comment 
1 10 minutes 50oC Reverse transcription 
1 5 minutes 95oC HotStart DNA Taq Polymerase activation 
35 10 seconds 95oC Denaturation 
35 30 seconds 60oC 
Exponential amplification & fluorescence data 
collection 
 
Baseline detection was set automatically by the cycler software from cycle 2 through 2 cycles.  
A standard curve was calculated based on b-actin & target gene serial dilutions.  Threshold CT 
was set manually based upon the log view of the amplification plots, specifically on the lower 
portion of the linear amplification phase.  CT values for triplicates not within 1 cycle of each 
other were removed, provided that there were at least 2 remaining.  Raw data was exported to 
a Microsoft Excel spreadsheet for use with Biorad IQ5 software. A melting (dissociation) curve 
analysis was performed to ensure single product amplification for each well and anomalies 







5.4.1 RT2 Profiler PRC Array Gene Expression 
No pre-amplification phase was performed.  The lower limit of detection was set to CT = 20, 
which was at the lower end of the Log-linear phase533. The average CT (PPC) was 23.73 and 
23.48 for control and test, respectively.  Delta CT (Average RTC – Average PPC) was 2.16 and 
2.13 for control and test, respectively. There was insignificant genomic DNA contamination. 
Normalisation (from which DD CT will be calculated) was set automatically by the analytical 
software based on the housekeeping genes (HKG) beta-2-microglobulin (BM2) and ribosomal 
protein, large, P0 (RPLP0) (Figure 5.4.1). Melt-curve analysis was satisfactory for each well. 
 
Figure 5.4.1. Geometric and average geometric mean CT for selected housekeeping genes. 
 
 
DLD-1 cells were cultured in control conditions or with AZA 0.50uM applied daily for 72hrs 
as described previously.  At the end of the treatment period, cells were harvested and counted 
both by coulter counter and on a haemocytometer to ensure no unexpected toxicity had 
occurred, but then diluted to a maximum of 5x106 cells as per the RNA harvest protocol. 
Harvested RNA was satisfactorily quantified and its purity ensured by spectrophotometery 
(Nanodrop) at 260 nm. Extracted RNA was then used to assess the changes in expression of 
genes associated with invasion using the RT-Profiler. Spare RNA was stored at -20oC for short-




Figure 5.4.2 demonstrates the fold-change results for genes significantly over or under 
expressed compared to control, where significant fold-change threshold is set to ±2 [2^(-DCT)]. 
Values for statistical significance (p)could not be calculated based on only a single repetition 
of the array; verification will be by targeted qRT-PCR. In order of fold-increase (relative fold-
increase in brackets), the genes significantly upregulated were; CKDN2A (18.00), TRPM1 
(7.28), ITGB3 (3.11), MMP13 (2.85), SSTR2 (2.63), VEGFA (2.62), TIMP4 (2.58), and 
MMP11 (2.45).   In order of fold-decrease (relative fold-decrease in brackets), the genes 
significantly downregulated were; IGF1 (-11.93), FN1 (-7.91), MMP2 (-4.10), MET (-3.75), 
CD44 (-3.68), GAPDH (-3.57), EPHB2 (-3.07), ACTB (-3.00), FGFR4 (-2.97), PNN (-2.73), 
TIMP2 (-2.68), CDH1 (-2.59), NME1 (-2.54), HPRT1 (-2.40), KISS1 (-2.30), CD82 (-2.55), 
TNFSF10 (-2.22), CXCR2 (-2.09), TGFB1 (-2.08), FLT4 (-2.06), FXYD5 (-2.06), CST7 (-
2.02).  None of the remaining 66 genes (out of a total of 96 profiled genes) demonstrated 








Figure 5.4.3. Scatter-plot of normalised expression for treatment (Group1) versus control, with 











5.4.2 qPCR of Metalloproteinases 
Candidate genes were selected on the basis of the qPCR array data and conceptualisation of 
the EMT and EMVI process as pertinent to early invasive rectal cancer.  Selected genes were 
MMP2, MMP9, MMP11, MMP13, TIMP2, and TIMP4.  Each of these genes was considerably 
up- or downregulated in the array when DLD-1 cells were exposed to AZA.  MMP9 was also 
included in this stage of the investigation as it is the partner gelatinase to MMP2. Both a 24-
hour and 72-hour exposure to 0.50uM AZA was used during this stage, although only a 72-
hour exposure to 0.50uM RRx-001 was employed. Quality control data for mRNA and cDNA 
are provided in Appendix II. 
 
All results for change in expression are described in terms of relative change in expression in 
target gene between control and treatment arm, versus change in housekeeping gene (HKG; b-
actin) between the two same arms; DDCT.  Where DDCT = 1, there is no change in expression 
of target gene versus housekeeping gene, given equal exposure.  DDCT <1 indicates relative 
downregulation versus HKG, DDCT >1 indicates relative upregulation versus HKG.  DDCT 
cannot be negative, but if the target gene is not expressed at all DDCT will be 0 irrespective of 
HKG expression. Synthesised results are demonstrated in Figure 5.4.4 and raw data provided 
in Appendix III. For each of the genes other than MMP9, no wells were excluded on the basis 




Baseline expression of MMP2 was 2.7x10-13 that of b-actin. Following 24hrs treatment with 
0.50uM AZA, relative expression of MMP2 compared to b-actin was DDCT 0.50 (CI ±0.28, 
p>0.05).  Following 72hrs treatment with 0.50uM AZA DDCT was 0.24 (CI ±0.01, p£0.001). 
Following 72hrs treatment with 0.50uM RRx-001 DDCT was 4.79 (CI ±0.30, p£0.01).  
 
5.4.2.2 MMP9 
qRT-PCR results for MMP9 were uninterpretable due to numerous anomalous results. Multiple 
wells provided CT values in excess of 1 cycle away from their technical replicates, frequently 
leading to 2/3 replicates being excluded. Melt curve analysis also highlighted multiple peaks 
suggesting dimerization and the formation of multiple PCR products. The fact that PCR 
products were generated suggests that the reactions were not impeded, in which case no 
amplification would be expected, but that there was a problem with at least one of the primer 
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Baseline expression of MMP11 was 3.5x10-5 that of b-actin. Following 24hrs treatment with 
0.50uM AZA, relative expression of MMP11 compared to b-actin was DDCT 2.25 (CI ±1.09, 
p>0.05).  Following 72hrs treatment with 0.50uM AZA DDCT was 3.26 (CI ±1.02, p£0.01). 
Following 72hrs treatment with 0.50uM RRx-001 DDCT was 1.47 (CI ±0.32, p>0.05). Three 
wells were excluded on the basis of CT values being in excess of 1 cycle away from each other, 
but this did not prevent meaningful analysis. There were no unfavourable melt curves resulting 
in replicate exclusion. 
 
5.4.2.4 MMP13 
Baseline expression of MMP13 was 4.0x10-4 that of b-actin. Following 24hrs treatment with 
0.50uM AZA, relative expression of MMP13 compared to b-actin was DDCT 0.70 (CI ±0.03, 
p£0.05).  Following 72hrs treatment with 0.50uM AZA DDCT was 0.77 (CI ±0.11, p>0.05). 
Following 72hrs treatment with 0.50uM RRx-001 DDCT was 1.32 (CI ±0.42, p>0.05).  
 
5.4.2.5 TIMP2 
Baseline expression of TIMP2 was 0.062 that of b-actin. Following 24hrs treatment with 
0.50uM AZA, relative expression of TIMP2 compared to b-actin was DDCT 0.87 (CI ±0.69, 
p>0.05).  Following 72hrs treatment with 0.50uM AZA DDCT was 0.37 (CI ±0.06, p<0.001). 
Following 72hrs treatment with 0.50uM RRx-001 DDCT was 1.23 (CI ±0.31, p>0.05).  
 
5.4.2.5 TIMP4 
Baseline expression of TIMP4 was 1.25x10-7 that of b-actin. Following 24hrs treatment with 
0.50uM AZA, relative expression of TIMP4 compared to b-actin was DDCT 1.45 (CI ±0.55, 
p>0.05).  Following 72hrs treatment with 0.50uM AZA DDCT was 5.89 (CI ±1.81, p<0.05). 
Following 72hrs treatment with 0.50uM RRx-001 DDCT was 2.94 (CI ±0.65, p<0.05).  
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Figure 5.4.4 qRT-PCR results for DDCT of a. MMP2, b. MMP11, c. MMP13, d. TIMP2, and 






















The aim of this chapter was to investigate an association between demethylation with agents 
AZA and RRx-001 and any potential biologic process that may underlie the observed reduced 
ability of DLD-1 cells to migrate and invade following exposure to each agent.  Through this 
insight any potential association between methylation and the specific genes that underlie the 
in vivo processes of EMT-like transformation and local invasiveness, such as those which 
characterises EMVI, may be gained. Results from the RT2 Profiler PRC Array indicated that 
there was significant dysregulation in the MMP and TIMP genes associated with demethylation 
with AZA. There was also a significant decrease in cadherin expression (CDH1), but no change 
in the expression of APC, KRAS, SMADs. Expressional change was confirmed with qRT-PCR 
for each of the MMP and TIMP target genes of interest when DLD-1 cells were exposed to 
AZA, but the changes in expression were not consistent when cells were exposed to RRx-001.  
There was also a degree of temporality to the expressional effects of AZA, where a longer 
exposure produced a more significant change in expression in some, but not all, genes. 
 
5.5.1 RT2 Profiler PCR Array 
The RT2 Profiler PRC Array demonstrated that 72hrs of exposure to 0.50uM of AZA induced 
significant up- and downregulation (in terms of fold-change) in numerous genes associated 
with the EMT, locally invasive, and metastatic processes. More genes were downregulated 
than upregulated, but the family of genes that had undergone widespread expressional change 
was the metalloproteinases and their respective inhibitors.  This group of enzymes are 
particularly important in the processes of local invasiveness as they define the ability of cells 
to metabolise the non-cellular components of the basement membrane and stroma506, 534.  This 
is consistent with the reduced ability of DLD-1 cells to invade the ECM during invasion assays 
following exposure the AZA, as described in Chapter 4. The specific expression change of 
each MMP or TIMP will be discussed in greater depth in Section 5.5.2 with corresponding 
qRT-PCR data. Selected other up- and downregulated genes, and those whose expression did 




5.5.1.1 Downregulated Genes 
Contrary to the change in expression theoretically expected with demethylation, based upon 
the reduced invasive potential of DLD-1 cells after treatment with AZA, was the relative 
decrease (-2.59) in expression of cadherin-1 (CDH1), the gene coding for E-Cadherin. As 
previously discussed, E-Cadherin is a vital transmembrane protein that both regulates and 
effects cell-cell adhesion in epithelial cells.  Mutations in CDH1 and subsequent loss of 
function have previously been strongly associated with epithelial cancers, particularly diffuse-
type lobular breast and gastric cancers535, 536. Furthermore, loss of E-Cadherin and reciprocal 
over-expression of N-Cadherin has been associated with colorectal cancer progression490, 537.  
However, some authors have reported a complex and dynamic relationship between CDH1 
expression and methylation. Graff and colleagues describe how increased methylation of CpG 
islands associated with CDH1 led to silencing during early invasion of the ECM (an EMT-like 
process) as might be expected, but that CDH1 can be re-expressed when the same cells are 
cultured in spheroid; suggesting a dynamic pattern of methylation and CDH1 expression.479.  
Re-expression was associated with demethylation and homotypic cell-adhesion in spheroids, 
and thus the authors therefore suggest that CDH1 methylation is dynamic and at-least partially 
dependent on stromal interactions and cell-cell relations. Decreased expression of CDH1 
coupled with demethylation with AZA and decreased invasion through the ECM is therefore 
difficult to explain on the basis of a straightforward reciprocal relationship between 
methylation and expression, although the interaction with the ECM during invasion after AZA 
exposure may differentially alter CDH1 expression when compared to exposure during 
monolayer culture. 
 
Another significantly downregulated (-11.93) gene identified on the array was Type 1 Insulin-
like Growth Factor (IGF1).  IGF1 has been shown to be associated with many cancer types, 
including colorectal cancer, and primarily exerts a tumourigenic effect via the MAPK and 
PIK3AK/Akt pathways538, 539. Activation of these pathways by IGF1 increases the risk of CRC, 
as well as increasing cell survival, invasion, and resistance to chemotherapy via a number of 
downstream mechanisms540, 541. Differential methylation has already been associated with 
colorectal cancer and irregular expression of IGF1, and also that aberrant IGF1 methylation is 
a shared pathway in other cancer types542. Downregulation of IGF1 corresponds with the 
observed propensity of AZA exposed DLD-1 cells to invade, as the tumourigenic effects of 
downstream signalling would be correspondingly downregulated. 
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Fibronectin (FN1) was also significantly downregulated by AZA (-7.91) based on the array 
data.  Fibronectin is a large glycoprotein secreted into the extracellular matrix by fibroblasts 
and other cells, and has important roles in integrin binding, cell signalling, adhesion, migration, 
and proliferation543. Fibronectin also has an important role in wound healing, where its cross-
binding with fibrin is important in clot formation and recruitment of fibroblasts413, 544. In 
colorectal cancer, over-expression of FN1 is associated with worse disease stage, and FN1-
knockdown in vitro results in decreased expression of MMP9 and increased expression of E-
Cadherin, leading to inhibition of cell migration, proliferation, and survival545. However, 
fibronectin has also been demonstrated to induce demethylation-dependent MMP2 expression 
in breast ductal carcinoma cells in vitro, and that by doing so cell migration and invasion 
increased546. No studies have yet investigated the role of methylation and fibronectin in 
colorectal cancer, although downregulation and corresponding reduced invasion in vitro would 
suggest it is pro-invasive as a chemoattractant, although it has been reported that fibronectin 
may sequester MMP2 by binding the fibronectin-like domain547.  This hypothesis corresponds 
with the observation that the addition of fibronectin in the lower chamber of the Boyden 
chamber assay increased the Percentage Invasion through the ECM (Chapter 4, Figure 4.4.7), 
although the overall Invasion Index remained equal across all doses. 
 
c-MET is a tyrosine-protein kinase coded by the MET gene that was also downregulated in the 
array (-3.75).  MET has an important role in many cancers via activation of a number of 
downstream oncogenic signalling pathways including ras, PIK3A, stat, and b-catenin.  MET 
has been associated with anti-EGFR resistance in colorectal cancer and is a poor prognostic 
marker for survival548, 549. The centrality of the c-MET in the development and progression of 
colorectal and other gastrointestinal cancers had led to much interest in this mechanism and the 
possibility for  novel targeted therapies, although thus far there has been little success in 
translating benchtop concepts through to successful clinical trials550. Part of the reason for these 
shortcomings is the complexity of the downstream effects of MET signalling, although 
accurate gene-typing could provide better targeted therapies for individuals who are more 
likely to benefit; this is the basis for the Framework 7 MErCuRIC programme. Only a limited 
number of studies have investigated methylation-dependent expression of MET, although 
methylation events have been associated with pancreatic cancer and insulinomas, all-be-it via 
aberrant methylation of its regulators rather than the MET epigene itself551.  
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CD44 is a cell surface glycoprotein that has important roles in cell-cell interaction and relations 
to the stroma, including in cell migration and adhesion.  CD44 was downregulated on the assay 
(-3.68) following exposure to AZA. CD44 is implicated in the progression and metastasis of 
cancers by facilitating pro-invasive mechanisms associated with tumour cell migration, 
angiogenesis, and activation of growth-factor receptors552. CD44 has previously been shown 
to interact with MMPs in cancer (MMP9 and transmembrane-MMP1) to facilitate the 
progression of prostate cancer, and knockdown of MMP9 has resulted in a change to the CD44 
isoform and the failure of cancer cells to produce invadopodia553-555. In colorectal cancer, CD44 
is upregulated and occurs early in the adenoma–carcinoma sequence; facilitating an EMT-like 
progression by associated loss of APC/β-catenin tumour suppression, as well as by promoting 
growth-factor binging and inhibition of apoptosis556. None of these effects have thus far been 
associated with aberrant methylation events, although there may be an oblique relationship (via 
canonical signalling) in gastric cancer557. Downregulation of CD44 corresponds with the 
hypothesis that a degree of reversal in the loss of APC/β-catenin tumour suppression may 
reduce the propensity of colorectal cancer cells to invade in vitro. 
 
5.5.1.1 Upregulated Genes 
The most prominently upregulated gene on the array was tumour-suppressor CDKN2A 
(+18.0). This well characterised gene is important in cell cycle regulation and exerts anti-
tumoural effects by initiating cell-cycle arrest at G2 phase (leading to apoptosis) or G1 into S 
phase (cell-cycle arrest) via its two coded proteins P16 and P14ARF, respectively558. 
Hypermethylation of CpG islands associated with CDKN2A has been shown to be associated 
with the progression of colorectal cancer and in poor prognosis, as well as in the pathogenesis 
of other cancer types (e.g. melanoma & pancreatic cancers)559, 560. However, in MSI-high 
colorectal tumours, methylation of CDKN2A has been demonstrated to occur in association 
with methylation of hMLH1 in a sub-population of tumours identified as having better overall 
survival, thus hypermethylation events associated with P16 function are not universally 
indicators of worse prognosis561. It must be noted, however, that this study included a limited 
number of patients (n=51), and that dual hypermethylation was associated with typically 
adverse features, such as poor-differentiation. Despite slight inconsistency, abnormal genetic 
and epigenetic events associated with CDKN2A, including hypermethylation, are generally 
considered pro-carcinogenic, although via proliferative and anti-apoptotic mechanisms, rather 
than invasive and migratory. 
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TRPM1 was an upregulated (+7.28) gene coding for a transmembrane cation channel found in 
the retina and associated with depolarisation of the synapse in response to light, particularly in 
night-sight562. TRPM1 is also expressed in melanocytes and is expressed inversely with the 
aggressiveness (invasiveness and metastatic potential) of melanomas563. Calcium (Ca2+) 
remodelling is an observed event in cancers and thought to promote tumour cell migration, 
encourage proliferation, and support resistance to cell death; although it the role of cation 
channels is not well characterised in colorectal cancers564-566. As calcium is a critical initiator 
of progression through the cell-cycle as well as being important to multiple other cellular 
processes, increased cation channel expression might be assumed to promote cell proliferation. 
However, this is contrary to the observed effect in melanomas, although the upregulation of 
other TRP-family genes has been shown to occur in association with the development and 
progression of other cancers567, 568. There is no published evidence examining a relationship 
between aberrant methylation events and expression of TRPM1 in cancers. The observation 
that upregulation of TRPM1 in DLD-1 following exposure to AZA may be associated with a 
reduction in invasion in vitro corresponds to the inverse relationship of expression and invasion 
in melanomas. 
 
ITGb1 (integrin-b1) was also upregulated based on array data (+3.11).  Integrins are a large 
group of cell surface receptors that bind a huge array of ECM ligands and help regulate the 
cellular processes that are required for multicellular organisms to function normally, but also 
to dysfunction in cancers569.  ITGb1 is one of the many integrin regulators of TGFb1 which 
can, as previously discussed, act as both a tumour suppressor and promotor483, 485, 570. Integrin-
dependent upregulation of TGFb1 and its downstream targets has been demonstrated in several 
cancer types and results in an EMT-like progression, including in colorectal cancer571. In breast 
cancer, Allen demonstrated that integrin-dependent activation of TGFb1 was a key indicator 
of malignant transformation to ductal carcinoma in situ, a process dependent on TGFb1 
induced upregulation of MMP2 and MMP9572. Integrins also function to prevent anoikis by 
maintaining contact with the ECM, a regulatory control that may be lost in cancers569. Upon 
loss of integrin binding a number of downstream pathways are activated, including PIK3AK, 
resulting in caspase-8 recruitment to the cell membrane and activation by non-liganded 
integrins573. In neuroblastomas this process may be prevented by hypermethylation of caspase-
8, resulting in silencing, but methylation events are not otherwise well characterised in 
integrins and cancer574. 
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5.5.1.3 Unchanged Genes 
As discussed, some genes of interest on the array that mechanistically could be important to 
the EMT-like and EMVI processes have been shown to be up- and downregulated following 
exposure to AZA. Other genes have however not demonstrated any significant fold-change in 
expression, some of which might have been important oncogenes in the progression of 
colorectal cancer. Of particular note were APC, KRAS, and SMADs. 
 
The central role of adenomatous polyposis coli (APC) and KRAS genes in the classical 
Vogelstein model of colorectal cancer development has already been discussed in Chapter 
1.3.1, but it is important to note that expression of these genes was not affected by 
demethylation with AZA.  DLD-1 cells are known to demonstrated APC truncation, although 
the downstream effects of APC on b-catenin phosphorylation (and therefore function) are not 
determined by a binary relationship262, 575, 576. With regards epigenetic events and APC, 
hypermethylation of CpG islands associated with APC is a frequently observed event in 
sporadic CRC, with a significant increase in frequency of methylation of APC observed as 
adenomatous polyps progress to early cancers.  Two recent meta-analyses have however 
demonstrated that APC promoter methylation does not correlate to any pathophysiological 
feature (including grade and TNM stage) of colorectal cancers, other than being a marker for 
distinguishing cancer from healthy or adenomatous tissue577, 578. These results suggest that 
APC may be important as an early initiator of colorectal cancer by stimulating proliferation 
and cell survival, but that it does not significantly affect the relationships that govern 
interactions with and invasion of the ECM119, 120. 
 
KRAS expression was also not affected by demethylation with AZA.  KRAS mutation in CRC 
leads to deactivation and subsequent negative-signalling in the MAPK-pathway leading to 
increased signalling and uncontrolled cellular proliferation111. This process is not methylation-
dependent and DLD-1 cells are known to demonstrate KRAS G13D amino acid substitution as 
a result of an underlying mutation that is not methylation dependent. This is consistent with 
KRAS-mutated tumours in vivo, where mutations most commonly occur at codon 12 and 13 
and occur as part of the microsatellite-stable adenoma-carcinoma pathway579. 
 
Another family of genes not affected by AZA exposure was the SMAD family of intracellular 
signalling proteins (specifically SMAD2 and SMAD4).  As previously discussed in Section 
5.1.1, SMADs are important in EMT-like and metastatic processes in colorectal (and other) 
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cancers as they act to induce transcription that is a negative control on cellular proliferation 
and migration in response to TGFb interactions with the stroma482. The lack of change in 
expression of these genes despite the marginally significantly decreased expression of TGFb 
(-2.08), suggests that their downstream transcriptional targets may also not be dysregulated by 
AZA demethylation, although this process is also heavily depended on a number of other co-
transcription factors not examined by the array580. Furthermore, as SMAD expression is 
associated with SLUG/SNAIL dependent transcription and subsequent CDH1 (E-cadherin) 




In addition to the MMP family of genes discussed in the following section, a number of gene 
important to EMT-like and invasive processes were up- and downregulated following exposure 
to AZA. Contrary to what might have been expected given the increased ability of DLD-1 cells 
to invade and migrate following demethylation as demonstrated in Chapter 4, the expression 
of E-cadherin (CDH1), an important cell-cell adhesion protein, was downregulated. Similarly, 
genes with important roles in the development of colorectal cancer, including early EMT-like 
progression, remained unchanged, although the genetic mechanisms linked to aberrant 
expression of these genes (APC and KRAS) in cancer is not methylation-dependent, although 
methylation may be observed. A number of canonical intracellular signalling genes associated 
with cancers were dysregulated (c-MET, ITGb1, IGF1) or showed no change (SMADs).  These 
results are difficult to interpret as there are multiple downstream targets of these pathways, 
many of which act in opposition to each other as a homeostatic mechanism, and some even 
display pro- and anti-tumoural activity depending on the stromal environment and other 
factors. However, classical tumour-suppressor gene CDKN2A was significantly up-regulated 
by demethylation with AZA, as was TRPM1, another gene associated with favourable features 
in melanoma. Clearly there is a mixed-picture in terms of the balance of up- and down-
regulated genes and those that may be hypothesised as pro- and anti-tumoural, and thus it is 
pragmatic to address the specific observations of the effects of AZA on DLD-1 cells when 
interreacting with and ECM-like substrate such as that encountered during the invasion assay. 
This might be best evaluated by examining the effects of AZA on the metalloproteinase group 




5.5.2. Metalloproteinases & qRT-PCR 
Based on array data, MMP and TIMP expression was significantly changed across the family 
(relative fold-change): MMP2 (-4.10); MMP11 (+2.54); MMP13 (+2.85); TIMP2 (-2.86); 
TIMP4 (+2.58).  For each of the genes highlighted by the array, qRT-PCR data individually 
validated and showed statistical significance for the up- or downregulation observed in the 
array following exposure to 0.50uM AZA for 72hrs, except for MMP13 which only showed an 
inverse but statistically significant DDCT after 24hrs exposure. Exposure to RRx-001 0.50uM 
for 72hrs universally upregulated every MMP or TIMP in a manner that was inconsistent with 
the effects of demethylation with AZA, but these effects only reached significance for MMP2 
and TIMP4. In the case of MMP2, exposure to RRx-001 upregulated MMP2 in a contrary 
manner to exposure to AZA (p£0.01). Unfortunately, MMP9 could not be included in the 
analysis due to unreliable qRT-PCR data.  These results are summarised in Table 5.5. 
 





24hrs AZA 72hrs AZA 72hrs RRx-001 
DDCT p DDCT p DDCT p 
MMP2 -4.10 0.50 NS 0.24 p£0.001 4.79 p£0.01 
MMP11 +2.54 2.25 NS 3.26 p£0.01 1.47 NS 
MMP13 +2.85 0.70 p£0.05 0.76 NS 1.31 NS 
TIMP2 -2.86 0.87 NS 0.37 p£0.001 1.22 NS 
TIMP4 +2.58 1.45 NS 5.89 p£0.05 2.94 p£0.05 
 
These results demonstrate that as well as having the biggest fold-change based on the array 
data, MMP2 and TIMP2 also had the most statistically significant expressional change 
following 72hrs AZA exposure, based on  DDCT qRT-PCR, although not necessarily the 
biggest absolute change. The large observed DDCT in MMP11 and TIMP4 were less 
statistically significant due to a relatively high standard deviation of mean DDCT for both genes, 
although they were above the threshold for significance.  The results for MMP13 demonstrated 
borderline significance for change in expression (actual figure p=0.03) at 24hrs exposure to 
AZA, but not at 72hrs, despite a minimal standard deviation from the mean DDCT for each 
exposure time.  This result was also contrary to that expected from the array data and suggests 
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the likelihood of a weak or insignificant effect of AZA on MMP13 at that dose across those 
time-points.  
 
The results for RRx-001 were in many ways inconsistent and divergent from those of AZA, 
although there was an increased expression of each gene examined.  Only MMP2 and TIMP4 
demonstrated statistically significant DDCT, but the absolute value for expressional change in 
each of these genes was high.  There was however a high degree of deviation in the mean DDCT 
values for most genes following exposure to RRx-001; even in the genes demonstrating 
significant expressional change and statistical significance, and thus the effects of this agent 
on this family of genes is probably highly variable. The variability on results is likely be the 
result of alkylation and free-radical generation being imprecise modes of action affecting 
multiple downstream processes, as opposed to AZA’s specific epigenetic effect. 
 
The data from this study indicate that MMP2, the primary proteolytic enzyme of type-IV 
collagen was significantly downregulated by exposure to AZA; corresponding with the 
observation that DLD-1 cell treated with AZA are less able to invade a type-IV collagen-rich 
ECM. However, simultaneous upregulation of MMP11 expression, which is itself a proteolytic 
inhibitor of alpha-1-antitrypsin (another inhibitor of proteases), may have increased overall 
non-MMP proteolytic activity via a double-negative effect. TIMP2 was also observed to 
decrease expression following AZA exposure, thus the inhibitory effect of TIMP2 on MMP2 
has also been down-regulated, contrary to the observed effect of less-ECM degradation. TIMP4 
expression on the other hand increased following exposure to AZA; an unexpected finding as 
this protein is not normally found in the colon. Although the reduced propensity of DLD-1 
cells to invade the ECM correlated with decreased MMP2 expression, the other findings of 
differential MMP and TIMP expression following AZA exposure do not fit well into a unified 
theoretical construct of hypermethylation resulting in increased potential for invasion.  
 
However, the relationship between expression and inhibition of MMPs and TIMPs is complex, 
and separating the homeostatic controls from direct demethylation is challenging581. The data 
from this chapter suggests that AZA significantly reduced the expression of MMP2 but also 
TIMP2, although in different proportions. However, whether the decreased expression of 
MMP2 is as a result of direct demethylation with AZA or a homeostatic mechanism in response 




RT-PCR array for gene expression associated with the EMT-like and invasive / metastatic 
processes associated with EMVI identified a number of genes of interest that may 
mechanistically account for the decreased propensity of DLD-1 cells to invade following 
exposure to AZA, and for CIMP-high tumours to demonstrate worse clinicopathological 
features.  The family of genes that showed the most global change in expression were the 
metalloproteinases and their associated inhibitors.  The MMPs and TIMPs are important in the 
EMT-like and invasive processes of colorectal cancer due to their actions on the components 
of the ECM503, 504.  qRT-PCR for these MMPs and TIMPs revealed a complex picture of 
increased and decreased expression; both temporally and in relation to known and putative 
demethylating agents, although 72hrs of exposure to AZA resulted in statistically significant 
expressional change in metalloproteinases and their inhibitors with low margins of error. 
Despite the observations of expressional change qRT-PCR does not elucidate the 
transcriptomal or homeostatic mechanisms responsible for the observed effects in vitro.  This, 
primarily, is due to the complexity of MMP and TIMP regulation, and how epigenetic 
modification may influence these processes. Chapter 6 will aim to explore these relationships 






Metalloproteinase Homeostasis and Demethylation  
 
6.1 Introduction 
6.1.1 Metalloproteinase Homeostasis 
The regulation and function of MMPs and TIMPs is complex, occurring at a transcriptomal, 
post-transcriptomal, and extracellular level581.  At a transcriptomal level, MMPs are regulated 
by trans activators such as AP-1, PEA3, Sp-1, etc, in response to a large number of cytokines, 
growth factors, and integrins; primarily via MAPKs and wnt/b-catenin canonical pathways582. 
Snail protein, for instance, has been shown to induce multiple MMPs and reduce E-cadherin 
expression, based upon downregulation of b-catenin in a process associated with EMT and 
differential intermediate filament expression583. Despite the consistency of cis elements within 
the MMP family, functionally similar MMPs often display different combinations of elements 
that may be shared between functionally unrelated MMPs, facilitating cis-element grouping 
(Groups 1-3)582. The balance and distribution of trans-activators and cis-elements across the 
MMP family is believed to facilitate homeostasis; a fall in one cis group being compensated 
by the reciprocal increase in expression of the other as they both express MMPs with a similar 
class of action. For instance, MMP9 (Gelatinase B) is in cis group 1, whilst MMP2 (Gelatinase 
A) in in cis group 3.  Loss of this reciprocal expression is thought to underlie the development 
of some cancers584, 585.   
 
Epigenetic events have also been identified in the transcriptomal regulation of MMPs and 
TIMPs, with both hyper- and hypomethylation (and histone modification) being implicated in 
the differential expression of several metalloproteinases586. In lymphoma cell lines it has been 
shown that pre-existing hypermethylation of MMP9 inhibits expression, an effect that can be 
overcome by demethylation with AZA587. MMP9 is itself important in the progression of 
tumours but has primarily been identified as a key factor in inducing angiogenesis by VEGF 
and the metastatic processes associated with MET, rather than EMT, whereas MMP2 is not 
critical in this function588. In Chapter 5, expression of MMP9 was not changed following 
exposure to AZA based on the array, but unfortunately qRT-PCR for MMP9 failed.  In another 
study, however, knockdown of DNMT1 and DNMT3a by homologous recombination in 
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colorectal cancer cell line HCT116 induced MMP3 expression whilst not affecting MMP1 and 
MMP2 expression significantly, thus the role of methylation, and the manipulation thereof, in 
inducing and repressing MMPs is complex589.  As well as promoter methylation, histone 
modification also has a role in the epigenetic regulation of MMPs and can act in tandem with 
DNA methylation to control the “inducibility” of MMPs. For instance, methylation-dependent 
chromatin restructuring, which was itself regulated by activation of the MEK-1/extracellular 
signal-regulated kinase and NF-kB signalling pathways, was found to be regulatory in 
inducible MMP9 expression590. The role of methylation and chromatin was also highlighted in 
the specific case of MMP2 regulation by Vincent, who reported that methylation does not 
directly regulate MMP14, MMP2, or TIMP2 expression in human placenta, although it may 
contribute to chromatin remodelling-dependent expression of the MMPs591. Similarly, Chernov 
indicated that DNA demethylation alone was insufficient to modify the expression of MMPs 
in number of cancer cell types but was important in a “multilayer epigenetic regulation” that 
also involved chromatin restructuring592. 
 
In addition to transcriptomic control, post-transcriptomal regulation also has a role in 
regulating the expression of gelatinase MMPs.  Such activity includes the prolongation of the 
half-life of MMP2 and MMP9 mRNA as may be observed in activated fibroblasts, or in 
response to innate cortisol, integrins, or applied therapeutics in the case of other MMPs593-596. 
Translational regulation of MMP & TIMP proteins in the ribosome may also contribute to the 
overall phenotypic expression of gelatinase-related activity, and dysregulation at this level has 
been associated with some forms of autism597, 598. However, once gene transcription and protein 
translation has occurred, the primary method of regulating MMP activity is by specific 
inhibitors secreted into the stroma. 
 
TIMPs are the specific inhibitors of MMPs (as well as some other ECM proteolytic enzymes) 
and classically are the primary regulators of ECM turnover through their direct inhibition of 
MMPs; inhibition thus resulting in a homeostatic shift towards EMC component deposition as 
opposed to degradation581, 599, 600. TIMPs therefore have an important role in healthy 
organogenesis and tissue regeneration but have also been associated with conditions 
characterised by maladaptive ECM turnover such as keloid, lung fibrosis, heart failure, and 
cancer601, 602. As Type-IV collagen is the primary component of the basement membrane, much 
of the focus of research has been directed towards MMP2 and TIMP2, both in cancer and other 
conditions603, 604.  
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MMP2 is inhibited by the wedge-shaped TIMP2 directly blocking its substrate binding site in 
a stochastic manner605, 606.  As well as its role as an inhibitor, TIMP2 also auto-antagonistically 
activates MMP2 from its zymogen by co-association with membrane-type-1 MMP 
(MMP14)602. The regulation of MMP2 activity in the stroma is therefore based upon the 
concentration of MMP2, activation by MMP14, and the balance of the dual roles of TIMP2: 
the MMP2/TIMP2/MT1-MMP axis592. MMP14 was not assessed on the array or in qRT-PCR 
in Chapter 5. The role of TIMP2 and membrane-type MMPs in modulating MMP2 remains 
controversial. Some authors report that the activating/inhibitory relationship is dependent of 
the induced over-expression of activating membrane-type MMPs by fibroblasts in the stroma 
adjacent to early tumours, with tumour cell expression of activating factors being a 
characteristic only of more advanced tumours607. The activation and secretion of MMPs has 
also been suggested as a role of pro-tumoural tumour-associated neutrophils; a mechanism 
potentially underling the observations that the ratio of neutrophils to lymphocytes can have 
prognostic implications for colorectal cancers608, 609. 
 
Like MMPs, most TIMPs have multiple transcriptional control sites and respond to a range of 
signalling pathways; TIMP2 includes a TATA box at -30 bp, as well as a Sp1, two AP-2 sites, 
three PEA3s, and an AP-1610. Methylation events in the regulation of TIMPs are not well 
characterised, and the overarching narrative of the MMP/TIMP literature is that TIMPs play a 
poor second-fiddle to their better studied counterparts. There is, however, some evidence that 
TIMP2 has dual CpG islands in its promotor region, and that the balance of methylation at 
these islands has an important regulatory role in transcription592. 
 
As well as MMP2 and TIMP2, the array and qRT-PCR data also highlighted significant 
changes to the expression of TIMP4, an inhibitor of metalloproteinases which may also be 
important in cancer611.  TIMP4 is a less well characterised inhibitor than TIMP2 that has also 
been shown to inhibit MMP2 by interaction with MMP14612, 613. However, unlike TIMP2, 
TIMP4 has no role in activating the MMP2 zymogen614, 615. TIMP4 has also shown activity 
against MMP9, and thus is considered as a less-potent but broader-acting inhibitor of 
Gelatinases, although its normal expression is limited to the heart, brain, and kidneys.  One of 
the reasons for the limited distribution of TIMP4 is the differential expression of initiator sites 
in the promotor region; which demonstrates sites for myogenin, GATA and Ets binding but 
lacks the AP1 or AP2 sites characteristic of other TIMPs and MMPs616, 617.  Although elevated 
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levels of MMP4 have been identified in a number of different cancers (ovarian, head & neck, 
and pancreatic adenocarcinomas), there is little evidence for its dysregulation in colorectal 
cancers611, 618. 
 
Clearly the regulation and function of MMPs and TIMPs is complex, occurring at a 
transcriptomal, post-transcriptomal, and the extracellular level581.  In many circumstances 
TIMP and MMP genes are transcribed simultaneously, though the specific subset of MMPs 
and TIMPs depends on the external stimulus or internal genetic or epigenetic factor promoting 
or limiting expression. Once secreted into the stroma, the action of MMPs is dependent on the 
balance of activation and inhibition, although the relationship between MMPs and their 
corresponding TIMPs is not binary, and in many cases likely to be multifaceted. There is 
however an established relationship between MMP2, TIMP2, & MMP14 (MT-1 MMP), and 
potentially an emerging role for TIMP4 in this axis. 
 
6.1.2 siRNA Knockdowns 
When investigating the function of a gene and its coded protein a key tool to the investigator 
is the ability to prevent that gene being expressed, thus the function can be analysed by its 
absence.  This is the principle behind knockdown technology, which can occur at the 
transcriptomal or post-transcriptomal levels. Pharmacological inhibition of target proteins is 
fundamentally different in terms of the phenotypic effects as the protein has already been 
synthesised so it is still present in the cell or microenvironment and its degree of function 
determined by the pharmacokinetics of the inhibitory agent619. At a genetic level, knockdowns 
are divided by their level of action; either to prevent transcription (as in the cases of 
CRISPR/Cas9 or TALE/TALEN) or post-transcriptional (such as RNA interference)620. 
However, the degree of knockdown is rarely 100%, meaning that a limited expression is usually 
apparent despite application of the technology due to a number of factors, including the binding 
saturations or transfection efficiency of the method used or cellular heteroploidy.  The degree 
of knockdown and its reversibility will determine partly which method is applied, but also the 
more rudimental considerations such as speed, complexity, local expertise, and cost of each 
technology620. Note that knockout technology (mice and, increasingly, rats) is different in that 
it describes otherwise fully functioning animals that have had genes completely removed or 
replaced at a stem cell level prior to embryologic development, and therefore completely lack 
a particular gene621. 
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At the post-transcriptomal level, short interfering RNAs (siRNAs) and their cousin the short 
hairpin RNA (shRNA) are a well-established method of preventing RNA transcription and thus 
gene knockdown622, 623. siRNA knockdown describes a process where RNA-targeted RNA 
oligonucleotides (20-25bp) bind intracellular proteins (following transfection) to form an 
RNA-induced silencing complex (RISC) that blocks translation of partially-complementary 
RNA sequences and degrades highly-complementary RNA sequences624, 625. As translation is 
prevented no protein is synthesised. siRNAs demonstrate less off-target effect than other 
knockdown technology, such as phosphorothioate S-DNA knockdowns, whilst being 
acceptably specific in terms of the sequence-specificity and thus gene of interest targeting. 
Concerns regarding the activation of the innate immune system by siRNAs is relevant only to 
their application in experimental systems or therapeutics involving live organisms with an 
intact immune system626. 
 
In an siRNA model dsRNA must be delivered into the target cell, necessitating penetration of 
the cell membrane.  This may be achieved by three methods; transfection, electroporation, or 
viral-vector.  Transfection involves the use of cationic liposomes, or other positively charged 
microparticles (such as polymer nanoparticles), that interact favourably with the negatively 
charged cell membrane to deliver siRNAs. This technique has the benefits of being cheap, 
reproducible, and effective at delivering siRNAs to most cell types, although it has a low 
efficiency in in vivo models627. Electroporation describes a process whereby an electrostatic 
field is applied to cells which transiently disrupts the cell membrane allowing passage in of 
siRNAs, but also the passage out of cell contents. This method has some advantages, including 
the potential for targeted siRNA delivery in vivo, but has a higher risk of toxicity and cell death 
than transfection628, 629. Viral-vector methods rely on engineered viruses, typically lentivirus 
but also retrovirus or adenovirus, to deliver siRNAs intracellularly630. Viral vectors have the 
benefit of being able to be applied to whole-organism systems, and may have a future role in 
delivering siRNA based therapeutic to hard-to-reach targets, such as the central nervous system 
in Huntingdon’s Disease631. As such, siRNA-based technologies are increasingly being 
regarded as potentially viable therapeutic systems and are established in the in vitro 
manipulation of cells to investigate the knockdown-phenotype632-634. 
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6.1.3 Immunocytochemistry & Protein Analysis 
In Chapter 5 the expression of genes was investigated by assessment of the relative amounts 
of mRNA that had been transcribed from DNA, thus demonstrating the relative transcription 
of the genes of interest (identification and quantification). Other methods of investigating gene 
expression examine the protein end-products of transcription via protein-specific methods; 
specifically, immunocytochemistry (ICC) and Western Blotting (WB) for proteins of interest. 
These techniques have the benefits of relatively rapidly demonstrating quantifiable changes in 
protein expression and can act as a verification of qRT-PCR.  
 
ICC exploits protein (or polypeptide) specific ligands (primary monoclonal antibodies (mAbs)) 
that bind the protein of interest and can then be detected by fluorescence microscopy, either 
directly if they primary antibodies are themselves conjugated to a fluorophore (direct 
immunofluorescence), or via a secondary antibody that targets the primary and is itself 
conjugated to a fluorophore (indirect immunofluorescence (IIF))635, 636. This method allows the 
detection of specific proteins and is able to facilitate in localising the target within the cell. As 
techniques in ICC have evolved the sensitivity and specificity of primary antibodies has 
improved, as has the stability of the fluorophore637. The combination of fluorescence 
techniques with electron microscopy have further refined the level detail available to 
investigators examining the intracellular distribution of proteins638. ICC does, however, have 
limitations as a process; specifically, that as the cells being studied have to be fixed and made 
permeable to the mAbs; cells are thus not live during assessment by standard techniques and 
dynamic changes are therefore more challenging to study.  Also, as cells require fixing and 
washing, ICC is limited in its ability to examine the extracellular distribution of secreted 
proteins, although it is able to determine intracellular stores of secreted proteins and proteins 
undergoing synthesis639. As with all laboratory investigations, it is important to use appropriate 
controls in ICC experiments to avoid confounding reults640. 
 
Western Blotting is a well-established and widely-used semiquantitative or quantitative 
technique for examining specific cellular proteins641. WB can be applied to samples as limited 
as a single cell and only a few µg of total protein, but care must be taken when processing 
samples during this multi-stage process to avoid erroneous results642. Like ICC, WB relies on 
specific mAbs binding target proteins and then a tagged secondary mAb facilitating 
visualisation, this time on polyacrylamide gels. Once protein-specific bands can be visualised 
a semiquantitative assessment of protein abundance can be made by densitometry or be used 
 174 
in combination with fluorescence techniques643. Despite the multi-step process, WB does has 
the advantage of being able to assess the quantity of extracellular proteins as well as 
intracellular proteins, unlike ICC, and therefore offers a more complete examination of the 




6.2 Aims & Objectives 
This chapter will examine the effects of demethylation with AZA on MMP and TIMP protein 
expression by two methods; immunocytochemistry and Western Blotting. These investigations 
will serve not only to aid in understanding the distribution of these proteins, how then interact, 
and how this is affected by demethylation, but also to cross-validate the results of the qRT-
PCR. siRNA was also applied to DLD-1 cells in control and in conjunction with AZA exposure 
and the same assessment of MMP and TIMP proteins made; providing an insight into the 
homeostatic mechanisms of MMP and TIMP at a protein rather than transcriptomal level.  Due 
to the divergence of the qRT-PCR results between AZA and RRx-001, and the unknown 






DLD-1 and HFL-1 cells were cultured in control conditions according to the protocols 
described in Sections 2.3 and 4.3.1.2.  Modification in culture protocols for siRNA knockdown 
(KD) and exposure to AZA are described in the relevant sections. HFL-1 were used as a 
positive control for the expression of MMPs & TIMPs. 
 
6.3.1 siRNA Knockdown & AZA Exposure 
The siRNA KD protocol employed in this assay indicates that, following a successful 
transfection, treated cells should be ready to assay 24-72hrs following treatment. However, 
because the effects of AZA require cell division to become evident, as demonstrated by the 
72hr exposure producing significant effects on qRT-PCR whereas 24hrs exposure did not, the 
manufacturers protocol was modified to facilitate longer AZA exposure. As transfection occurs 
in a serum-free medium, the transfection reagent removal and 1x complete medium 
replacement method was employed, rather than the addition of 2x medium to transfection 
reagents.  This was to avoid toxicity associated with transfection and to facilitate AZA 
exposure. KDs were performed against TIMP2 and TIMP4 and with a scrambled siRNA 
control.  
 
DLD-1 and HFL-1 cell lines were cultured according to maintenance protocols and prepared 
in normal (1x) antibiotic-free growth medium at a concentration of 3x104 cells ml-1 (coulter 
counter assessment). Glass coverslips were sterilised in ethanol for 2 minutes and allowed to 
air dry in the bottom of a 6-well plate; three coverslips per well.  Cells were then transferred to 
the wells containing coverslips allowed to adhere overnight. This technique facilitated both the 
production of control, AZA, and KD cells for subsequent ICC (cell on coverslips) and for 
protein analysis by WB (cells in the gaps). Three experimental arms were run: control, KD 
only, and KD with AZA. 
 
All solutions (A&B) were prepared in accordance with the manufacturer’s protocols for siRNA 
transfection. 100µL of the siRNA Duplex Solution (Solution A) was added directly to 100µL 
of the dilute Transection Reagent (Solution B) per well and mixed by pipetting and incubated 
at room temperature for 30 minutes. Normal growth medium then was removed from the wells 
by pipette aspiration and the cells washed once with 2ml of Transfection Medium which was 
then aspirated. 800µL per well siRNA Transfection Medium was added to the siRNA 
Transfection Reagent mixture and mixed gently by pipetting. 1ml total volume per well of 
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complete transfection and siRNA KD preparation was then overlaid onto the washed cells. 
Cells were then incubated for 6 hours in standard incubator conditions.  
 
Following incubation, the transfection and KD preparation was removed and replaced by 1x 
antibiotic-free normal growth medium (containing serum) and the cells allowed a recovery-
period of 2 hours. Following recovery, growth medium was removed and replaced with fresh 
medium for all wells, with the addition of 0.50uM AZA for treatment wells (fresh medium 
only for KD only) and incubated overnight. The entire process of transfection, recovery, and 
treatment with AZA or control was repeated for three consecutive days to allow effective 
demethylation with AZA. Following the final overnight incubation, the cells were assayed by 
ICC or protein analysis as described below. Figure 6.1 demonstrates a flow chart of treatment 
protocols for siRNA KD and AZA cell culture. 
 
Figure 6.1 Flow-chart demonstrating treatment algorithms for siRNA KD and AZA cell 
culture of DLD-1 and HFL-1 cells. NGM = normal growth medium; D1-5 = Day 1-5. 
 
 
DLD-1 or HFL-1 
Cells: Seed to 
coverslips  D1 & 
incubate 
overnight NGM








ICC & WB D5
Knockdown only: 
AM KD protocol
PM: Recovery & 
overnight 
incubation in 1x 
NGM
ICC & WB D5
Knockdown & 
AZA: AM KD 
protocol
PM: Recovery in 
1x NGM + 
overnight in 
0.50uM AZA
ICC & WB D5
Repeat 3x D2-4 
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6.3.2 Immunocytochemistry & Immunofluorescence 
An indirect immunofluorescence (IIF) method was adopted for all ICC studies. Working 
concentrations of each primary and secondary mAb was determined by means of a serial 
dilution and probe test. Serial dilutions of primary antibodies in PBS and 1.5% normal blocking 
solution were 1:50, 1:100, 1:200, 1:500; and 1:1000 and 1:2000 for secondary antibodies. 
Primary and secondary antibodies are listed in Chapter 2, Table 2.4. 
 
Cells (DLD-1 and HFL-1; control, AZA, KDs, & KDs + AZA) were grown on coverslips 
according to the appropriate protocols as described in Section 6.3.1. Cell-covered coverslips 
were then removed from growth medium using sterile forceps and scalpel-blades and then 
washed twice in PBS by submersion to ensure removal of phenol-red, and then fixed by 
submersion in 3.7% paraformaldehyde (PFA) in PBS at 4oC for 10 minutes. This was a 
deviation from the manufacturers protocol (recommending methanol, acetone, or formalin 
fixation), but 3.7% PFA is equivalent to 10% formalin and is thus considered 
interchangeable639. Following fixation coverslips were kept wet and rinsed in PBS 3 times and 
then permeabilised by incubation for 3 minutes in a solution of 0.1% Triton X-100 in PBS. 
Coverslips were then rinsed 3 times with PBS and then incubated in 10% normal blocking 
agent (3% BSA in PBS) for 30 minutes at room temperature. Following blocking, coverslips 
were then washed 3 times in PBS by submersion for 5 minutes. Coverslips were then replaced 
in 24-well plates and the primary antibody applied to completely cover each slide. The plate 
was sealed with biofilm to prevent drying and the cells incubated overnight at 4oC.  
 
Following primary antibody incubation, coverslips were washed 3 times in PBS by submersion 
and then incubated for 60 minutes at room temperature with the appropriate Alexa FluorÒ 488-
conjugated secondary antibody (mouse or rabbit to match the primary mAb) diluted in PBS 
with 1.5% normal blocking serum. Incubation with the fluorophore-conjugated secondary mAb 
was conducted in a darkened room with the plate wrapped in tinfoil to prevent degradation of 
the fluorophore. Coverslips were then washed 3 times in PBS by submersion for 5 minutes and 
immediately mounted to slides with VECTASHIELD mounting medium with DAPI nuclear 
stain (Vector Laboratories, Burlingame, CA, USA). Following incubation at 37oC for 10 
minutes, slides were imaged on the Metafer Automated Slide-Scanning platform (fluorescence 
intensity assessment: RAPIDSCORE) and Olympus BX51 Fluorescence Microscope (high-
resolution images for cellular localisation of signal). Microscope settings were controlled for 
laser power and detector gain. 
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6.3.3 Western Blotting 
Total protein was prepared by gently pipetting excess growth medium off cells cultured in a 
12-well plate so that cells remained in a thin film of medium containing their secreted 
extracellular proteins.  Plates were kept on ice throughout protein extraction and an ionic 
detergent method of cell membrane disruption was employed, exploiting the sodium 
dodecylsulfate and sodium deoxycholate constituents of RIPA Buffer645. Cells were then 
scraped from the bottom of their wells with a sterile scalpel until fully detached and then 
resuspend in 200μL ice-cold RIPA Buffer supplemented with 2μL of protease and 2μL of 
phosphatase inhibitors. The cells and RIPA buffer were mixed thoroughly by pipetting and 
transfer to pre-chilled microcentrifuge tubes and incubated for 5 minutes at 4oC. Cells were 
then lysed by vortexing thoroughly and then centrifuged for 10 minutes at 12,000rpm in a 
centrifuge pre-cooled to 4°C. The supernatant was then transferred to a fresh microcentrifuge 
tube and stored at -80oC until required for WB.  
 
The Bio-Rad DC Protein assay kit was used to determine the protein quantity in each sample. 
All reagents were prepared as per kit instructions and all consumables were supplied by BioRad 
(except Tris buffers and gel ingredients). A protein standard of Bovine Serum Albumin (BSA) 
was diluted in RIPA buffer at 5 concentrations plus a negative control (0 to 2.5 mg/mL). 
Aliquots of 5μL of each protein sample or standard curve was then added to wells of microtiter 
plate (3 technical replicates). 25μL of working Reagent A was then added to every well plus 
200μL of Reagent B and the plate was agitated for 15 minutes. The POLARstar Omega 
Microplate reader was then used to determine the protein concentration in each well, based on 
absorbances at 750 nm relative to the standard curve. 
 
The proteins in the solution were the separated according to their molecular weight using the 
SDS-PAGE technique646. Two densities of gels were prepared for use as a stacking gel (4%) 
and a resolving gel (10%). Gels were hand-cast by the same method described in Section 3.3.6 
but with different recipes and the additional step of 0.5mL of isopropanol being added to the 
top of each gel to ensure that it was level. Gel recipes are listed in Table 6.1.  The gels were 




Table 6.1 Recipes for stacking (4%) and resolving (10%) gels. Listed quantities make 2 gels. 
 4% Stacking Gel 10% Resolving Gel 
30% Acrylamide 650µl 5ml 
ddH2O 3ml 6ml 
1.5M Tris 1.25ml 3.75ml 
1.0M Tris 50µl 150µl 
10% SDS 25µl 75µl 
TEMED 5µl 15µl 
 
Proteins were thawed to room temperature and diluted at a 1:1 ratio with Laemmli buffer and 
then sonicated and heated at 95oC for 5 minutes. The first two wells of the gel were loaded 
with 8μL of dual-colour standard and biotinylated standard, respectively, and then a total of 
40μg of each protein sample was loaded into subsequent individual wells. Gels were the run at 
160 volts for 5 minutes (until the samples had reached the end of the stacking gel) and then 
120 volts until the dye front approached the base of the resolving gel. 
 
Immunoblotting was then performed to transfer the proteins onto PVDF membranes for 
antibody-probe analysis.  One Immuno-Blot PVDF membrane per gel was activated by 
immersion in 100% methanol until translucent. All materials required for the protein transfer 
cassette, including fibre pads, filter paper, gels and membranes were equilibrated for 10 
minutes in transfer buffer pre-cooled to 4oC. The transfer cassette was then assembled closed 
tightly to ensure that no air bubbles were present between the gel and the membrane. 
Electroblotting was performed at 400mA for 1h at 4oC. Following transfer, membranes were 
carefully removed from the transfer cassette using forceps and briefly washed in TBS/T wash 
buffer. 
 
The PVDF membranes were then blocked for 60 minutes in 5% BSA at room temperature and 
then washed with TBS/T.  Membranes were then incubated at 4oC overnight in 8mL of primary 
antibody solution diluted in blocking buffer to 1:1000. The same set of primary antibodies for 
MMP2, TIMP2, and TIMP4 employed in IIF were used for WB as they are all recommended 
for use in both processes by the manufacturer, and are listed in Chapter 2, Table 2.4. 
Membranes were then washed in TBS/T washing buffer 4 times each for 5 minutes with strong 
agitation. A second blocking process was then carried out at room temperature for 60 minutes 
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and with 1:1000 times diluted horseradish peroxidase conjugated secondary antibody (anti-
mouse or anti-rabbit) for chemiluminescent detection. Membranes were again washed in 
TBS/T washing buffer 4 times each for 5 minutes with strong agitation. 
 
Visual analysis of the protein quantities was then carried out the ImmunoStar 
Chemiluminescence Kit (BioRad). A 1:1 ratio of luminol/enhancer and peroxide solution was 
applied over the membrane and the ChemiDoc XRS (BioRad) system used to assess and 
quantify the relative band intensities on the membrane. Following imaging, the membrane was 
then stripped of the bands of interest using a stripping buffer (Thermo Scientific) at room 
temperature for 10 minutes with strong agitation, followed by washing 4 times for 5 minutes 
with a gentle agitation in TBS/T solution. A primary antibody for b-actin was then applied to 
the membrane (pre-mixed laboratory consumable supplied by a colleague) and the membrane 
re-incubated overnight at 4oC before being washed, blocked, and imaged using the ChemiDoc 
XRS as described above. This visualisation using the beta-actin was then used to normalise the 
absolute protein quantities for MMP2, TIMP2, and TIMP4. 
 
6.3.4 Statistics and Data Presentation 
Results for change in abundance are described in terms of relative change in target protein 
abundance from the control based on either change in fluorescence or chemiluminescence. 
Control abundance will always be 1.0 with no standard deviation. Results of <1.0 indicates 
relative downregulation and >1.0 indicates relative upregulation.  If absolute values for 
baseline are 0.0 (no protein detected) then the control abundance will still be 1.0, and 
subsequent results returning no protein detection will remain as 1.0. In the case of WB, protein 
abundance will also be controlled against b-actin abundance to provide internal normalisation 
of bands using ChemiDoc XRS. Standard descriptive statistics will be employed as appropriate 
and a Student’s-T test used to assess any significance between two data-arrays. Cut-off for 





Protein abundance was assessed by indirect immunofluorescence (IIF) for MMP2, TIMP2, and 
TIMP4 following the 4-arm exposure protocol described in Section 6.3.1. These proteins were 
selected as their corresponding genes were most significantly changed by AZA exposure based 
on array and qRT-PCR data in Chapter 5, and the MMP2-TIMP2-MMP14 axis is important 
in regulating degradation of Type-IV collagen rich extracellular components. Unfortunately, 
some technical and methodological issues limited the results gathered in this section of the 
investigation, although meaningful results were still recorded. Firstly, although HFL-1 cells 
were able to be maintained in normal culture medium in control conditions they did not survive 
the transfection process adequately, meaning that although data could be collected for their 
baseline MMP2 and TIMP expression, the relative effects of AZA and KD could not be 
assessed. This technical issue was unexpected as HFL-1 cells are generally easy to culture and 
have been shown to tolerate siRNA transfection targeting their metalloproteinase activity in a 
number of pervious studies647, 648. Specific issues relating to ICC and WB will be mentioned in 
the relevant results sections and explored further in the Discussion. Raw proteomic data is 
provided in Appendix IV. 
 
6.4.1 Immunocytochemistry and Immunofluorescence 
All treated samples underwent successful fixation, permeabilization, and primary and 
secondary antibody conjugation.  There was not an apparent high-degree of cellular 
dehydration during fixation, consistent with the use of PFA649. Control HFL-1 cells 
demonstrated appropriate fluorescence when probed with each primary mAb an a manner 
consistent with the Human Protein Atlas (HPA) indicating adequate permeabilization with  
Triton X-100 and appropriate probe-access to crosslinked proteins650. A significant 
methodological limitation of this element of the experimental design is that MMP2 protein is 
only normally weakly present inside colonic cells and TIMP2 and TIMP4 are usually 
undetectable as they are almost exclusively extracellular, although significant upward 
expression of any protein may be detectable immediately following intracellular synthesis and 
before secretion, as should any decrease in MMP2. Results are presented graphically in Figure 




Figure 6.2. Relative fluorescence RAPIDSCORE for MMP2 and TIMP2 normalised to 
control fluorescence of 1.0. Error bars are standard deviation from the mean corrected 
fluorescence. [D mean fluorescence from control* p£0.05; ** p£0.01; *** p£0.001. DD mean 




Note that the relative fluorescence is normalised to control and does not represent absolute 
values, thus TIMP2 and TIMP4 values are controlled to an expression of close to zero and 
subsequent negative fluorescence will return a result of 1.0 and standard deviation will be low. 
Demethylation with AZA resulted in a de novo expression of TIMP4 as well as a reduction in 
MMP2, but that KD of TIMP4 in association with AZA did not prevent the MMP2 response, 
therefore reduction in MMP2 expression is not dependent of the presence of TIMP4. The lack 
of significance observed in the response of TIMP4 to KD of TIMP2 and AZA is due to the 
high degree of deviation in individual TIMP4 RAPIDSCORE values (precise figures for 
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Figure 6.3 Representative immunofluorescence (IIF) images for MMP2, TIMP2, and TIMP4 




Control ICC for baseline signal from each of MMP2, TIMP2, and TIMP4 was consistent with 
that expected based upon the HPA; specifically, that MMP2 demonstrated a detectable signal 
and that TIMP2 and TIMP4 were undetectable. This was due to limited abundance of these 
TIMPs within the cell. Control ICC for DLD-1 cells demonstrated the presence of intracellular 
MMP2 but neither TIMP2 nor TIMP4. This was consistent with the predicted result of the HPA 
which predicted no intracellular TIMPs, but not with the array or qRT-PCR data that suggested 
that there was a baseline expression of each gene, although this was much higher for MMP2 
and TIMP2 than TIMP4. 
 
Following exposure to 0.50uM AZA for 72hrs, ICC demonstrated a relative decrease in MMP2 
expression (D=0.34 ±0.09; p=0.006), no change in TIMP2 expression, but an increase in 
TIMP4 expression (D=3.74 ±0.51; p=0.011). These results are partially consistent with the 
qRT-PCR data, confirming the relative change in abundance/expression of MMP2 and TIMP4, 
but not demonstrating any significant change in TIMP2. As baseline TIMP2 was negative, the 
expected decrease in protein abundance/expression would not be expected to be evident. 
 
Following siRNA KD of TIMP2, TIMP4, or TIMP2 & TIMP4, DLD-1 cells demonstrated no 
change in abundance of MMP2 and no change to the lack of signal for TIMP2 and TIMP4. 
Scramble knockdowns did not result in any change in baseline signal for any target. Validation 
was provided by Western blotting, see Section 6.4.2. 
 
When KDs were performed in association with treatment with 0.50uM AZA, the previously 
observed decrease in MMP2 following AZA exposure alone was preserved in each 
experimental arm (D=0.32-0.35 ±0.07-0.11; p=0.005-0.01). The increased expression in 
TIMP4 following exposure to AZA was also observed when anti-TIMP2 siRNA was employed 
in combination with AZA but did not reach statistical significance due to a high degree of 
deviation, although a strong trend was observed (D=4.10 ±1.46; p=0.07). This effect was lost 
when TIMP4 was knocked down. These observations confirm the effective KD of TIMP4 and 
also indicate that the increase in TIMP4 observed with AZA is not dependent on TIMP2 
downstream signalling (TIMP2 KD was confirmed by WB). The results also indicate that the 
reduction in MMP2 abundance is not dependent on TIMP4 protein abundance, as the effect is 
preserved when TIMP4 is knocked down. 
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Fluorescence microscopy images acquired using the Metafer platform are provided in Figure 
6.3 to illustrate the differing abundance of detected proteins.  The quality of slide preparation 
and resulting image blurring prevented meaningful evaluation of the cellular distribution of 
MMP2 and TIMP4 and was thus abandoned. 
 
6.4.2 Western Blotting 
Protein abundance was observed for MMP2, TIMP2, and TIMP4 following the 4-arm exposure 
protocol described in Section 6.3.1. Unfortunately, a technical difficulty was encountered in 
the primary antibody probing or secondary conjugation for TIMP4 as chemiluminescence 
failed to detect any bands irrespective of experimental arm. Protein extraction and other 
processes for these samples were however adequate as b-actin did produce visible bands after 
stripping and re-probing. All results are illustrated in Figure 6.4. 
 
Baseline expression of MMP2, TIMP2, and TIMP4 in HFL-1 cells was in keeping with the 
expected phenotype; with both MMP2 and TIMP2 detectable, although probing for TIMP4 
failed. This is consistent with typical fibroblast activity and confirms that ICC results for 
TIMP2 are due to lack of intracellular protein, rather than no transcription or protein synthesis. 
As stated previously, HFL-1 cells did not tolerate transfection and thus only this baseline 
assessment produced reliable results. In DLD-1 cells, baseline abundance of MMP2 and 
TIMP2 was in keeping with that observed in the qRT-PCR data and matched that observed in 
HFL-1 cells. Detection of MMP4 failed.  
 
Following exposure to AZA, DLD-1 cells demonstrated reduced abundance of both MMP2 
(D=0.35 ±0.11; p=0.009) and TIMP2 (D=0.36 ±0.06; p=0.003). These results are in keeping 
with the results of the array and qRT-PCR data. Although TIMP4 was not detectable by WB 
due to technical failure, increased abundance was previously demonstrated by IIF. 
 
Following knockdown of TIMP2 there was a significant reduction in the abundance of TIMP2, 
although minimal amounts were still detectable, confirming effective but incomplete KD with 
siRNA (D=0.06 ±0.05; p=0.001). This was important as IIF had shown no change to TIMP2 as 
it was not detectable due to its extracellular location. KD of TIMP2 did not significantly affect 
the abundance of MMP2 (D=1.02 ±0.08; p=NS). KD of TIMP4 did not significantly affect the 
abundance of MMP2 or TIMP2, although combined KD of TIMP2 and TIMP4 produced a 
reduction in TIMP2 abundance consistent with TIMP2 KD alone. 
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Following exposure to AZA and KD of TIMP2 both a reduction in TIMP2 and MMP2 
abundance was observed; the reduction in MMP2 being proportionate to that observed with 
AZA alone (D=0.27 ±0.04; p=0.001) and that of TIMP2 being proportionate to siRNA KD 
alone (D=0.06 ±0.04; p=0.001). There was also a significant difference between the reduced 
abundance of MMP2 and TIMP2 (p=0.009).  KD of TIMP4 in association with AZA also 
produced a decreased abundance of both TIMP2 (D=0.34 ±0.06; p=0.003) and MMP2 (D=0.32 
±0.08; p=0.005) but was proportionate to that observed with AZA alone. Combined KD of 
TIMP2 & TIMP4 with AZA exposure resulted in a response identical to TIMP2 KD and AZA.  
 
The most important findings based on WB data is that KD of TIMP2 alone did not significantly 
affect the abundance of MMP2, and that demethylation with AZA in combination with KD of 
TIMP2 produced a reduced abundance of MMP2 that was proportional to that of AZA alone. 
It can be inferred from these results that a reduction in TIMP2 protein, whether by 
demethylation or KD, is not necessary for the decrease in MMP2 following AZA exposure. 




Figure 6.3. Relative protein abundance for MMP2 and TIMP2 normalised to control 
abundance of 1.0. Error bars are standard deviation from mean corrected abundance. A 
corresponding blot excerpt is shown to demonstrate abundance for MMP2. [D mean abundance 
from control* p£0.05; ** p£0.01; *** p£0.001. DD mean abundance between target proteins@ 
p£0.05; @@ p£0.01; @@@ p£0.001] 
 
 
    





Note the significant reduction in abundance of MMP2 and TIMP2 observed with AZA alone 
[2] (p£0.01), and that there was an effective siRNA KD of T2 [3] (p£0.01), but that this did 
not affect MMP2 abundance (p=NS). However, when TIMP2 was KD, MMP2’s abundance 
was significantly reduced by AZA [6], indicating that the reduction in abundance of MMP2 in 
response to AZA is not dependent on the abundance of TIMP2. KD of TIMP4 had no effect on 
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6.5 Discussion 
The aims of this chapter were to assess the effects of demethylation on the protein abundance 
of MMP2, TIMP2, and TIMP4 by both an immunocytochemistry and Western Blotting 
methodology.  Further to this baseline assessment, the knockdown of TIMPs singularly, in 
combination, and concurrently with AZA exposure was intended to provide insight into the 
homeostatic dependency of any relationship between MMP2 and TIMP abundance, and to 
isolate the effects of AZA at a transcriptomic level. 
 
As previously discussed, the regulation of MMP and TIMP expression is complex and occurs 
at a transcriptomal, post-transcriptomal, and protein level; the balance of which determines 
phenotype581, 600. The results demonstrate that the reduced expression (qRT-PCR) and 
abundance (IIF & WB) of MMP2 observed with AZA is independent of the abundance of 
TIMP2 and TIMP4 and must therefore be assumed to be dependent on a direct demethylating 
effect at a transcriptomic level, or due to AZA’s effect on another regulatory mechanism that 
is not dependent on these TIMPs. The results also indicate that the increase in expression of 
TIMP4 observed following exposure to AZA does not independently affect MMP2 or TIMP2 
expression.  Unfortunately, due to a number of technical and methodological shortcomings, 
cross-correlation between protein abundance studies was not possible, although the observed 
effects on MMP2, TIMP2, and TIMP4 were consistent with those observed in Chapter 5. 
 
The expression of MMP2 in relation to methylation status has been reported to be variable 
across a number of different studies; some indicating that hypomethylation of MMP2 promotor 
sequences increased expression in breast cancer and glioma cell lines, and was in associated 
with an increasingly aggressing phenotype546, 592, 651. However, whole-genome pyrosequencing 
studies have confirmed the frequent occurrence of MMP2 CpG island hypermethylation in 
colorectal cancer, a finding which has been supported by clinical datasets652, 653. The findings 
in this study are in alignment with the whole-genome pyrosequencing studies. The divergent 
findings relating to the expression of MMPs and methylation status across tumour types is not 
unexpected; Couillard having previously shown that expression of MMPs (based on mRNA 
techniques) in response to demethylation was not only variable between MMPs in colorectal 
cell lines, but also that often the directly opposite effect was observed between different tumour 
types589. The implication of the acknowledgement that different tumour types express different 
patterns of MMP and TIMP methylation, and that they respond differently to manipulation of 
methylation at transcriptomal and phenotypic level, should not undermine the concept of 
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hypermethylation-associated upregulation of MMP2 being important in the pathogenesis of 
colorectal cancer. Breast cancers and gliomas are, after all, different cancer types with different 
cells-of-origin and a different phenotype; particularly considering the differences in phenotype 
expected between diffuse-type and solid-type tumours.   
 
With regards to the potentially reciprocal transcriptomal control of MMPs, the findings of this 
Chapter do not help delineate MMP or TIMP response to demethylation based on promotor 
motif grouping582. The system proposed by Yan and Boyd suggest that MMP2 is a Group 3 
MMP characterised by no TATA box and no proximal AP-1, instead demonstrating a number 
of GC boxes, AP-2, and STAT581, 582. However, TIMP2 shares GC boxes, STAT, and AP-2 
sites with MMP2, but also has a TATA box and AP-1 as well as NF-kB sites. TIMP4 on the 
other hand, like MMP2, has no TATA box, but does have NF-kB, AP-1, and AP-2, although 
reduced GS sites. Due to the divergence in transcriptional response to AZA and the lack of 
clear association between this response and putative grouping based on promotor motifs, or 
indeed any specific promotor sites, no direct (motif demethylation) or indirect (motif activator 
effect) action of demethylation effecting MMP and TIMP transcription via one-or-other 
binding site or group can be identified. Furthermore, the mechanisms by which nuclear 
hormone receptors interact with MMP promotor motifs is complex and diverse, and do not 
necessarily correspond to neat binary relationships between co-active or counter-active MMPs 
and TIMPs, suggesting an additional layer of complexity in constitutive and induced 
transcriptomal regulation654. This is despite previous studies indicating that specific promotor 
motifs influence the balance between constitutive MMP2 and TIMP2 expression, although 
admittedly not in relation to methylation but instead to polymorphism585, 655, 656.  
 
As the promotor motifs in the promotor regions in MMP2 and the two TIMPs are highly 
overlapping but the effects of demethylation not convergent, promotor demethylation affecting 
transcription is not occurring at the identified activator motifs but may be occurring at another 
upstream site. CpG islands and differential methylation in approximation to MMPs and TIMPs 
have been associated with a variety of diseases, including cancer, stroke, clotting disorders, 
and placental defects657-659. Although epigenetic events have previously been identified in 
metalloproteinase transcription, including the MMP2/TIMP2/MT1-MMP axis, CpG islands 
are not well characterised in relation to MMPs and TIMPs, and these genes do not contribute 
to the classical CIMP classification systems, although some of the ADAM group of proteinases 
are included in a limited number panels (see Chapter 1, Table 1.2)592, 660, 661. 
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As well as DNA methylation, transcriptomal regulation of MMP2 and TIMP2 by chromatin 
restructuring has also been shown to be important in cancers including colorectal cancer, and 
indirect effects of DNA demethylation affecting chromatin structure cannot be excluded (such 
as DNA methylation-dependent deacetylase expression)189. However, as AZA specifically 
affects DNMT activity, the effects observed in this study are not due to direct modification of 
histone methylation as might be observed following dysregulation with enhancer of zeste 
homolog 2 (EZH2) in breast and ovarian cancers662, 663. 
 
At the post-translational level, over-expression of TIMP2 has been associated with suppression 
of wnt/b-catenin and subsequent upregulation of proliferative and pro-tumoural cell activity in 
ovarian cancer mediated via ubiquitination664. The effects of low TIMP2 were overcome with 
application of lithium in this study, which re-activated the previously down-regulated 
signalling pathway. The results in this chapter are to a degree contrary to this study, as the 
reduction of MMP2 following AZA exposure was not dependent of the abundance of TIMP2, 
and therefore not reliant on a post-translational process dependent on TIMP2. This was 
demonstrated by the persistence of the change in abundance of MMP2 following TIMP2 KD. 
The independence of MMP2 abundance and TIMP4 abundance also indicates a lack of 
dependency between these two proteins. 
 
When considering the results of this chapter however, it should be acknowledged that there are 
several limitations that prohibit the transference of the hypothesis that hypermethylation-
related upregulation of MMP2 drives invasiveness of DLD-1 cell in vitro, an effect that can be 
reversed by direct demethylation with AZA, to the in vivo colorectal cancer. One limitation is 
that the investigations in this Chapter were somewhat limited by both the methodological 
construct (probing for extracellular proteins with intracellular ICC techniques) and technical 
failures (failure of chemiluminescence for MMP4). There was however consistency across 
each of the elements of this Chapter and the findings of Chapter 5’s qRT-PCR and thus they 
are, together, confirmatory. 
 
With regards the detection of TIMP2 (or failure thereof) in the intracellular cytoplasm, 
although primarily an extracellular protein, other authors have reported being able to detect 
TIMP2 with standard techniques and the product literature supplied with the kit demonstrates 
intracellular detection in HeLa cells following a standard methanol-fixation technique665, 666. 
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The use of intracellular transport blockers such as monensin or Brefeldin-A was avoided due 
to increased complexity and the potential for confounding (monensin has been shown to 
interfere with wnt signalling in colorectal cancers), especially in the siRNA arms of the 
experiment667, 668. The use of novel single-cell dynamic intracellular inducible protein analysis 
was beyond the remit of this study669. 
 
The lack of detectable bands against TIMP4 in the WB analysis was also disappointing.  Protein 
extraction was successful as bands were demonstrated for b-actin, but no chemiluminescence 
was detectable when probed for TIMP4. The first possibility is that the primary antibody is not 
effective in the WB assay, although it worked adequately in ICC and is supported for both of 
these uses in the product literature670. The second possibility is that the conjugation to the 
secondary antibody was not effective due to a cross-reactivity issue or other fouling. The host 
for the primary antibody used for TIMP4 was rabbit and thus specific anti-rabbit secondary 
was acquired for ICC, but the anti-rabbit horseradish peroxidase secondary for WB was not 
ordered specifically for use with this primary (laboratory stock, different manufacturer), and 
thus there is a possibility it was not compatible with the primary or was degraded. 
Unfortunately, due to time and resource constraints, the re-running of the whole assay 
(including cell culture, siRNA transfection, etc) was not possible, and since results from ICC 
for TIMP4 were in accordance with the qRT-PCR data, was also deemed unnecessary. 
 
Another consideration is that the experiments conducted in this and the previous Chapter were 
performed on cells not interacting with an ECM-like environment, as was the case for the 
invasion assays in Chapter 4671. When cells of any kind interact with the stroma their 
phenotype is changes by ligand activation of multiple pathways, and thus the expression of 
important genes of interest and translation of proteins will be markedly different from cells 
cultured on plastic or glass.  These differences are likely to be augmented when cells are not 
only interaction with the ligands of the ECM but with other cell types, as would be encountered 
in the in vivo tumour microenvironment672. It should be noted, however, that the initial array 
and RT-PCR data in Chapter 5 was based on expression following exposure to AZA on cells 
not cultured in an ECM-like environments (e.g. on Matrigel), thus the effects of demethylation 
were not confounded by other changes in cellular phenotype in response to ECM ligands. 
Furthermore, the methods employed in this Chapter do not model the heterogeneity observed 
in in vitro tumours; the assessment of gene expression by mRNA and protein techniques having 
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been performed for total culture extracts.  This homogeneity, or apparent homogeneity, is 
unlikely to be representative of the tumour environment in vivo399, 477.  
 
Despite these issues an overarching narrative is emerging linking demethylation of DLD-1 
cells in vitro, reduced transcription and protein abundance of MMP2 and TIMP2, and a reduced 
propensity of demethylated cells to migrate and invade. These finding are summarised in Table 
6.2. 
 
Table 6.2 Summary of findings relating to expression of genes of interest and the methylation 
status of DLD-1 cells in vitro. Direction of arrows denotes direction of regulation, X denoted 




ARRAY qRT-PCR IIF WB 
AZA@ AZA* AZA$ AZA$ 
MMP2  -4.10  0.24  0.34  0.35 
MMP9   x  -  -  
MMP11  +2.45  3.26 -  -  
MMP13  +2.85   -  -  
TIMP2  -2.68  0.37 x   0.36 






The results of this Chapter demonstrate that exposure to AZA reduces the protein abundance 
of MMP2 & TIMP2 and increases TIMP4, as demonstrated by ICC and WB methodologies. 
These findings are in keeping with those observed based on expressional array data and 
individual qRT-PCR (the results for exposure to RRx-001 were divergent and prone to 
statistical deviation). AZA has also been shown to decrease the abundance of MMP2 & TIMP2 
protein and increase TIMP4 protein in a manner that was not dependent upon the presence of 
the counterpart proteins, suggesting AZA is directly affecting the transcription of each gene 
rather than via a post-translational homeostatic mechanism within the MMP2/TIMP2/MT1-
MMP axis. Furthermore, as the motifs in the promotor regions of MMP2 and the two TIMPs 
are highly overlapping but the effects of demethylation not convergent, demethylation affecting 
these sites is less likely to be responsible for the observed change in expression which is more 
likely occurring at another upstream site, such as a CpG island. 
 
MMP2 and TIMP2 are the major gelatinase and respective inhibitor responsible for degradation 
of Type-IV collagen in the basement membrane. Demethylation with AZA results in a reduced 
propensity for DLD-1 CRC cells to migrate and invade in vitro. The relative decrease in MMP2 
and dysregulation to gelatinase expression and abundance may be able to account for the 
reduced ability of AZA exposed DLD-1 cells to invade in an EMT-like model of early cancer 
development and metastasis that is analogous the processes involved in EMVI. These findings 
do not however directly translate to the in vivo process of early cancer progression and EMVI 
due to the relative crudity of the in vitro modelling (lack of ECM, stromal cells, 
microenvironmental hypoxia, etc). Investigating the effects of methylation status on gelatinase 
expression and tumour histopathological characteristics (including EMVI) will be the 




Extramural Vascular Invasion (EMVI) in Rectal 
Cancer and the In Vivo Expression of 
Metalloproteinases & their Inhibitors. 
 
7.1 Introduction 
Chapter 3 introduced the concept of extramural vascular invasion (EMVI) in rectal cancer and 
how this radiological and histopathological feature of rectal cancers is associated with poor 
prognosis and the requirement of adjunct therapies. The diagnostic challenges in detecting the 
presence of EMVI pre-operatively, thus presenting the possibility of neoadjuvant therapies in 
an effort to improve outcomes, were also discussed. Chapter 3 also examined the association 
between EMVI and the CpG Island Methylator Phenotype (CIMP), demonstrating a 
statistically significant association between the epigenetic events characterised by CIMP and 
the presence of histopathologically demonstrated EMVI, although the presence of the CIMP 
phenotype did not translate to poorer clinical outcomes258. 
 
Subsequent Chapters in this thesis have examined the relationship between the biological 
effects of methylation on colorectal cancer cell lines in vitro, and how manipulation of 
methylation can alter the phenotype. Demethylation with 5-azacytidine (AZA) has been shown 
to reduce the migratory and invasive ability of DLD-1 cells in association with dysregulation 
of metalloproteinases (MMPs) and their inhibitors (TIMPs) gene expression and protein 
abundance. Investigation with putative demethylator RRx-001 produced less consistent results. 
The reduced ability of cancer cells to migrate and invade is important in vivo as these abilities 
are crucial to the processes defining the epithelial-to-mesenchymal transition (EMT) and 
metastasis, processes analogous to EMVI and early rectal cancer progression476, 490. 
 
Novel associations between EMVI, MMP & TIMP expression, CIMP, and clinicopathological 
features and outcomes may, therefore, be beneficial in facilitating the diagnosis of EMVI or in 
risk-stratifying rectal cancers: Can metalloproteinases serve as biomarkers in rectal cancer? 
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7.1.1 Metalloproteinases as Biomarkers 
As already introduced in Chapter 5, MMPs and TIMPs have an established role in the 
progression of many cancers, specifically relating to their ability to remodel the extracellular 
matrix as early cancer cells interact with the cellular and acellular components of the stroma505, 
510. The MMP2/TIMP2/MT1-MMP axis has itself already been identified as a potentially 
important mechanism for early cancer progression in colorectal cancer and has been associated 
with a worse Duke’s Stage511, 512. However, the translation of benchtop observations into the 
manipulation of MMPs in in vivo therapeutics has been limited in success, suggesting 
additional layers of complexity in the relationship between MMP expression and cancer 
biology514. This is also reflected in the failure of MMPs and TIMPs to be adopted as diagnostic 
and predictive biomarkers. 
 
Aside from MMPs’ and TIMPs’ mechanistic role in cancer progression, their potential as 
biomarkers has been investigated via a number of methods for over 25 years. In 1991, Levy 
examined the mRNA expression of MMP2 in 18 colorectal cancers and compared expression 
to adjacent normal mucosa, demonstrating an increase in expression in 13 cases (72%)511. 
Immunohistochemical examination of a further 70 specimens, including 30 adenomas, 
demonstrated a statistically significant increase in staining for MMP2 (expressed as a 
percentage of positively stained cells) in Duke’s A/B over adenoma, and Duke’s C over Duke’s 
A/B (all p<0.001). However, contrary to these findings, Ring (1997) demonstrated that MMP2 
and MMP9 were not correlated with worse Duke’s stage or to survival, but that TIMP2 was 
inversely proportional to worse Duke’s stage and tumour differentialtion512. Interestingly, IHC 
demonstrated that MMP9 expression in tumour-associated macrophages was significantly 
associated with poorly differentiated tumours in this study (p<0.05) and MMP2 demonstrated 
a trend (p=0.08). In another series of 71 colorectal cancers, Zeng showed that MMP9 
expression (assessed by mRNA Northern blot hybridisation) was associated with synchronous 
distant metastasis (p=0.004) and worse Duke’s Stage (p=0.008), and that dichotomisation into 
MMP9-high and -low groups was a predictor of shorter disease-free and overall-survival 
(p<0.0001 and p<0.0002, respectively)673. Circulating concentrations of MMP1 have also been 
found to be associated with and predictive of metastasis and Duke’s C stage by other authors, 
based on ELISA-like assessments674. What this early research best illustrates is that there is 
huge variability between studies in terms of the association with disease stage and prognostic 
significance of individual MMPs and TIMPs, and that these associations have been found to 
be variably demonstrable between different investigations.  
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Very few studies have investigated the role of MMPs and TIMPs specifically in rectal cancer. 
This is largely due to colorectal disease being considered one biological entity in much of the 
literature despite a growing appreciation of the longitudinal differentiation between molecular 
subtypes along the colon202. In 2007, Schwandner examined 94 rectal cancers by IHC for 
multiple MMPs and TIMPs, finding that MMP2, TIMP2, and MT1-MMP were associated with 
the depth of invasion of the tumour, but not with differentiation, overall tumour stage (UICC), 
pre-operative CEA level, or nodal status675. None of the studied MMPs or TIMPs was 
associated with OS or DFS, although pre-operative CEA was significantly associated with both 
(both p<0.01). However, Tohoku found that only MMP9 was associated with worse survival 
(p=0.03) and nodal involvement in a series of 64 rectal cancers examined by IHC, whereas 
MMP2, TIMP2, and TIMP3 bore no association676. Again, the divergence in finding between 
studies is highlighted, and note that neither study examined any association between MMPs & 
TIMPs and EMVI. 
 
More recent reviews of the utility of MMPs and TIMPs in the diagnosis and staging of 
colorectal cancer have highlighted the challenges of the multiple different techniques in 
quantifying transcription, translation, and activity of MMPs; and have attributed the failure of 
this group of mechanistically important proteins to translate to useful biomarkers on the 
reliability and variability of different methodologies677. Although a variety of methodologies 
are employed, the assessment of proteases in cancer diagnosis and prognosis has been blighted 
by inconsistencies in findings, leading to few such genes and associated proteins being used as 
viable biomarkers604, 678. These issues are not unique to colorectal cancer and MMPs have also 
failed to become viable biomarkers in urological, breast, and other cancers despite extensive 
investigation. There are however ongoing efforts to build consensus that MMPs and TIMPs 
are potential diagnostic and prognostic biomarkers, with a particular focus on MMP2 and 
MMP9, although none has yet been adopted682, 683. Even given promising predictive values of 
MMPs in symptomatic patients (specifically circulating MMP9 assessed by ELISA), the focus 
on screening and diagnostic tools aimed at unselected populations has led to the predominance 
of faecal testing and other risk-stratification tools that direct patients towards colonoscopy (or 
equivalent)679-681. No studies have examined any association between metalloproteinases and 
EMVI from the perspective of being a potential biomarker that may aid in identifying at-risk 




7.1.2 Tissue Microarrays 
Tissue microarrays (TMA) are a high throughput method of assessing intact tissue at a 
genomic, transcriptomic, or proteomic level684. The fundamental principle of a TMA is the 
precision micro-sampling of tissue blocks and side-by-side mounting onto a limited number of 
slides so that multiple sections can be exposed to the same assay and then assessed 
rapidly685.These techniques allow assessment and storage of multiple tissue samples and are 
an evolution of the pre-existing “sausage” techniques686. The primary time and resource 
advantage of TMAs is that once representative specimens have been selected the process may 
then be automated and the number of new slides, as well as consumables employed to process 
them, dramatically reduced. Samples are then mounted sequentially on slides without 
individual labelling, thus keeping input samples in the same order as the mounting is crucial687. 
 
The pairing of TMA slide preparation with modern techniques in IHC facilitates internal 
control as multiple specimens can be exposed to the same probing and resolving process 
symaltaneously688. The biological principles in IHC are essentially the same as those exploited 
in ICC and IIF (see Chapter 6) but are employed on an intact tissue sample, thus facilitating 
an appreciation of the tissue-distribution of staining689. This advantage is therefore beneficial 
in examining potential intra-sample heterogeneity (such as tumour heterogeneity) and also the 
distribution of targets across different cell types when compared to ICC, although is less 
powerful than traditional full-slide assessment. TMAs have therefore become a standard and 
invaluable method of molecular profiling and can be combined with bioinformatic techniques 
to generate large datasets and meaningful insights into in cancer and other diseases690, 691. 
 
When assessing TMAs, as in other forms of IHC, it is important to adhere to standards of 
reporting and interpreting data. Standard methods for ensuring the reliability of data is dual 
specimen selection and reporting by pathologists, but also techniques in intensity and 
distribution scoring are important692, 693. As such, the five-step process of masking, 
examination, lesion parameters, scoring definitions, and interpretation consistency advocated 
by Gibson-Corley is recommended694. By employing these methods, a semi-quantitative output 
can be achieved that is robust and meaningfully descriptive, avoiding vague descriptions of 





7.2 Aims & Objectives 
This Chapter will investigate any associations between the histopathological and clinical 
features of resected rectal tumours and metalloproteinase expression and CpG-methylator 
phenotype (CIMP), with a particular focus on EMVI. The principle source for the 
histopathological and clinical data will be the database from which similar data was extracted 
and investigated in Chapter 3. Tissue microarrays will be employed to probe the expression 
of key MMPs and TIMPs in resected cancers and an inductive semi-quantitative methodology 
employed to cross-correlate against the clinical dataset and the observed effects of 
demethylation in vitro. The objective is to close the circle on a potential association between 
clinical outcomes in rectal cancer, EMVI, hypermethylation, and differential expression of 






7.3.1 Patient Selection, Data Collection, & Storage 
Sixty rectal cancer patients were extracted from the prospectively maintained database as 
described in section 2.1.1 & 2.1.2, and in accordance with the ethics laid out in section 2.1.3. 
The sixty patients were selected to provide an even split between those patients demonstrating 
EMVI on the histopathology examination of their resected tumours. Patients were in all other 
ways unselected and otherwise drawn at random from the pool. As previously stated, patients 
were neoadjuvant therapy naïve, and exclusion criteria also included patients with hereditary 
or other identifiable predispositions to carcinogenesis, such as inflammatory bowel disease. 
All patients underwent index surgery between January 2010 and May 2013 at a single centre 
(ABMU, Morriston Hospital, Swansea, SA6 6NL, UK) by a team of surgeons participating in 
the Swansea Pelvic Oncology MDT. Tumour characteristics were defined as per the ACPGBI 
or Royal College of Pathology guidelines with respective relation to pre-operative (mTNM) or 
postoperative (pTNM) staging and other tumour characteristics (CRM, differentiation, 
EMVI)35, 206. Adjuvant chemotherapy was administered based on current guidelines and best-
practice. Patient identifiable data was stored in keeping with the principles of NIHR Good 
Clinical Practice (GCP) and the UK Policy Framework for Health and Social Care Research364. 
For further specific detail of patient selection, data collection, and storage please refer to 
Chapter 3, Section 3.3.1. 
 
7.3.2 Tissue Microarrays & IHC 
TMAs were constructed by biomedical scientists of the Pathology Department of Singleton 
Hospital. Tumours were retrieved from storage and assessed by a consultant histopathologist 
to ensure representative areas of solid tumour were being sampled. Samples were anonymised 
after retrieval and mounting to TMA by means of dual-coding to remove any patient 
identifiable data from the data collection phase. Data was then re-coupled to patient clinical, 
histopathological, and CIMP datasets for analysis. 
 
The Ventana BenchMark ULTRA IHC/ISH System (Roche, Basel, Switzerland) was 
employed to process TMAs as it fully automates the baking, deparaffinization, cell 
conditioning and staining, counter stain and titration processes. Each primary antibody was 
optimised for antibody concentration and incubation time and temperature by the automated 
BenchMark ULTRA System and checked against positive control (human liver) by biomedical 
scientists. Details of the primary antibodies are found in Chapter 2 (Table 2.4), but each was 
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supplied by Abcam (USA) and chosen based on experimental requirement (for targeting 
MMP2, MMP9, MMP11, TIMP2, and TIMP4) and the expertise of the biomedical scientists 
(choice of supplier, variant of mAb, process optimisation, etc). Positive control was also 
mounted on the TMA to ensure internal validity of the staining process.  
 
Unstained FFPE TMA sections (4um) were mounted onto glass slides according to standard 
protocol and baked for 60 minutes at 60°C. The slides were then barcode labelled and placed 
on the BenchMark ULTRA System. Complimentary Ventana reaction buffer was used 
throughout the process to rinse slides and all other consumables were drawn from existing 
histopathology laboratory stock that had previously been optimised for the equipment. Liquid 
cover slip solution and reaction buffer is applied to the slides before each step and after each 
wash. Dewaxing is carried out at 72°C with EZprep solution. Retrieval with CC1 (cell 
conditioner) was then be performed at 98°C for between 8 and 48mins depending on antibody. 
Pre-peroxidase inhibitor was added. 100µl of diluted (dilution determined during optimization) 
primary antibodies was titrated onto the slides and incubated for between 4 minutes and 2 hours 
(depending on the protocol determined during optimization of the antibodies) at either room 
temp, 40°C, 37°C or 42°C (depending on the protocol determined during optimization of the 
antibodies). OV HQ Universal linker containing secondary antibody was then applied and 
incubated for 8 minutes, followed by OV- HPR multimer for 8 minutes. Sections were then 
treated with OV DAB and H2O2 for 8 minutes before finally being incubated in copper for 4 
minutes. An optional final incubation with OV AMP multimer was carried out depending on 
the antibody for 4-8 minutes. The slides were then be counterstained with Heamatoxylin for 8 
minutes.  
 
IHC staining was assessed according to a modified protocol based upon the recommendations 
set out in the Fedchenko review and with reference to the Gibson-Corley recommendations692, 
694. Scoring was carried out by a panel of at least three expert observers comprising at least one 
consultant histopathologist. The remaining participants were the investigator and academic 
supervisor (clinical or non-clinical), or biomedical scientist or other parallel Doctorate co-
investigators. Disputes were resolved by the consultant histopathologist who had the deciding 
opinion. TMAs were observed using light microscopy at 40-100x magnification and a 
consensus scoring system was adopted. The scoring system is set out in Table 7.1 and the 
scoring proforma in Appendix V. The overall staining metric Mx was determined by 
multiplying the score for the proportion of tumour cells stained by the score for the intensity 
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of staining; giving a maximum score of 12. Multiplying the scores (as opposed to adding the 
scores) ensured that uniformly non-staining tissues scored 0 (p4 x i0 = 0, rather than 4), and 
that the score was powered towards the more objective proportion of stained cells rather than 
the subjective intensity of staining for those that did score692. TMAs were performed in 
triplicate for each tumour (patient) sampled and the metrics averaged. This method provides 
semi-quantitative data for non-parametric analysis. 
 
Table 7.1 IHC scoring system for TMAs 
Proportion of Cells  p-Score Intensity of 
Staining 
i-Score 
None 0 None 0 
<10% 1 Weak 1 
10% – 50% 2 Intermediate 2 
51% - 90% 3 Strong 3 
>90% 4   
MAX Multiplication Score (Mx) = 12 
 
7.3.3 Statistical & Test Analysis 
Multiplication scores (Mx) were for each MMP or TIMP (0-12) in sample triplicates and then 
averaged to provide the overall score, as described in Section 7.3.2. Scores were then 
categorised (Cat scores) according to the system set out below. Nominal categorisation was 
preferred as the data is discrete rather than continuous. 
• Category 0 (Cat 0): Mx 0  
• Category 1 (Cat 1): Mx 1 to 4 
• Category 2 (Cat 1): Mx 5 to 8 
• Category 3 (Cat 2): Mx 9 to 12 
 
Categorisation is consistent with the methods set out by other authors in benchmark papers on 
methods in IHC695-697. Following categorisation, global assessment of association to EMVI was 
made for each MMP and TIMP by logistic regression and Cox proportionate hazard (time-to-
event) modelling698. A survival analysis by Kaplan-Meyer method (survival-distribution 
function by Log-rank) was also estimated for each MMP and TIMP. Following global 
assessment, if association was indicated, test optimisation was performed by Category sub-
analysis for sensitivity and specificity so that the optimal combination of categories could be 
constructed into the best test by binarisation. Binarised tests were then re-assessed for 
proportionate hazard and survival modelling. This process is summarised in Figure 7.1. 
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Pearson’s correlation matrix was them employed to demonstrate association between CIMP 
and both MMP2 and EMVI in the sample population. 
 
Data analysis was performed using the Microsoft Office Excel (v.16.12) and the XLStat 
Addinsoft (v.2017) plug-in (macro).  Normalcy of data distribution was determined using a 
Kolmogorov-Smirnov test. If data were normally distributed, statistical significance was 
determined using Student’s t-test for single comparisons or one-way ANOVA where more than 
one comparison was made. If data were not normally distributed, Mann-Whitney’s test was 
used to compare unpaired means and Wilcoxon test used for paired data.  Log-Rank (Mantel-
Cox) tests were used where data was right-side skewed and censored.  Comparison of expected 
frequencies was performed with two-tailed Chi Squared or Fishers exact test if observed events 
were less than 10. Survival curves were calculated using Kaplan-Meier estimate. The null 










p-score x i-score = Mx
TMA 2:
p-score x i-score = Mx
Average Mx
Categorised Mx =
Cat 0 - 3 
Primary Binarisation:
Cat 0 - 1 vs Cat 2 - 3
Secondary Binarisation:
Cat 0 - 2 vs Cat 3
TMA 3:
p-score x i-score = Mx
Regression, Cox, &  
K-M Analysis 
Test Accuracy (Sensitivity, Specificity, 




7.4.1 Patient and Tumour Characteristics 
There were 60 patients included in this study (30 patients with an EMVI-positive tumour and 
30 with no evidence of EMVI). Forty-two patients were male (70%) and males were 
statistically more likely to demonstrate EMVI than females (p=0.005). The median age was 68 
years (range 45 – 89 years), and patients were of a similar age in both groups.  Nineteen patients 
had died at the time analysis was undertaken.  Median follow up was 56.5 months (IQR 25 – 
71 months).  Mean overall DFS and OS were 28 and 33 months, respectively, but DFS was 26 
months in the EMVI-positive group and 31 months in the EMVI-negative group (p=0.20).  OS 
between EMVI-positive and -negative groups was 32 and 34 months, respectively (p=0.51). 
When differences between both groups were analysed between groups, patients with EMVI-
positive tumours had more advanced pathological staging by pT, pN, and AJCC classifications 
(p=0.038, p=<0.0001, and p=0.001, respectively). Specifically, when the T-grade was 
compared against EMVI, pT1 and pT2 were significantly less frequently occurring events than 
others within the contingency table (each Fisher’s exact text p<0.05). There was a 
corresponding association between EMVI-positive tumours and the need for adjuvant 
chemotherapy (p=<0.0001).  There was, however, no statistically significant difference in 
CRM positivity, tumour perforation, or tumour differentiation (all p=NS). These findings are 
demonstrated as three-dimensional (3D) contingency tables in Figure 7.2.   
 
7.4.2 Staining Characteristics and EMVI 
TMAs for 60 tumour specimens were successfully constructed and stained against the targets 
MMP2, MMP9, MMP11, TIMP2, and TIMP4. All staining was successful and controlled 
against the human liver positive control except for MMP11 which failed to stain against tumour 
and control despite multiple attempts at automised and manual optimisation. Following 
percentage and intensity scoring, the multiplied metric (Mx) was calculated and tumour 
Categorised scoring (Cat) performed; these results are demonstrated in the frequency 
histograms in Appendix VI.a. Representative TMAs stained for MMP2 and TIMP2 are 
demonstrated in Figure 7.3 a & b. Logistic regression analysis of the Cat scores demonstrated 
a significant relationship between EMVI and MMP2 and TIMP2 (both p<0.0001). No 
relationship was discernible between EMVI for and Cat scores for MMP9 or TIMP4 (both 
p=NS). The receiver operating characteristic (ROC) analysis of global MMP2 Cat scores 






































d. Contingency table EMVI vs Adjuvant 
Chemotherapy
However, ROC analysis for TIMP2 was less favourable (AOC 0.560). These results are also 
demonstrated graphically in Appendix VI.b. 
 
Figure 7.2 3D contingency tables for EMVI against a. pT; b. pN; c. AJCC classification, and 
















b. Contingency table for EMVI vs P 
stage
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Figure 7.3a & &.3b.  Selected representative light microscopy images at x4 and x10 
magnification of IHC for MMP2 & TIMP2 in EMVI-positive and EMVI-negative tumours. 
 
a. 
 Selected representative light microscopy images at x4 and x10 magnification of IHC 
for MMP2 in EMVI-positive and EMVI-negative tumours. 
EMVI-positive EMVI-negative 





    
    
    
    
  
 
Note the differential staining intensity between EMVI-positive and EMVI-negative tumours in 
this selected representative series. Following scoring categorisation, this differential staining 
was demonstrated to be significant (p<0.0001). Binarised scoring was then demonstrated to be 






 Selected representative light microscopy images at x4 and x10 magnification of IHC 
for TIMP2 in EMVI-positive and EMVI-negative tumours. 
EMVI-positive EMVI-negative 





    
    
    
    
 
 
Although staining intensity was associated with EMVI-status in this series (p<0.0001), TIMP2 
was not found to be a predictive discriminator for EMVI, as was the case for MMP2. This 
series has been constructed to also highlight the differential degrees of staining proportion and 
intensity used to calculate the multiplication score, Mx, in the IHC analysis (top row = high 




7.4.3 Proportional Hazards in relation to EMVI and Staining Characteristics 
The Cox Proportionate Hazards Model was used to examine the proportionate risk of poor 
disease-free (DFS) and overall (OS) survival in relation to EMVI, and Global MMP2 & TIMP2 
Cat scores. Cox modelling demonstrated that EMVI was significantly related to DFS and OS 
with Hazard Ratios of 3.32 (p=0.027) and 3.05 (p=0.043), respectively. The same analysis for 
MMP2 and TIMP2 demonstrated statistical non-significance for their risk relating to DFS and 
OS, (p=0.11 and p=0.15, respectively, for DFS and OS). These results are demonstrated in 
Appendix VI.c with the accompanying Log(-Log(SDF)) curves demonstrating similar slopes 
for each test, although there is a degree of left-shift for each and more so for EMVI, indicating 
that the risk-ratio is divergent, and hence it reaching significance for increased risk in this time-
point model. 
 
7.4.4 Survival Analysis 
Kaplan-Meyer (KM) analysis was performed for DFS and OS in relation to EMVI, and Global 
MMP2 & TIMP2 Cat scores. This analysis showed that EMVI was significantly related to both 
DFS and OS (p=0.029 and p=0.046, respectively). Similar to the results demonstrated in Cox 
modelling, the KM analysis demonstrated non-significance for both MMP2 and TIMP2 when 
Cat scores were analysed as a group, (p=0.15 and p=0.20, respectively, for DFS and OS). These 




Figure 7.4 Kaplan-Mayer Survival Distribution Functions for Disease-Free (DFS) and Overall 
Survival (OS) assessed on EMVI and categorised staining (Cat) scores for MMP2 & TIMP2. 
 
a. EMVI  
 
b. Global MMP2 Cat Score.  
 











7.4.5 MMP2 Biomarker Test Optimisation 
Global MMP2 Cat scores have been shown to be associated with EMVI on logistic regression 
analysis but the sensitivity and specificity thresholds for each Category has not been 
established. Additionally, sensitivity & specificity may be improved by test binarisation into 
MMP2-high or -low (combining Cat scores). Table 7.2 demonstrates Primary and Secondary 
Binarisation strategies. Optimal binarisation is indicated by the threshold-based diagnostic 
accuracy analysis (table) and ROC curve in Figure 7.5, demonstrating superior sensitivity, 
specificity, and AOC for Primary Binarisation over Secondary Binarisation for global MMP2 
Cat score (AOC 0.973 vs 0.947). These analyses indicate an optimal binarisation of individual 
Cat scores was produced by Primary Binarisation (accuracy 0.900).  
 
Table 7.2 MMP2 Category Binarisation 
MMP2 Primary Binarisation Secondary Binarisation 
Low Cat 0 & Cat 1 Cat 0 to Cat 2 
High Cat 2 & Cat 3 Cat 3 
 





MMP2 Cat Sensitivity Specificity PPV NPV TP TN FP FN Accuracy 
0.000 1.000 0.000 0.500   30 0 30 0 0.500 
1.000 1.000 0.067 0.517 1.000 30 2 28 0 0.533 
2.000 1.000 0.800 0.833 1.000 30 24 6 0 0.900 
3.000 0.733 1.000 1.000 0.789 22 30 0 8 0.867 
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When binarisation (Primary or Secondary) is applied and Cox and KM modelling re-applied 
the hazard estimations indicate that Primary Binarisation is a better indicator of early adverse 
event than Secondary Binarisation, as demonstrated in Table 7.3. However, for DFS and OS 
based on KM analysis, Secondary Binarization of Cat scores was found to be significantly 
(p=0.030 & p=0.049) associated with MMP2 and outperformed Primary Binarisation (p=0.041 
& p=0.057 [NS], respectively). These results are demonstrated in Figure 7.6. 
Table 7.3 Cox Proportionate Hazard modelling for binarized MMP2 scores. 
MMP2 Disease-free survival Overall Survival 
Hazard Ratio p-value Hazard Ratio p-value 
Primary Binarisation 3.45 0.033 3.21 0.047 
Secondary Binarisation 2.97 0.037 - 0.055 [NS] 
 
Figure 7.6 Kaplan-Mayer Survival Distribution Functions for Disease-Free (DFS) and Overall 







DFS p=0.030 OS p=0.049 
OS p=0.057 
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7.4.6 CIMP, MMP2, & EMVI 
When correlation between CIMP, MMP2 binarised score, and EMVI was examined, X2-based 
contingency tables illustrated an association between CIMP and both MMP2 and EMVI in the 
sample population (p=0.004 and p<0.001, respectively). However, correlation matrix (Pearson) 
indicated a stronger and more significant association between EMVI positivity and MMP2 
(Person=0.816, p<0.0001), than between CIMP and any other factor. These results are 
demonstrated in Table 7.4 and Appendix VI.d. 
 
Table 7.4 Pearson correlation matrix for CIMP, EMVI, and MMP2. 
Variable CIMP  EMVI  MMP2 
CIMP 1 0.415     p=0.001 
CI 0.108 – 0.605 
0.367     p=0.004 
CI 0.125 – 0.568 
EMVI 0.415     p=0.001 
CI 0.108 – 0.605 
1 0.816     p<0.0001 
CI 0.710 – 0.887 
MMP2  0.367     p=0.004 
CI 0.125 – 0.568 
0.816     p<0.0001 






The aims of this Chapter were to investigate any associations between the histopathological 
and clinical features of resected rectal tumours, metalloproteinase expression in these tumours, 
and CpG-methylator phenotype (CIMP); with a particular focus on EMVI. The data from this 
Chapter clearly demonstrate that, in this selected trial population, there was an association 
between tumours strongly expressing MMP2 and those demonstrating EMVI. This was 
demonstrated by global MMP2 scoring based on logistic regression modelling and the 4-teir 
system as described but was further improved by binarisation of the scoring system (AUC 
0.947 vs 0.973). There was also an association between TIMP2 and EMVI, but TIMP2 was not 
a good discriminator between EMVI positive and negative tumours. No other marker 
demonstrated association with EMVI (MMP9 and TIMP4) and staining with MMP11 was 
unsuccessful. 
 
Primary Binarised MMP2 scores demonstrated a sensitivity and specificity for EMVI positivity 
of 100% and 80%, respectively, with overall accuracy of 90% and a positive-predictive value 
of 88.3%. When this model of binarisation was tested against hazard (RR; Cox) and survival 
modelling (KM), relative risk for adverse DFS and OS was estimated at 3.45 and 3.21 in 
MMP2-positive tumours, respectively (both p<0.05), although this only translated into 
significant observed difference in DFS (p=0.041) based on Kaplan-Meyer analysis (OS was 
not significantly affected but was nearing significance (p=0.057)). Overall survival was 
however observed to be worse for those patients demonstrating higher MMP2 staining when a 
Secondary Binarisation protocol was employed, although the Cox hazard ratios were not as 
significant. Based on these assessments, the Primary Binarisation strategy produced the better 
accuracy when compared to Secondary Binarisation, produced significant RR and KM survival 
analysis, and was thus deemed to be a better test than Secondary Binarisation. Given the limited 
difference in significance for DFS and OS between the binarisation strategies, and the findings 
that insignificant p values were approaching threshold (p<0.05), there was only a minor degree 
of discrepancy between each of the two binarised scoring systems. However, care must be 
taken when indicating “trend”, as this can often be misleading when assessing small 
populations699. 
 
When assessed as a factor associated with EMVI, MMP2 was more strongly associated with 
EMVI than CIMP, as demonstrated by superior Pearson correlation (0.816 vs 0.415), although 
both were significantly associated (p<0.0001 and p=0.001, respectively). This finding 
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correlates with the findings in Chapter 3; where although CIMP was associated with EMVI it 
did not translate into a predictor of survival. In the analysis in this Chapter, MMP2 Primary 
Binarised score was a predictor of EMVI and was associated with adverse survival. These 
findings have not however been validated in an unselected or external cohort, which is vital for 
the complete evaluation of a novel biomarker, although the findings do indicate its potential700, 
701. 
 
Following the discovery of an association between Duke’s stage and MMP2 abundance, the 
role of MMPs in colorectal cancer has been studied for some decades from both a mechanistic 
and biomarker persective511. Much of the recent interest in MMPs as biomarkers has fallen on 
circulating (serum) MMP9 and TIMP1, as these potential markers have been most powerfully 
associated with diagnosis. The quality of evidence for the association ranges from evidence 
derived from several small series where the identification and prognosis of colorectal cancers 
was found to correlate to circulating MMP9 activity (assessed by zymography) to much larger 
population based studies702-704. For instance, in a series of 748 asymptomatic patients, Wilson 
identified that serum MMP9 has a sensitivity and specificity of 79% and 70%, respectively, 
and thus might serve as a potential tool for rationalising screening colonoscopy when employed 
as part of a larger panel of genetic biomarkers705. However, more recent studies from the UK 
have indicated that MMP9 may be more useful as an adjunct to FOB testing in symptomatic 
patients entered into the screening programme, as the diagnostic accuracy is improved within 
the symptomatic population and augments faecal testing679, 705. A further study of 4509 
symptomatic patients from Scandinavia indicated that serum TIMP1, in combination with 
CEA, was also a good diagnostic biomarker for colorectal cancers, but that its diagnostic 
accuracy was superior specifically for colonic tumours than for rectal tumours or the cohort as 
a whole706. When considering these studies, it must be noted that they are each examining 
serum levels of their respective biomarkers in either asymptomatic or symptomatic patient 
populations who then go on to have colonoscopy as a means of validating the test. This focus 
on diagnostic biomarkers has been driven by the prioritisation of preventative medicine and 
the high cost and resource burden associated with colonoscopy, especially given the  high false-
positive rates associated FOB and symptomatic screening, and thus the need for better 
discriminators to reduce “unnecessary” endoscopy8, 328. The patients in this study, by contrast, 
all have had rectal cancers resected with curative intent, and the test hypothesis was directed 
towards the detection of EMVI and thus is dissimilar to the screening population. However, 
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the investigation of staging and prognostic biomarkers in colorectal cancer, including the MMP 
family, is still a valid exploit as it may aid in delivering precision medicine683, 707. 
 
With regards prognosis, MMP9 and TIMP1 have previously shown some promise as potential 
biomarkers, and have been associated with worse DFS and OS, especially in compound metrics 
with pre-operative CEA708, 709. One study identified TIMP1 as a factor in predicting colorectal 
cancer liver metastasis and their recurrence, although VEGF was a better discriminator in this 
study710. The findings in this Chapter indicated that MMP2 but no other marker was associated 
with survival in terms of DFS and OS.  This association between MMP2, EMVI, and survival 
is constructive, but the lack of association with MMP9 and TIMP2 is also important, especially 
since MMP9 has previously been found to be potentially useful as a screening tool or as a 
prognostic biomarker. Again, this study in comparison to the screening-oriented studies is 
highly selective, thus the results are unlikely to be representative of the whole population of 
colorectal cancers. However, this study’s divergent findings may fit with the hypothesis that 
MSI-high hypermethylated tumours of the rectum form an under-recognised cohort of cancers 
with an atypical phenotype, including MMP expression, and a poorer prognosis.   
 
Beyond survival data and metastasis, there has been some evidence to indicate that some 
MMPs may be valuable biomarkers in stratifying the response of cancers to chemotherapy, as 
has been found in gastric cancer711, 712. However, in colorectal cancer the data has been more 
inconsistent; two studies from Denmark, for instance, found that TIMP1 levels correlated to 
response in patients receiving combination  irinotecan, 5-fluorouracil, and folinic acid, but not 
in patients receiving combination capecitabine and oxaliplatin, although baseline TIMP1 was 
a predictor of eventual progression-free survival713, 714. The findings in this study do not aid in 
predicting response to adjuvant therapy, although this would be an interesting avenue for 
investigation, as if MMP2 is a good predictor of EMVI and thus increase the number of patients 
considered for neoadjuvant therapy, knowing that those patients would have a significant 
response would valuable. Currently, only a limited number of studies have investigated MMP2 
as a biomarker in predicting response to adjuvant chemotherapy. One found that an elevated 
ratio of MMP2 to MMP9 in osteosarcoma was associated with poor response, although another 
study in inflammatory breast cancer found exactly the opposite715, 716.  
 
Although associations between MMP2 staining, EMVI, and survival have been demonstrated 
in this chapter, and that MMP2 is a good predictor of EMVI, there are some limitations to its 
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application. Firstly, as already mentioned, the methodology employed in this Chapter relied 
upon the construction of TMAs form resected cancers, thus the ability to identify EMVI in 
these tumours is more than a little post hoc. For this method to be clinically useful it would 
need to be applied to biopsies taken at the point of diagnosis and initial staging so that if high 
MMP2 was identified, and therefore EMVI predicted, neoadjuvant therapies may be 
considered irrespective of MRI findings. Furthermore, as this trial population was highly 





In a selected trial population, MMP2 was a predictor of EMVI based upon the Primary 
Binarised score for staining. Higher MMP2 was also demonstrated to have a significant hazard 
ratio for DFS and OS and was significantly associated with poor DFS on Kaplan-Mayer 
analysis. OS for MMP2 did not quite reach significance. MMP2 score demonstrated better 
correlation to EMVI than did CIMP status. MMP2 has the potential to be useful as a diagnostic 
biomarker for EMVI in rectal cancers, and may also act as a prognostic biomarker, although 










The overarching aim of this thesis was to investigate the relationship between methylation and 
EMVI in rectal cancers, its implications for prognosis, and seek to illuminate the biological 
processes that underlie any relationship. Three primary strands of enquiry were followed in 
order to achieve these aims; the investigation of the methylation status of resected rectal 
cancers and correlations to clinical outcomes; the in vitro manipulation of methylation to assess 
biologic effects on colorectal cell lines; and the investigation of putative epigenetic processes 
that may underlie the in vitro and in vivo observations. The investigation of potential 
biomarkers associated with EMVI was an additional objective, as it may serve to facilitate the 
staging and management of progressing rectal cancers. Each of these features is discussed in 
the context of consensus molecular subtyping in colorectal cancer and the potential for 
precision medicine118, 201. 
 
Throughout this Chapter the findings of this research are discussed and the overarching 
narrative pieced together. The limitations of each stage of the enquiry will be highlighted and 
complementary or tangential investigation suggested. The first comment in this vein, however, 
is the acknowledgement of the limitations of the principle investigator and author: As a 
clinician, stepping into the laboratory has been a challenging and rewarding process; 
methodologies and techniques that are the bread-and-butter of the undergraduate, graduate, and 
doctoral scientists have had to be learned from scratch and on-the-fly. The concepts of the 
scientific enquiry into cellular physiology and epi-/genetic investigation have all been novel 
and will inform my future clinical and academic insight, but as a novice there were hard barriers 
to overcome and thus the primary limitation in this investigation is my own limited expertise. 
On the other hand, my experience as a clinician and surgeon has greatly facilitated by insight 
into the translational aspects of this research and I hope that I have been able to support 
colleagues in the laboratory with clinical aspects of their own research, as they have supported 
me with the science. 
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8.2 The CpG Methylator Phenotype and Extramural Vascular Invasion 
As highlighted in Chapter 1 & 3, the molecular and genetic aberrations that underlie CRC 
carcinogenesis are complex and not fully understood, although there is a consensus that there 
are divergent processes responsible for tumour development at different sites throughout the 
colon and rectum118. DNA methylation is one epigenetic process implicated in CRC, as well 
as other cancers, and CpG island methylator phenotype (CIMP) has drawn interest as a 
potential mechanism underlying both carcinogenesis and as a potential biomarker148, 717.  
CIMP, however, has primarily been associated with carcinogenesis in the right colon that is 
characterised by hypermethylation and microsatellite instability (MSI) (the serrated pathway), 
rather than the traditional chromosomal instability pattern typical of other sites in the colon and 
rectum125, 136, 718.  Despite the preponderance in the right colon, CIMP tumours are known to 
occur in the rectum, although the clinical significance of this molecular tumour type occurring 
at this site is poorly understood, although some authors have suggested they represent a poor-
prognostic subgroup149, 719.  Many of the studies that have examined the role of methylation in 
rectal cancer or indeed colorectal cancer as a whole have focused on a single gene locus or 
have relied upon small cohorts, making outcomes interpretation challenging353, 720.   
 
The primary findings of Chapter 3 were that a clear association was demonstrated between 
the presence of pEMVI and male sex, T and N stage, AJCC classification, and the requirement 
for adjuvant chemotherapy258. This study confirms the association of EMVI with worse 
clinicopathological features and that these translated into a statistically significant survival 
disadvantage, in keeping with the findings of other authors280. Although a significant 
relationship was demonstrated between CIMP-intermediate status and EMVI positivity 
(p=<0.001), this was not translated in to a disease-free or overall survival disadvantage for 
CIMP-intermediate patients (Log-rank p=0.66 and p=0.46, respectively). This was despite 
EMVI-positivity being an independent risk-factor for disease recurrence (Cox Proportional 
Hazard r=5.98 (1.10-32.50), p=0.038).  
 
In order to gain a fuller understanding of the role of CIMP in EMVI in rectal cancer, a meta-
analysis including the data gathered in Chapter 3 was undertaken721. Briefly, a systematic 
search was performed of PubMed, Embase, MEDLINE, PubMed Central, and Cochrane 
electronic databases for articles pertaining to CIMP and rectal cancer.  Articles were analysed 
and data extracted according to PRISMA standards – see Appendix VI for further detail. Six 
studies including 1529 patients were included in analysis149, 204, 258, 318, 366, 719. Following 
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dichotomisation, the prevalence of CIMP-positive tumours was 10% to 57%, with a median of 
12.5%. Meta-analysis demonstrated the pooled odds ratio for all-cause death for CIMP-positive 
tumours vs CIMP-negative tumours was 1.24 (95% CI 0.88-1.74).  Z-test for overall effect was 
1.21 (p=0.23), therefore no significant association between CIMP and poor outcomes in rectal 
cancer was demonstrated (Figure 8.1). Heterogeneity between the studies was low (X2 5.96, 
d.f. 5, p=0.31, I2=16%) but total of 15 different loci were used for assessing CIMP across the 
studies, with a median of 6.5 loci (range 5-8).  Another major finding was that rectal cancer 
datasets were frequently not extractable from larger colorectal cohorts, limiting analysis. 
 
Figure 8.1 Pooled analysis on CIMP and overall survival (adapted from Kokelaar)721. 
 
 
From the investigation in Chapter 3 and subsequent meta-analysis, there does not appear to 
be a significant relationship between CIMP and poor DFS or OS, despite the association 
between CIMP and EMVI. The differentiation in outcomes suggests an additional layer of 
complexity beyond a binary relationship between EMVI and CIMP. The significant limitation 
of all CIMP studies in all cancer types is the heterogeneity in assessing CIMP, a concern 
highlighted by many authors148, 361. With regards consensus molecular subtyping (CMS) of 
colorectal cancers, the original CMS study identified the frequency of CMS1 in the rectum as 
3%, whereas this study of 100 consecutive patients with rectal cancers, given exclusions, 
demonstrated a higher than expected proportion of CIMP-intermediate and -high tumours 
(49%) which may be considered as analogous to CMS1 tumours. These findings must, 
however, be considered in the context of the methodology chosen to determine CIMP as other 
less discriminatory methods may have returned a lower frequency185, 186. The limited 
extractability of rectal datasets is also a constraint to analysis. Due to these limitations, the 




8.3 Demethylating Agents in Colorectal Cell Lines 
Chapter 4 investigated the biologic effects of demethylation on the colorectal cancer cell line 
DLD-1. The well characterised DNA-methyl transferase inhibitor azacytidine (AZA) was 
employed as the primary controlled variable to effect demethylation, but the putative 
demethylator RRx-001 was also investigated. These chemicals were first screen and optimised 
against standard tests for cytotoxicity and inhibition of cellular proliferation to ensure that the 
effects of biologic assays for invasion and migration were as a result of demethylation. Both 
agents demonstrated tolerable cytotoxicity at biologically effective doses. This was 
demonstrated by effective locus-specific and pan-DNA demethylation (msPCR and ELISA-
like assays) at doses that were not cytotoxic but did reduce propensity of cells to migrate and 
invade.  
 
The implications of the findings in this Chapter are twofold; firstly, they serve as a useful link 
to the findings in Chapter 3, as the same CIMP markers employed in assessing resected tumour 
methylation were employed, thus linking in vivo observations to potential in vitro processes. 
The second implication is that the findings serve to confirm the demethylating activity of the 
two investigated compounds and associate them to changes in cell behaviours (phenotype), 
thus allowing investigation of underlying mechanisms to be linked to both demethylation, 
cellular phenotype, and potentially tumour behaviour. 
 
There were however limitations in each stage of this part of the investigation, although attempts 
at mitigation were made. With regards to the baseline investigation of cytotoxicity, only 
reasonably basic assays (RPD and trypan blue) were undertaken, although they were done in 
multiple biologic and technical replicates. Other more sophisticated methods of assessing 
cytotoxicity and the effects of potentially genotoxic agents are possible, although the methods 
employed in this study are well-established and accepted as adequate439, 440, 722. There was 
perhaps an additional element of concern in this assessment, however, when considering the 
investigation of RRx-001, which is not well characterised, and its modes of biologic action not 
well understood235, 239. The full investigation of new compounds in biologic processes, 
especially in humans with a view to potential therapeutic applications, is the basis of the 
pharmaceutical industry, and thus a more global and in-depth investigation of RRx-001 beyond 
the remit of this research. The addition of RRx-001 to the experimental construct was however 
insightful and will be pursued by the compound’s proprietor, EpicentRx. 
 
 221 
The assessment of DLD-1 cell propensity to migrate and invade based on scratch and Transwell 
assays was successful, although to some degree limited as biological models. The assessment 
by time-to-convergence was a simple and precise method of assessing cell activity and did not 
depend on more operator-dependent metrics that might have been more prone to confounding. 
Similarly, the Transwell system was effective at demonstrating the change in cell activity 
following demethylation and provided a link to EMT-like processes of early cancer progression 
due to the addition of an extracellular matrix component. These assays were, however, limited 
in their sophistication by the use of monoculture and monolayer techniques which do not model 
the tumour microenvironment well447. The addition of, for instance, tumour-associated 
macrophages or fibroblasts, could provide additional insight into the biologic activity of 
colorectal cancer cells in vitro and exposure to demethylating agents, as discussed in Chapter 
5 & 6 when considering EMT and metalloproteinase activity. Both scratch and Transwell 
systems are however widely used and accepted as robust methodologies for cellular 
investigation and the results gathered valid. 
 
Finally, the demethylating effects of AZA and RRx-001 on DLD-1 cells was demonstrated by 
locus-specific and whole-DNA assays. These techniques showed that although both agents 
caused demethylation, it was to different degrees and at different rates; AZA causing a more 
profound demethylation at both levels, whereas RRx-001 demonstrating a slightly more dose-
dependent whole-DNA effect and less effective locus-specific effect. The results for AZA are 
not unexpected as its mode of action is well characterised216, 220. Although identified as an 
alkylating agent, the demethylating action of RRx-001 is not understood, although it is 
apparently effective. However, the reduced ability of RRx-001 to demethylate at more locus-
specific sites that AZA suggests that it’s action as a demethylator is dependent on other genetic, 
epigenetic, or cellular events. One culprit in this effect may be chromatin restructuring, which 




8.4 Mechanisms Underlying the Response to Demethylation  
Chapters 5 & 6 were designed to investigate the potential cellular mechanisms underlying the 
observed biologic effects of demethylation with AZA and RRx-001. The first stage in this 
process was identifying genes of interest that could then be investigated further, hence the 
initial approach was by a RT-PCR profiler array. As the array was only intended as a screening 
tool and to be controlled for demethylation, it was only performed once and only against AZA, 
as this was deemed to provide the best benchmarking for investigating the biologic effects. The 
RT2 Profiler PCR Array – Human Tumour Metastasis (QIAGEN, Germany) was selected as it 
ties together the biologic effects observed in vitro (reduced migration and invasion) with the 
putative processes involved in EMVI in vivo. Arguably other arrays could have been chosen 
but the array selected provided coverage not only of genes associated with the EMT process, 
which is characterised by proliferative as well as early invasive changes, but also genes 
associated with metastasis. As the process of EMVI is not well understood as an individual 
biological process, the coverage of genes possibly associated locally invasive and locally 
metastatic processes is appropriate. Less focus was given to proliferative (primary tumour 
growth) and angiogenic (distantly metastatic) genes as they were deemed less likely to be 
important in the EMVI process. The array highlighted a number of up- and down-regulated 
genes, as well as many that did not change significantly, but the family of genes most that 
demonstrated the broadest and greatest magnitude in change was the metalloproteinases 
(MMPs) and their inhibitors (TIMPs). 
 
As discussed in the respective Chapters, the MMPs and TIMPs are responsible for degrading 
and regulating the protein components of the ECM and have been implicated in a broad range 
of diseases, including colorectal cancer683. Due to the significant dysregulation demonstrated 
in the array, the preferred substrate of Type-IV collagen, and previous association with 
colorectal cancer drawn from the literature, the MMP2/TIMP2/MTP1-MMP axis was primarily 
investigated as a target for further expressional investigation by qRT-PCR. Complementary 
MMPs and TIMPs were also included for further depth of analysis. Following exposure to 
AZA, the qRT-PCR demonstrated a robust change in expression of MMP2, TIMP2, and 
TIMP4. Response in MMP11 and MMP13 was less pronounced and MMP9 uninterpretable 
due to reaction fouling. As MMP2 is the primary protease responsible for the degradation of 
collagen in the basement membrane, it’s reduced expression in DLD-1 cells following 
demethylation may be causative in the reduced propensity of these cells to migrate and invade. 
The results obtained from RRX-001 were divergent from those of AZA, thus, due to this 
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inconsistency and previous discrepancy in demethylating effect, no further investigations were 
conducted with RRx-001. 
 
The regulation and homeostasis of MMPs is complex, occurring at a transcriptomal, post-
transcriptomal, and post-translational level. This was perhaps reflected in the finding that as 
well as the downregulation of MMP2, its primary inhibitor TIMP2 was also downregulated; 
challenging the notion that demethylation simply swings that balance of homeostasis towards 
anti-MMP2 activity. To discern between AZA having a direct transcriptional effect on MMP2 
expression and one mediated via TIMP2 or TIMP4 in a homeostatic feedback mechanism, 
knockdown (KD) experiments and cross-correlation with PCR data was performed utilising 
proteomic techniques (immunocytochemistry/immunofluorescence and Western blotting). 
These experiments, however, proved challenging to interpret and suffered somewhat from 
fouling, although they did confirm the decrease of MMP2 protein abundance in response to 
AZA exposure. One limitation encountered in this phase of investigation was the inability to 
detect TIMP2 with ICC techniques, largely due to the protein predominantly being expressed 
extracellularly. This was despite other authors having success in detecting TIMP2 
intracellularly under similar experimental conditions and the product literature suggesting it 
was possible. ICC was however successful for MMP2 and TIMP4 and corroborated the 
findings of PCR. Western blotting for MMP2, TIMP2, and TIMP4 was also undertaken, but 
this time was somewhat limited by a failure of the conjugation of the TIMP4 and secondary 
antibody in this protocol, the same primary antibody having probed adequately during ICC. 
Despite this there was sufficient data from WB to support the findings of the PCR for MMP2 
and TIMP2, therefore providing proteomic cross-validation for each of the genes against PCR 
by one or other of the techniques. 
 
When the proteomic data was considered in combination with the quantitative PCR, exposure 
to AZA was found to decrease MMP2 expression independently of TIMP2 and TIMP4, and 
thus could be assumed to be occurring via a direct effect of AZA on MMP2 transcription rather 
than via a homeostatic mechanism dependent on the expression of the counter-acting proteins. 
A greater understanding of the specific mechanism by which AZA prevents MMP2 expression 
could be addressed in further research, perhaps by focused study of the methylation of 
promotor sequences and transcriptomal binding sites by techniques such as methylation-
specific pyrosequencing, but limited time and resources prevented this element (which would 
have required out-sourcing) being included in this study724. 
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8.4 Metalloproteinases in Rectal Cancers & EMVI  
Chapter 7 aimed to close the loop on the presence of EMVI in rectal cancers, the incidence of 
methylation assessed by CIMP-status, and the potential mechanisms underlying the 
relationship by examination of metalloproteinases and their inhibitors. The metalloproteinases 
were also investigated as potential biomarkers for the diagnosis of EMVI and as prognostic 
indicators. In the highly selected trial population, MMP2 was a predictor of EMVI based upon 
the Primary Binarised score. Higher MMP2 was also demonstrated to have a significant Cox 
hazard ratio for DFS and OS and was significantly associated with poor DFS on Kaplan-Mayer 
analysis. OS for MMP2 did not quite reach significance based upon Primary Binarisation but 
did on Secondary Binarisation. MMP2 score demonstrated better correlation to EMVI than 
CIMP status. These assessments were made on the basis of the scoring of 
immunohistochemically stained tissue microarrays where MMP2, MMP9, MMP11, TIMP2, 
and TIMP4 were targeted. MMP2 was the only factor identified that was a significant 
biomarker for diagnosis of EMVI and prognosis, although TIMP2 did demonstrate association 
with EMVI but was not a discriminator.  
 
Although MMP2 has previously been associated with advancing Duke’s stage in colorectal 
cancer, no previous study has identified MMP2 as a prognostic biomarker in rectal cancer, nor 
as a diagnostic biomarker in the identification of EMVI511. However, the method employed to 
assess MMP2 during this part of the research process is limited in that the trial population was 
highly selected, both in terms of the prevalence of EMVI (50% incidence of EMVI versus 44% 
in the unselected population in Chapter 3 and 17-70% in published series), and in the fact that 
all patients included in this research were those treated by surgery with curative intent and 
neoadjuvant naïve271-273. Its utility as a biomarker must therefore be tempered by this 
selectivity, and the need for large-scale validation in external cohorts. Furthermore, if MMP2 
is to be considered as a viable biomarker, it would need to be examined in a test that can be 
applied at the time of diagnosis and staging such as blood test or IHC of biopsy specimens. 
Biopsies taken during the endoscopic diagnosis of rectal cancer are notorious for not being 
adequately diagnostic or representative of the tumour as a whole; partly due to tumour 
heterogeneity, but also due to the limitations of superficial sampling477, 725, 726. Serum detection 
of MMPs is feasible, but the specificity of MMP2 to rectal cancer (avoidance of confounding 




8.5 Concluding Remarks 
The overarching aim of this body of research was to investigate epigenetic events in rectal 
cancer and their relationship, if any, to EMVI. The initial hypothesis was that 
hypermethylation, as defined by the CpG island phenotype (CIMP), was associated with EMVI 
and this was demonstrated to be the case. However, CIMP status did not correspond to survival 
as EMVI does and does not in itself elucidate how methylation status may be mechanistically 
associated with EMVI. By use of demethylating agents, primarily 5-azacytidine (AZA), 
invasive colorectal cancer cells were rendered less invasive and at the same time dysregulation 
in metalloproteinase (MMP) expression was observed. The association between demethylation 
and MMP dysregulation was confirmed by means of knockdown and observation of biologic 
effect by both immunocytochemistry and Western blotting. As MMPs are vital in the epithelial-
to-mesenchymal transition and to metastasis, due largely to their role in remodelling the 
extracellular matrix, they constitute a good mechanism for the observed in vivo effects of 
demethylation. This is particularly the case for MMP2, which is the primary protease 
responsible for degradation of type-IV collagen in the basement membrane. On assessment of 
resected tumours, MMP2 was found to be expressed significantly more strongly in tumours 
exhibiting EMVI those that did not, and MMP2 demonstrated good diagnostic accuracy in 
discriminating tumours with and without EMVI. MMP2 was also shown to be associated with 
survival and is a hazard for early poor outcomes in rectal cancer. By these means MMP2 may 
serve as a potential biomarker for the diagnosis of EMVI and in the prognosis of rectal cancers 
and serves as a means of understanding the fundamental biological processed underlying EMVI 
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Forward Primer Sequence (5’-
3’) 

















ACTCTATAAATTACTAAATCTCTTCA 52.5 35 37 93 
hMLH M GATAGCGATTTTTAACGC TCTATAAATTACTAAATCTCTTCG 52.5 35 37 »100 
MINT1 U AATTTTTTTATATATATTT
TTGAAGTGT 
AACAAAAAACCTCAACCCCACA 55 35 37 »100  
MINT1 M AATTTTTTTATATATATTT
TCGAAGC 





50 35 37 243 
SOCS1 M TTGTTCGGAGGTCGGATT
T 
ACTAAAACGCTACGAAACCG 50 35 37 218 
HAND1 U AATAGTTTAGGGTGTTGG
TT 
AAATTTTACACTCAACCCA 55 30 35 184 
HAND1 M AATAGTTTAGGGCGTTGG
TC 




















ACCAACTTAACCCGAACCGA 59 30 35 118 
IGFBP3 U TTATTTTGGTTTTTATATA
GTGGTT 
AACAAAAAACAACTAATCCTCAACA 51 35 35 »100  
IGFBP3 M TTTCGGTTTTTATATAGCG
GTC 
AAAAAACGACTAATCCTCAACG 54 35 35 »100  
THBD U ATGTGTTTGTTTTTATTTG
GTGTT 
CATAACTAACCAAAAACCCACA 57 30 35 158 
THBD M CGTTCGTTTTTATTCGGCG
TC 




RTPCR Input Quality Control  
 
NanoDrop RNA assessment 
 
RNA-40 260 280 260/280 260/230 ng/uL 
Blanks OK      
Control 7.468 3.503 2.13 1.50 298.7 
vC1 8.168 3.849 2.12 0.98 326.7 
vC2 6.736 3.171 2.12 0.68 269.4 
vC3 6.989 3.275 2.13 0.98 279.6 
1dA1 7.599 3.537 2.15 0.62 303.9 
1dA2 6.604 3.107 2.13 1.16 264.2 
1dA3 6.953 3.229 2.15 1.84 278.1 
3dA1 3.326 1.529 2.18 0.29 133.0 
3dA2 2.930 1.382 2.12 0.23 117.2 
3dA3 3.273 1.538 2.13 1.88 130.9 
3dR1 6.081 2.844 2.14 0.91 243.3 
3dR2 6.304 2.955 2.13 1.34 252.2 
3dR3 5.864 2.727 2.15 1.19 234.6 
reblank ok            
 
NanoDrop cDNA quantification & normalisation 
 
DNA-50 260 280 260/280 260/230 ng/uL 
Blanks OK      
Control 35.536 18.986 1.87 2.20 1776.80 
vC1 34.764 18.520 1.88 2.13 1738.20 
vC2 35.521 18.988 1.97 2.07 1776.10 
vC3 36.451 19.528 1.87 2.15 1822.60 
1dA1(spot) 34.620 18.491 1.87 1.94 1731.00 
1dA2 34.507 18.409 1.87 2.14 1725.40 
1dA3 34.555 18.452 1.87 2.13 1727.70 
3dA1 33.789 18.141 1.86 1.93 1689.50 
3dA2 33.408 17.937 1.86 1.83 1670.40 
3dA3 33.759 18.066 1.87 2.17 1687.90 
3dR1(spot) 33.856 18.098 1.87 2.05 1692.80 
3dR2 33.876 17.998 1.88 2.10 1693.80 
3dR3 33.335 17.781 1.87 2.10 1666.80 
reblank ok    AVE= 1723.00 
    SD= 46.54857678 
    AVE-1SD= 1676.45 
    AVE+1SD= 1769.55 
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SD p     
  Control 1 0           
  24hrs 0.50uM AZA 
0.495052368 0.279883246 0.346         
  72hrs 0.50uM AZA 
0.239147378 0.013174096 0.000         
 72hrs 0.50uM 
RRx-001 
4.789059429 0.298013198 0.002     
         
  0.00000000000
02782 
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    0.00003551629
8330 
    
 
 
RtC SD      
  Control 1 0           
  24hrs 0.50uM AZA 
2.252176977 1.09159706           
  72hrs 0.50uM AZA 
3.260019667 1.021140969           
 72hrs 0.50uM 
RRx-001 
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MMP13 bACT R HK R Cont SD 
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   0.0003964405754
79 
     
 
 
RtC SD      
  Control 1 0           
  24hrs 0.50uM AZA 
0.701398464 0.032996996           
  72hrs 0.50uM AZA 
0.768377806 0.111788527           
 72hrs 0.50uM 
RRx-001 
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   0.062169555129
067 
     
 
 
RtC SD      
  Control 1 0           
  24hrs 0.50uM AZA 
0.871270198 0.698684476           
  72hrs 0.50uM AZA 
0.367814806 0.060386531           
 72hrs 0.50uM 
RRx-001 












    
Control 0.0011
3 
9573.92110 1.17886E-07 1 





6261.27349 2.35669E-07 1.999128973 





1124.13516 3.92426E-07 3.328864832 





3806.41091 1.6823E-07 1.427054421 
    
     
1 
   
     
1 
   
     
1 
   
Biological Reps 
       
  
TIMP4 bACT R HK R Cont SD p RtC 




b 0.00024 5314.60594 4.5459E-08 1 
   
 
c 0.00136 5973.83717 2.27591E-07 1 
   
1D 
AZA 








c 0.00155 6425.54087 2.40451E-07 1.0565050
28 
   
3D 
AZA 








b 0.00040 1237.77796 3.25899E-07 7.1690693
48 
   
 
c 0.00038 987.62135 3.84224E-07 1.6882203
34 
   
3D 
RRX 








b 0.00051 3290.86637 1.54494E-07 3.3985216
65 
   
         
     
1.25141E-
07 
   
   
RtC SD 
    
  
Control 1 0 
    
  
24hrs 0.50uM AZA 1.445828101 0.550585971 
    
  
72hrs 0.50uM AZA 5.886316904 1.814085903 









Proteomics Raw Data 
 
Western Blot (Normalised) Data 
 
Prot Fold Change MMP2 TIMP2 TIMP4  MMP2 TIMP2 TIMP4 
Control 1 1 1 x Control 1 1 x 
Control 2 1 1 x AZA 0.35 0.36 x 
Control 3 1 1 x KD T2 1.026666667 0.063333333 x 
AZA 1 0.26 0.29 x KD T4 1.006666667 0.99 x 
AZA 2 0.47 0.39 x KD T2&4 0.993333333 0.076666667 x 
AZA 3 0.32 0.4 x KD T2 + AZA 0.276666667 0.06 x 
KD T2 1 0.94 0.02 x KD T4 + AZA 0.343333333 0.323333333 x 
KD T2 2 1.1 0.05 x KD T2&4 + AZA 0.346666667 0.066666667 x 
KD T2 3 1.04 0.12 x     
KD T4 1 1.07 0.92 x     
KD T4 2 0.86 0.99 x  MMP2 TIMP2  
KD T4 3 1.09 1.06 x Control SD 0 0  
KD T2&4 1 1.12 0.05 x AZA SD 0.108166538 0.060827625  
KD T2&4 2 0.89 0.1 x KD T2 SD 0.080829038 0.051316014  
KD T2&4 3 0.97 0.08 x KD T4 SD 0.127410099 0.07  
KD T2 + AZA 1 0.32 0.1 x KD T2&4 SD 0.116761866 0.025166115  
KD T2 + AZA 2 0.27 0.02 x KD T2 + AZA SD 0.040414519 0.04  
KD T2 + AZA 3 0.24 0.06 x KD T4 + AZA SD 0.061101009 0.080208063  
KD T4 + AZA 1 0.33 0.24 x KD T2&4 + AZA SD 0.077674535 0.047258156  
KD T4 + AZA 2 0.41 0.33 x     
KD T4 + AZA 3 0.29 0.4 x  MMP2 TIMP2 M vs T SdT 
KD T2&4 + AZA 1 0.41 0.03 x Control SdT - -  
KD T2&4 + AZA 2 0.37 0.05 x AZA SdT 0.009 0.003 0.852 
KD T2&4 + AZA 3 0.26 0.12 x KD T2 SdT 0.625 0.001 0.002 
    KD T4 SdT 0.936 0.828 0.856 
    KD T2&4 SdT 0.930 0.000 0.008 
    KD T2 + AZA SdT 0.001 0.001 0.009 
    KD T4 + AZA SdT 0.003 0.005 0.788 





Immunocytochemistry RapidScore (Normalised) Data 
 
RapidScore MMP2 TIMP2 TIMP4  MMP2 TIMP2 TIMP4  
Control 1 1 1 1 Control 1 1 1  
Control 2 1 1 1 AZA 0.343333333 1 3.736666667  
Control 3 1 1 1 KD T2 1.076666667 1 1.01  
AZA 1 0.25 x 4.21 KD T4 0.966666667 1 1.026666667  
AZA 2 0.43 x 3.2 KD T2&4 1.033333333 1 1.006666667  
AZA 3 0.35 x 3.8 KD T2 + AZA 0.326666667 1 4.096666667  
KD T2 1 0.99 x 1.01 KD T4 + AZA 0.35 1 1.003333333  
KD T2 2 1.09 x 1.03 KD T2&4 + AZA 0.346666667 1 1.036666667  
KD T2 3 1.15 x 0.99      
KD T4 1 1.12 x 1.01      
KD T4 2 0.86 x 1.05  MMP2  TIMP4  
KD T4 3 0.92 x 1.02 Control SD 0 0 0  
KD T2&4 1 1.2 x 1.03 AZA SD 0.090184995 0 0.507969815  
KD T2&4 2 0.91 x 1.01 KD T2 SD 0.080829038 0 0.02  
KD T2&4 3 0.99 x 0.98 KD T4 SD 0.136137186 0 0.02081666  
KD T2 + AZA 1 0.32 x 3.67 KD T2&4 SD 0.149777613 0 0.025166115  
KD T2 + AZA 2 0.24 x 5.72 KD T2 + AZA SD 0.090184995 0 1.457612203  
KD T2 + AZA 3 0.42 x 2.9 KD T4 + AZA SD 0.111355287 0 0.02081666  
KD T4 + AZA 1 0.33 x 1.01 KD T2&4 + AZA SD 0.077674535 0 0.045092498  
KD T4 + AZA 2 0.47 x 0.98      
KD T4 + AZA 3 0.25 x 1.02  MMP2  TIMP4 M vs T SdT 
KD T2&4 + AZA 1 0.41 x 1.08 Control SdT -  -  
KD T2&4 + AZA 2 0.37 x 1.04 AZA SdT 0.006  0.011 0.010 
KD T2&4 + AZA 3 0.26 x 0.99 KD T2 SdT 0.242  0.478 0.329 
    KD T4 SdT 0.713  0.157 0.569 
    KD T2&4 SdT 0.737  0.691 0.766 
    KD T2 + AZA SdT 0.006  0.067 0.052 
    KD T4 + AZA SdT 0.010  0.808 0.013 
    KD T2&4 + AZA SdT 0.005  0.294 0.001 
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Immunohistochemistry Scoring Sheet 
 
Scoring system for IHC 
(with reference to Fedchenko and Reifenrath, 2014) 
 
Proportion of Cells  p-Score Intensity of 
Staining 
i-Score 
None 0 None 0 
<10% 1 Weak 1 
10% – 50% 2 Intermediate 2 
51% - 90% 3 Strong 3 
>90% 4   
  MAX SCORE 7 
 
 





Number p-score i-score p-score i-score p-score i-score 
 Rep… A   B   C   
SH1015214             
MH127050             
SH1001950             
SH1003461             
SH1014485             
SH1016041             
SH1204044             
SH1115961             
SH1301209             
SH1125646             
SH105224             
SH1101201             
SH1242267             
SH1006849             
SH1211596             
MH1100593             
SH1300417             
SH1005494             
SH1014844             
MH1204971             
SH1209984             
etc…             




Frequency histograms demonstrating multiplied metric (Mx) and Categorised staining scores 















Logistic regression modelling for EMVI in relation to nominal categorised (Cat) scores for a. 
MMP2 and b. TIMP2 
 
a. MMP2 Summary Statistics & Test of the Null Hypothesis H0: Y=0.5. 
Variable Categories Frequencies Percentage  Statistic DF X2 PR>X2 
EMVI 1 30 50%  -2 Log 3 64.467 < 0.0001 
 0 30 50%  Score 3 46.286 < 0.0001 
     Wald 3 14.477 0.002 
Cat Score 0 2 3.3%      
 1 22 36.7%      
 2 14 23%      
 3 22 36.7%      
 
Standardised Coefficient Model & ROC Curve. 
 
 
Classification Table for the training sample. 
from / to 0 1 Total % correct 
0 24 6 30 80.0% 
1 0 30 30 100.0% 
Total 24 36 60 90.0% 
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b. TIMP2 Summary Statistics & Test of the Null Hypothesis H0: Y=0.5. 
Variable Categories Frequencies Percentage  Statistic DF X2 PR>X2 
EMVI 1 30 50%  -2 Log 2 26.406 < 0.0001 
 0 30 50%  Score 2 17.130 0.0002 
     Wald 2 7.450 0.024 
Cat Score 1 11 18.3%      
 2 37 61.7%      
 3 12 20.0%      
 
Standardised Coefficient Model & ROC Curve. 
 
 
Classification Table for the training sample. 
from / to 0 1 Total % correct 
0 30 0 30 100.0% 
1 18 12 30 40.0% 




Cox Proportionate Hazard modelling for Disease-Free (DFS) and Overall Survival (OS) 
assessed on EMVI and categorised staining (Cat) scores for MMP2 & TIMP2.  
(HR, Hazard Ratio; T, Statistical Trend; NS, Statistical Non-Significance) 
a. EMVI. (DFS HR 3.32, p=0.027; OS HR 3.05, p=0.043) 
 
b. MMP2. (DFS p=0.11, OS p=0.15) 
 











Meta-analysis Search Strategy & Consort Diagram 
 
Aim: Meta-analysis of CIMP in rectal tumours and relationship to outcomes (DFS/OS). 
Boolean Search Term:  CpG island methylator phenotype AND (cancer OR carcinoma OR 




PubMed:  223 
Cochrane:  8 
Medline:  10 
After duplications removed:  203 
Excluded based on title/abstract:  160 
 Not colorectal cancer - 2  
 Non-CpG methylation focus of analysis – 89 
 Single gene methylation only – 3 
 Not related to prognosis – 59 
  Review articles - 7 
Screened for eligibility: 43 
 Excluded on full text assessment:   
 Colon assessed as single cohort – 13 
 Rectum not separated from left / distal  





Screened for eligibility: 43
Analysis: 6
Excluded on full text 
assessment: 37
Colon assessed as single 
cohort: 13
Rectum not separated from left 
/ distal colon: 24
Excluded based on 
title/abstract: 160
Not colorectal cancer - 2 
Non-CpG methylation focus of 
analysis – 89
Single gene methylation only –
3
Not related to prognosis – 59
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Characteristics of Included Studies 












Samowitz et.al. 2009  864 1997-
2001 
30-79 (nr) nr I-IV nr 6 
Jo et.al. 2011  150 2004-
2006 
nr (61) 71 II-IV NO 6 
Bae et.al. 2013  168 2004-
2006 
36-87 (62) 67 I-IV NO 7 
Williamson et.al. 2017  160 2002-
2011 
nr (65) 71 II-IV YES 7 
Kim et.al. 2017  87 2006-
2007 
31-88 (65) 59 I-IV nr 7 
Kokelaar et.al. 2018 100 2010-
2013 
24-89 (71) 70 I-IV NO 7 
 
 
